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Where did it start? 
(1) 
General Introduction 
The renin-angiotensin system and aim of the thesis 
Chapter 1 
General Introduction 
Cardiac hypertrophy, i.e., enlargement of individual myocytes that results in an 
increase in cardiac mass, is part of the proces of remodelling of a heart under long-
term stress and is an effective phenotypic adaptation to compensate for increased 
(systolic and diastolic) left ventricular wall stress. Increased wall stress has several 
independent causes, e.g. physical training, hypertension or the presence of scar 
tissue after a myocardial infarction. In pathological situations cardiomyocyte 
hypertrophy is a mechanism to compensate for the loss of individual cardiomyocytes 
due to necrosis (i.e., unregulated cell death) and/or apoptosis (i.e., regulated cell 
suicide). This process is often accompanied by fibrosis (i.e., collagen deposition) 
resulting in increased stiffness. Cardiac remodeling, although advantageous at start, 
may ultimately evolve into overcompensation and end-stage heart failure. 
The renin-angiotensin system (RAS, see figure 1) is one of the important regulators 
of blood pressure and cardiac hypertrophy. Originally, the RAS was thought of as an 
endocrine system (i.e., the active endproduct, angiotensin II, acts at a distant 
location), required to regulate blood pressure and retention of Na• and H20. 
According to this concept, kidney-derived renin cleaves liver-derived 
angiotensinogen in the circulation, thereby leading to the release of angiotensin I. 
prorenin 
\ angiotensinogen 
renin ..... ~ ~ ~···· 
·· ... 
angiotensin I alternative ?? enzymes 
angiotensin 
converting 
enzyme 
I •. ·· 
·····~ ........ · 
angiotensin II 
angiotensin II receptor, 
type 1 or 2 
Figure 1: Scheme of the renin-angiotensin system. 
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This peptide of 1 0 amino acids is then converted to the octapeptide angiotensin II by 
angiotensin-converting enzyme (ACE), an enzyme that is abundantly present on the 
endothelial cells lining the vasculature. Angiotensin II subsequently binds to 
angiotensin II receptors resulting in contraction of vascular smooth muscle cells in 
the vessel wall, aldosterone synthesis and release by the adrenal, enhancement of 
thirst and vasopressin secretion in the brain, and Na• and H20 reabsorption in the 
kidney. 1 In these processes mainly type 1 angiotensin receptors (AT1 receptors) are 
involved. 1 Likewise, angiotensin II binding to AT1 receptors on cardiac cells can lead 
to hypertrophy of these cells. 1 
It is generally thought that the levels of renin are the main rate-limiting factor for 
angiotensin II generation. Renin levels fluctuate depending on its regulated release 
from juxtaglomerular cells in the kidney. The main determinants of renin release are 
the sympathetic nervous system, angiotensin II, blood pressure and the tubular Na• 
concentration. Like many secreted proteases, renin is synthesized as a larger 
inactive precursor, preprorenin. Preprorenin contains a signal peptide directing the 
protein to a cellular excretion route. During maturation, ending in the trans-Golgi 
network, the signal peptide is removed and carbohydrates are added to prorenin. 
Following its synthesis, prorenin is sorted to secretory granula, where it is stored, 
after proteolytic cleavage to renin. Part of prorenin escapes proteolytic cleavage to 
renin and is constitutively released into the circulation. Normally, the blood plasma 
concentration of prorenin in humans is 1 0-fold the concentration of renin.2 
In native prorenin, the prosegment covers the active site of renin (Figure 2). The 
prosegment can be temporarily displaced by "unfolding", a process known as non-
proteolytic activation. Under physiological conditions (pH 7.4 and 37°C} about 2% of 
prorenin is in the active, open conformation.3•4 At lower temperatures, or in acid 
milieu (as present in endosomal and lysosomal vesicles) this percentage is higher.'·5 
ACE is a transmembrane protein with its two active domains located extracellularly.6 
Following cleavage of its membrane anchor, it is also present as a soluble enzyme in 
blood plasma. ACE activity, which may vary by a factor of 5 between individuals, is 
regulated in part by ACE gene polymorphisms.' 
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native, inactive 
prorenin 
non-proteolytic (\l {J 
activation ~
~v 
active 
prorenin 
proteolytic 
activation 
renin+ prosegment 
Figure 2: "Closed" (top) and "open" (left) conformation ofprorenin. Temporal non-proteolytic 
activation of pro renin leads to exposure of the active site and display of intrinsic activity. 
Proteolytic removal of the prosegment generates renin (right). 
However, in view of its ubiquitous presence, it is generally assumed that these 
differences in ACE concentrations have little influence on the angiotensin II levels in 
blood. In this regard, it is of interest that the ACE upregulation that occurs under 
certain pathological conditions .. 10 has never convincingly been associated with 
enhanced angiotensin II generation.11 
The concentration of angiotensinogen in blood is relatively stable and approximates 
the Michaelis-Menten constant (Km) for renin, so that plasma angiotensin production 
is sensitive to small changes in angiotensinogen concentration. Both renin and 
angiotensinogen are capable of crossing the endothelial barrier and their interstitial 
fluid concentrations most likely resemble the levels in the circulation.12"15 
Angiotensinogen appears to be the only substrate of renin, although there are other 
enzymes (e.g., cathepsin D) capable of cleaving off angiotensin I. In contrast, ACE 
is a relatively non-specific protease and, among others, also cleaves the potent 
vasodilators bradykinin and substance P. Angiotensins in extracellular fluids are 
degraded within seconds by several proteases ("angiotensinases"). 
The recognition of the importance of the RAS with regard to blood pressure 
regulation and its contribution to cardiovascular diseases, like the development of 
10 
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cardiac hypertrophy and/or heart failure, led to the search and synthesis of 
angiotensin receptor blockers and inhibitors of ACE and renin. ACE inhibitors 
(prototype: captopril) were the first to be used on a large clinical scale. Pfeffer et al. 
provided experimental data on the improvement of ventricular function and survival 
of infarcted rats following chronic treatment with ACE inhibitors.16 The animal data 
were confirmed in large clinical trials (e.g., SOLVD and SAVE).17•18 1mportantly, the 
beneficial effects that were observed were greater than could be expected on the 
basis of the decrease in blood pressure that was caused by the ACE inhibitor. 
Recently, this was confirmed in the HOPE trial.19·20 
Consequently, the idea has arisen that, in addition to the circulating endocrine RAS, 
local tissue-specific angiotensin 11-generating systems may exist, for instance in the 
heart and blood vessel wall 21 •22 Locally generated angiotensin II is now believed to 
influence cell number, cell size, and extracellular matrix composition, and to act as 
an inflammatory agent, thereby enhancing the destabilization of atherosclerotic 
plaques. 21 ' 23 The tissue sites where angiotensin is generated (i.e., extra- and/or 
intracellular) and exerts its multiple actions are still under investigation. 
Local generation of angiotensin II could not only depend on the local synthesis of 
renin, angiotensinogen and ACE, but also on the uptake of one or more of these 
proteins from the circulation. With regard to renin, uptake of its inactive precursor, 
prorenin, is also feasible, particularly as prorenin is present in blood plasma at much 
higher concentrations than renin. Capture of pro renin by tissues should however be 
followed by local activation (proteolytic or non-proteolytic), on the cell surface and/or 
intracellularly. Evidence for this concept is currently lacking, except for in vitro data 
supporting the presence of (pro)renin binding proteins and/or receptors, for instance 
mannose 6-phosphate/IGFII receptors, on isolated cells."<-28 
AT1 receptor blockers (prototype: losartan) appear to be as successful as ACE 
inhibitors in clinical trials (e.g. ELITE 11).29 Importantly, the AT, receptor blockers 
have less side effects than ACE inhibitors, thus resulting in better compliance. This is 
mainly related to the fact that AT receptor blockers, unlike ACE inhibitors, do not 
interfere with bradykinin metabolism. Renin inhibitors are currently not available for 
clinical use, mainly due to their low oral bioavailability and high costs of synthesis.30 
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Studies investigating the underlying mechanisms of local angiotensin 11 generation 
may eventually lead to new treatment possibilities. For instance, if prorenin is 
proteolytically activated in a cardiac-specific manner, then interruption of this 
mechanism might enhance or replace ACE inhibition and/or AT, receptor blockade. 
Also, interference with the presumed (pro)renin binding might be worthwhile to 
investigate. 
Aim of thesis 
The knowledge concerning the formation of angiotensins at cardiac tissue sites in 
relation to the presence and origin of cardiac renin, angiotensinogen and ACE is 
evaluated in chapter 2. To gain insight in the functional importance of locally 
generated angiotensin 11, the response of human forearm blood flow to infusion of 
either angiotensin I or angiotensin 11 was investigated (Chapter 3). To extend our 
results in the perfused isolated rat heart,31 experiments were performed to detect de 
novo synthesis of RAS components by neonatal rat cardiomyocytes and -fibroblasts 
under basal conditions and after stretch (Chapter 4). In addition, we characterized 
the binding and activation of human recombinant prorenin via mannose 6-
phosphate/IGF11 receptors on the surface of human endothelial cells, and neonatal 
rat cardiomyocytes and -fibroblasts (Chapters 5 and 6). To validate our results 
obtained with human recombinant prorenin, neonatal rat cardiomyocytes were also 
incubated with human (pro)renin- containing body fluids (Chapter 7). The latter 
studies also addressed the importance of soluble mannose 6-phosphate/IGF11 
receptors. 
Finally, since 1) under certain conditions man nose 6-phosphate/IGF11 receptor 
activation initiates transcellu\ar signaling pathways,'2 and 2) renin binding to 
glomerular mesangial cells leads to plasminogen activator inhibitor type-1 release 
and an increase in 3H-thymidine incorporation,25 we investigated whether prorenin 
binding and/or uptake by rat cardiomyocytes, in the presence or absence of 
angiotensinogen, resulted in a cellular response (Chapter 8). In these latter studies 
we also investigated intra- and extracellular angiotensin 11 generation and compared 
the effects of prorenin with those obtained with angiotensin II in parallel experiments. 
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Abstract 
The existence of alOC<ll renin-angiotensin system in the hemt is still a controversial issue. This review discusses the evidence, obtained 
from studies in cardiac cells, in isolated perfused hearts and in intact animals and hum:l!IS, both under normal and pathological conditions, 
for local production of prorenin. renin. angiotensinogen. angiotensin-converting enzyme, angiotensin I and angiotensin II at cardiac tissue 
sites. In addition. the role of alternative angiotensin~genernting enzymes (cathepsin. chymase) and the possibility of (pro)renin uptake 
from the circulation is ev::U.wted. © 1999 Elsevier Science BY. All rights reserved. 
Keywords: Angiotensin; ACE inhibitors: Intcrstitial ~-pace: Myocytes; Renin :mgiotensin system 
1. Introduction 
The renin-angiotensin system (RAS) bas traditionally 
been viewed as a circulating system. Kidney~derived renin 
cleaves liver-derived angiotcnsinogen to form angiotensin 
(Ang) I in circulating blood. Subsequently, Ang I is 
converted into Ang JI. the main effector peptide of the 
RAS. by angiotensin-converting enzyme (ACE) located at 
the luminal side of the endothelium. Ang JI exerts its 
effects via stimulation of Ang JI receptors. of which at 
least two types have been described, AT 1 and ATz. Based 
upon discrepancies. observed more than 15 years ago. 
between RAS blocker~induced changes in the circulating 
levels of RAS components and the blood prcssure~lower~ 
ing effects of these drugs. it wns proposed that so-called 
local renin-angiotensin systems exist in addition to the 
circulating RAS. Subsequent studies showing the presence 
of RAS components at tissue sites appeared to confirm this 
theory. However, one has to keep in mind that the mere 
presence of RAS components in tissue cannot be taken as 
direct evidence for their local production. With regard to 
the heart. more convincing evidence for local Ang JI 
18 
production comes from the recently discovered beneficial 
effects of the ACE inhibitors in heart failure, which are 
independent. at least partly, of their effect on blood 
pressure [1-4]. Local Ang JI production may depend on 
(1) in~situ synthesis of all RAS components required for 
Ang IT production (i.e .• renin, angiotensinogcn and ACE). 
(2) uptake of these components from the circulation. or (3) 
a combination in~situ synthesis and uptake of RAS com~ 
poncnts (e.g .. uptake of circulating renin and angioten~ 
sinogen in combination with local synthesis of ACE). The 
latter two definitions would no longer require in~situ 
synthesis of renin. so that one should better speak of a 
system generating Ang JI locally rather than a local RAS. 
This review addresses the question whether a local RAS 
exists in the heart. 
2.. Studies in cardiac cells 
The uncertainties concerning local synthesis ansmg 
from tissue measurements (i.e .. local synthesis vs. uptake 
from circulating blood) can be avoided largely when 
measurements are made in cells cultured in the absence of 
serum. The use of serum~free medium is necessary to 
exclude the uptake of RAS components present in serum. 
However, serum"free conditions are always preceded by 
cell-.culturing conditions in the presence of serum. so that 
even under 'serum" free' conditions RAS components may 
be detected in cells that have been sequestered from the 
serum to which the cells were exposed earlier. Table 1 
summarizes the findings in cardiac cells that are discussed 
below. 
2.1. Renin 
Several attempts have been made to measure renin. both 
at the mRNA and protein level in myocytes and fi" 
broblasts obtained from hearts of neonatal and adult rats. 
Some [5-7], but not all [8] authors were able to detect 
renin mRNA. using sensitive PCRs. Renin immuno--
reactivity was present in the perinuclear region in neonatal 
rat cardiomyocytes and fibroblasts [5], or throughout the 
cytoplasm in adult rat cardiomyocytes and non"myocytes 
[6]. In these latter two studies. no distinction between renin 
and its inactive precursor, prorenin, was made. nor was 
(pro)renin release into the culture medium investigated. 
This is remarkable, since most so--called renin--expressing 
extrarenal cells produce prorenin rather than renin [9-12]. 
These cells do not store prorenin. and secrete it in a 
constitutive manner. Studies with cardiac cells where renin 
and prorenin (the latter after in"vitro activation to renin) 
were measured enzyme"kinetically. were unable to support 
either the release of (pro)renin into the medium [13] or the 
intracellular presence of (pro)renin [13,14]. The lack of 
(pro)renin release in combination with the low to undetect" 
able renin mRNA levels in cardiac cells does not support 
the concept of (pro)renin synthesis by these cells. The 
discrepancy between the absence of renin"dependent Ang 
!"generating activity in cardiac cells on the one hand. and 
the presence of immunoreactive renin in these cells on the 
other hand can be explained as follows: 1) the polyclonal 
antibodies used to demonstrate intracellular renin immuno--
T!lble 1 
The renin-angiotensin system of the heart 
histochemically [5,6] may have crossreacted with renin" 
like enzymes such as cathepsin D [15], or 2) the cells may 
indeed have contained renin. not due to local synthesis but 
due to uptake from the serum to which the cells were 
exposed prior to the serum"free period. In support of the 
latter explanation we have recently demonstrated that 
neonatal rat cardiac cells are capable of internalizing both 
renin and prorenin [16]. Internalized prorenin is rapidly 
activated to renin. The amount of serum to which the cells 
were exposed. the serum source. the duration of exposure 
to serum, and the intracellular half life of internalized 
(pro)renin may have differed between studies. and this 
might explain why under certain conditions renin still is 
present within cells. whereas in others it is not. 
2.2. Angiotensinogen 
Studies on angiotensinogen synthesis by cardiac cells 
are scarce. Angiotensinogen mRNA bas been demonstrated 
in both neonatal and adult rat cardiac cells by several 
investigators [5-8.17-20]. However. the actual presence 
of the angiotensinogen protein has been investigated in two 
studies only. Dostal et al. described positive immuno--
reactive staining in the perinuclear region for angioten" 
sinogen in both neonatal rat cardiomyocytes and fibro--
blasts. without investigating its release into the medium 
[5]. Van Kesteren et al., who measured angiotensinogen by 
radioimmunoassay after its conversion to Ang I by renin. 
was unable to detect angiotensinogen in neonatal rat 
cardiac cells or in the conditioned medium of these cells 
[13]. All other cells described to synthesize angioten-
sinogen secrete this substrate constitutively. without stor-
ing it intracellularly [21-23]. In vivo. angiotensinogen is 
also limited to the extracellular fluid compartment. and not 
located in cells [14,24,25]. Thus, despite the reports 
demonstrating angiotensinogen mRNA in cardiac cells 
with the help of sensitive PCRs. evidence for the release of 
angiotensinogen from these cells is lacking. 
Presence of renin. :.mgiotcnsinogen :.md ACE (mRNA :.md/or protein) in serum--deprived c:u'diac myocyte:; :.md fibroblasts vs. their relea.'\e into or uptake 
from tbe mediuma 
mRNA Protein 
lmmunohistocbcm.icnl Enzyme-kinetic 
measurement mem.'UI'ement 
Myocytes 
(Pro)renin ~' y~ No 
Angiotensinogen ~ y~ No 
ACE y~ Yes Yes 
Fibroblasts 
(Prol=ffi ~ Yes No 
Angiotensinogen ~ y~ No 
ACE Yes y~ y~ 
aD:l!:l are taken from Refs. [5-8.13.14.16-20,26-29]. 
bStudied after tbe addition of e;4;ogenous protein to tbe medium under serum-free conditions. 
c ::!:: denote:; a Jack of conseru.w in tbe existing literarure. 
Release into medium Uptake from medium b 
No y~ 
No Not done 
Not done Not done 
No Yes 
No Not done 
Not done Not done 
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2.3. ACE 
ACE, a cell membrane-bound enzyme. bas been demon-
strated in cardiac cells by enzyme-kinetic and immuno-
histochemical methods [13.26-29]. Both neonatal rat 
cardiomyocytes and fibroblasts generate Ang rr when 
incubated with Ang I under serum-free conditions. and 
ACE inhibitors fully inhibit this Ang IT generation [13,29]. 
The presence of ACE protein or activity in cardiac cells 
correlates well with the demonstration of ACE mRNA in 
these cells (5-8]. 
2.4. Angiotensin I and II 
According to several studies. serum-deprived cardiac 
cells release angiotensins into the culture medium. The 
Ang I and IT levels in the medium. however. showed huge 
variations. from <10 fmol/ml to >1000 fmol/ml 
[13.17 .26.2830]. Part of these discrepancies may be due to 
the fact that angiotensins were sometimes measured by 
direct radioimmunoassays (i.e .. without prior purification 
and/ or separation from material crossreacting with the 
Ang I and ll antibodies applied in these assays). This 
approach will lead to an overestimation of the "true" 
angiotensin levels, or even to the detection of angiotensins 
in medium that does not contain angiotensins [31 J. It 
should also be kept in mind that, in view of the cardiac 
angiotensin levels measured in vivo (Ang L ""'5 fmollg 
wet weight; Ang IT. ""'20 fmollg wet weight) [24,32-34]. 
even levels of 5-10 fmol/ml are very high. since in most 
Table 2 
Effect of stretch on renin-angiotcn.<ci.n S)ll>'tem components in cardiomyocyte:;~ 
Study Presence of Cyclic/sutic Renin 
= stretch 
Sudoshlma ct No St:ltic No change in 
:11.. 1993 (17] renin-like 
activity 
M:llhotr:l. et al., No St:ltic mRNA 7 
1994 [7] 
Shyu et al., 1995 No Cyclic 
[18] 
Y:una2'11kiet:ll., No St:ltic 
1995 [30] 
:Miyata et al., No St:ltic 
1996 [29] 
Tamura et a!., No St:ltic 
1998 [19] 
studies medium was collected from only 1-10 million 
cells. with an estimated wet weight of less than 10 mg 
[35]. Sadosbima et al. [17] found the Ang IT concentration 
in the medium of serum-deprived cardiomyocytes to 
increase nearly 100-fold upon stretch (Table 2). This Ang 
II. which is assumed to be responsible for the hypertrophic 
[8,17-19.2830] or apoptotic [20] response of car-
ctiomyocytes after stretch, appeared to originate from 
intracellular storage sites. since its release was not affected 
by captopril and not accompanied by Ang I release [17]. 
Immunoelectron microscopy confirmed the existence of 
secretory granule-like structures containing Ang n in 
ventricular cardiomyocyteS [17]. Dostal et al. [26] did not 
observe these granule-like structures and localized intracel-
lular Ang IT in the perinuclear region of neonatal rat 
cardiomyocytes and fibroblasts. Stretch is assumed to 
cause an upregulation of RAS components in car-
ctiomyocytes. and this would explain why the Ang IT levels 
in the medium are also elevated 20-24 h after the initiation 
of stretch [20]. However, the reports on elevated renin -
and ACE mRNA levels were not supported by protein 
measurements (17,28], suggesting that increases in expres-
sion may not be translated to the protein level. In addition, 
not all authors were able to observe a rise in Ang II 
following stretch [13,30]. Taken together therefore, the 
initial report by Sadosbima et al. on Ang ll release after 
stretch has not been unequivocally confirmed by others. It 
is possible that differences in experimental conditions have 
played a role (Table 2). Furthermore. the Ang II in 
intracellular storage sites may have been derived. via AT 1 
Angiotcn~inogen ACE Ang D relea.'lC 
mRNA i No change 100-fold increase 
in ACE-like to -450 pmolll 
activity after 10 min 
mRNA r mRNA r _, 
mRNA r 
Undetectable 
No change 2-fold increa.">e to 
in ACE-like =30 pmolll after 
activity 24h 
mRNA r 
Liang eta!., Yo< Cyclic mRNA undetccbble mRNA r mRNA 7 
1998 [3] 
Leri ct a!., 1998 No St:ltic mRNA r 4-fold increase: to 
[20] 
van Kcsteren et No Cyclic 
al.. 1999 [13] 
n All ~dies employed neon:rtai rat cardiomyocytes, except the study by Leri et al., in which adult rnt cardiomyocyte:; were u:>ed. 
b -: not studied. 
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=10 pmol!l after 1 
hr and after 24 h 
undetectable 
receptor~mediated endocytosis [36], from the serum-con-
taining medium used to culture the cells prior to stretch. 
3. Studies in isolated perfused hearts 
The isolated perfused heart has been used widely to 
study the effects of RAS blockers on coronary flow and 
cardiac function. In these studies. it is generally assumed 
that all RAS components are present in cardiac tissue and 
that Ang IT is generated continuously. However, evidence 
to proof this notion is currently lacking. Studies investigat-
ing the presence of RAS components in the isolated 
perfused heart are scarce. despite the fact that an isolated 
perfused preparation is ideal to study local synthesis. The 
buffers used to perfuse the heart are free of renin and 
angiotensinogen. thereby eliminating the problems arising 
from in~vivo measurements. when the heart is perfused 
with blood containing these components. 
3.1. Renin 
Renin or prorenin release by the heart has never been 
demonstrated. Angiotensin release from isolated perfused 
hearts occurred only after the addition of renin to the 
perfusion fluid [37-40]. thereby demonstrating that (1) 
renin is not present in the isolated buffer~perfused heart. 
and (2) renin is the only enzyme involved in cardiac Ang I 
generation. The kinetics of renin uptake into the heart have 
been studied extensively by de Lannoy et al .. using a 
modified version of the rat Langendorf£ heart. allowing 
separate collection of both coronary effluent and interstitial 
fluid [38]. Renin could not be demonstrated in either the 
coronary effluent or the interstitial fluid of buffer~perfused 
hearts. When renin was added to the perfusion buffer, it 
slowly entered the interstitial space. reaching steady~state 
levels in interstitial fluid comparable to those in coronary 
effluent after approximately 30 min. Calculations on the 
basis of the steady~state renin levels in coronary effluent. 
interstitial fluid and cardiac tissue. revealed that the 
majority of cardiac renin was present in extracellular fluid. 
After stopping the renin infusion. the washout of renin 
from the heart followed a biphasic pattern. suggesting that 
renin may also be present in an additional compartment. In 
support of this finding. Miiller et al. observed Ang IT 
release from isolated hearts of rats overexpressing the 
human angiotensinogen gene even after discontinuation of 
renin infusion. at a time when renin had already dis-
appeared from the coronary perfusate [40]. It is therefore 
possible that some renin is located outside the extracellular 
fluid compartment. for instance bound to the membrane of 
vascular or cardiac cells. This notion is in agreement with 
the recent observation that both endothelial cells [41] and 
cardiac cells [16] are capable of binding renin and 
prorenin. Proreuin kinetics in the isolated perfused heart 
were comparable to those of renin: release of activated 
The renin-angiotensin system of the heart 
prorenin into either the coronary effluent or interstitial fluid 
could not be demonstrated [42]. 
3.2. Angiotensinogen 
A.ngiotensinogen release from isolated buffer~perfused 
rat Langendorf£ hearts has been investigated in two 
studies. Lindpaintner et al. [37] observed a rapid decline of 
the angiotensinogen levels in coronary effluent to levels 
that were <1% of the levels in blood plasma De Lannoy 
et al. [38] were unable to demonstrate angiotensinogen in 
coronary effluent. but found low angiotensinogen levels 
(corresponding to <0.1% of the plasma levels of angiotenM 
sinogen) in interstitial fluid. which decreased even further 
(to levels below the detection limit) during prolonged 
buffer perfusion of the heart. The most likely explanation 
for these findings is that some blood-derived angiotenM 
sinogen is still present in the isolated heart preparation (for 
instance in the interstitial space). which is slowly washed 
away during perfusion with buffer. In support of this 
assumption. angiotensinogen. when added to the perfusion 
buffer of the isolated rat heart. entered the interstitial space 
[38]. Steady~state levels comparable to those in coronary 
effluent were reached 30-40 min after the start of the 
angiotensinogen perfusion. The steady~state tissue levels of 
angiotensinogen were also compatible with its presence in 
extracellular fluid. Following discontinu:ltion of the an-
giotensinogen perfusion. angiotensinogen disappeared 
monophasically from cardiac extracellular fluid. This out-
come contrasts with the findings on renin. which dis-
appeared in a biphasic manner. and suggests that angiotcn-
sinogen is limited to one compartment (the extracellular 
fluid) only. Indeed. binding of angiotensinogen to cardiac 
or vascular membranes could not be demonstrated [24.43]. 
3.3. ACE 
Many investigators have shown that Ang I is converted 
to Ang II in the isolated perfused rat heart [39.40,44-46]. 
ACE inhibitors prevented the A.ng I-II conversion com~ 
pletely. Thus. there is no doubt that ACE is present and 
functionally active in the isolated perfused heart. The 
conversion of arterially delivered A.ng I was usually low ( < 10%) and appeared to depend on both endothelial and 
extra-endothelial ACE [46]. 
3.4. Angiotensin I and ll 
Buffer~perfused rat hearts do not release Ang I or A.ng 
II. unless renin is added to the perfusion buffer [37-39]. 
Renin~induced angiotensin release diminishes rapidly. sug-
gesting that it depends on a limited amount of trapped 
plasma~derived angiotensinogen [3738]. Cardiac angioten-
sin release during renin infusion can only be maintained 
over longer time periods by adding angiotensinogen simul~ 
taneously to the perfusion buffer [38.39]. or by using 
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hearts of rats overexpressing the angiotensinogen gene 
[40]. Interestingly, angiotensin release via coronary ef~ 
fluent reached a steady state after 30-40 min of combined 
renin and angiotensinogen perfusion. whereas renin and 
angiotensinogen in coronary effluent had reached a steady-
state level within 5 min after the start of their infusion into 
the perfusion buffer. This finding. in combination with the 
fact that angiotensin release continues after discontinuation 
of the renin perfusion. at a time when renin is no longer 
present in coronary effluent [40]. strongly suggests that 
cardiac angiotensin release depends largely on tissue-
bound renin. The most likely binding site for renin 
involved in the release of Ang I into the intravascular 
compartment is the vascular wall, Angiotensin production 
also occurred in cardiac interstitial fl.uid. and under steady-
state conditions. the interstitial fluid Ang I and II levels 
were 2-3 times higher than those in coronary effluent 
[38.39]. In view of the low interstitial fluid flow (50-100 
times lower than the coronary flow) and the extensive 
metabolism of angiotensin in the vascular wall. it is 
unlikely that interstitial angiotensin production contributed 
importantly to the angiotensin levels in the coronary 
effluent. Frnally, Ang II was present in cardiac tissue 
during combined renin and angiotensinogen perfusion, at 
levels higher than those expected on the basis of the Ang II 
levels in extracellular fluid [39]. This was not the case for 
Ang I: per gram tissue the amount of Ang I was as high as 
expected on the basis of the assumption that Ang I is 
present only in extracellular fluid. Thus, cardiac Ang I is 
largely confined to the coronary vascular bed and the 
interstitial fluid compartment, whereas cardiac Ang II is 
also located outside these compartments. Tissue Ang II 
may therefore be present in cells. either because it is 
synthesized intracellularly. or because, following its syn-
thesis outside the cell. it is rapidly internalized via AT1 
receptors [36]. 
4. Studies in intact animals and humans 
Results from in-vivo studies on the tissue levels of RAS 
components are difficult to interpret because these levels 
might be partly or wholly contributed to the presence of 
blood in tissues. Even when the levels are considerably 
higher per gram of tissue than per millilitre of plasma. one 
should keep in mind that an active uptake process (e.g .• 
receptor binding) rather than local synthesis may underlie 
these high levels. 
4.1. Renin 
Renin rnRNA concentrations in normal hearts are close 
to or below the detection limit [47-50]. suggesting that 
under normal circumstances cardiac renin synthesis may 
not occur. We compared the renin levels in the heart with 
its level in blood plasma in normal and nephrectomized 
pigs [24]. Ang !-generating activity of cardiac tissue was 
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identified as renin by its inlribition with a specific active 
site-directed renin inhibitor. The levels of renin in cardiac 
tissue (expressed per gram wet weight) were similar to 
those in blood plasma (expressed per ml plasma) and could 
therefore not be attributed to trapped blood plasma. 
However. both in cardiac tissue and in plasma renin fell to 
undetectable levels after nephrectomy. These data, which 
were confirmed in the rat heart by Katz et al. [25]. suggest 
that most, if not all renin present in the normal heart 
originates from the kidney. Apparently. the heart is capable 
of sequestrating renin from the circulation. Renin may 
either diffuse into the interstitial space [38] or bind to the 
recently described renin receptor(s) and/or renin binding 
proteins [16.41,43,51-53]. In support of the latter, we [24] 
and others [43] found renin to be enriched in a purified 
membrane fraction prepared from either left ventricular 
tissue or mesenteric arteries. Such enrichment in cardiac 
.and vascular tissue is in agreement with the existence of a 
renin receptor. It is currently not known what cardiac cells 
are responsible for the binding of renin. Based on studies 
in isolated cells (16.41]. endothelial cells as well as 
cardiomyocytes and fibroblasts might be involved in the 
uptake process. Interestingly. these cells were not only 
capable of binding renin. but bound prorenin as well. 
Moreover. following binding. renin and prorenin were 
internalized. and prorenin was activated to renin. These 
findings may explain why in the normal heart virtually no 
prorenin can be detected [24,53]: prorenin taken up by the 
heart from the circulation may have been activated locally 
to renin. The receptor involved in the binding and inter-
nalization process of (pro)renin and prorenin activation 
appeared to be the mannose 6-phosphate receptor [16.41]. 
Renin acquires phosphomannosyl residues during its bio-
synthesis that enable it to bind to this receptor [54]. Katz et 
al. [25] found that, following bilateral nephrectomy. high~ 
mannose renin glycoforms disappeared from the heart at a 
much slower rate than from plasma. thereby indirectly 
confirming that (phosphorylated) oligosaccharide attach-
ments to renin determine its binding to cardiac tissue. 
4.2. Angiotensinogen 
Angiotensinogen mRNA can be detected in the heart 
[49.55-57]. at levels that are <0.1% of the angioten-
sinogen rnRNA levels in the liver [57]. The angioten-
sinogen concentrations in porcine cardiac tissue are 10-
25% of the levels in plasma. a figure compatible with the 
diffusion of angiotensinogen from plasma into the inter-
stitium [24]. In hearts of humans and rats. the angioten-
sinogen levels. measured by enzyme-kinetic assay. were 
lower than expected on the basis of diffusional equilibrium 
between plasma and tissue [25.53]. either because these 
hearts were washed with buffer after their removal from 
the body [25]. or because significant consumption of 
.angiotensinogen had occurred at cardiac tissue sites [53]. 
In support of the latter possibility, a negative correlation 
was found between angiotensinogen and renin in human 
hearts [53]. Despite the low levels of angiotensinogen that 
could be demonstrated in the human heart by enzyme-
kinetic assay [53]. Sawa et al. [58] found intense immuno-
reactivity for angiotensinogen in the atrial muscles. the 
muscles of the conduction system and those of the 
subendocardial layers of human autopsy hearts. Remark-
ably however. despite the intense immunoreactivity in 
myocardial cells. Sawa and colleagues were unable to 
show positive immunostaining of angiotensinogen in the 
liver. Taken together therefore. although the data for 
angiotensinogen are less clear than those for renin, it 
appenrs that the majority of cardiac angiotensinogen is 
derived from the circulation. Most likely angiotensinogen 
diffuses freely from plasma into the interstitial space. 
where cleavage by interstitial fluid renin and/or mem-
brane-bound renin may occur. 
4.3. ACE 
ACE mRNA is readily detectable in cardiac tissue 
[45.59,60]. ACE has been demonstrated in the heart by 
autoradiography [61]. using a radiolabelled ACE inhibitor. 
as well as by measurement of its activity in cardiac 
homogenates [45.62]. Most likely. cardiac ACE is normal-
ly limited to the coronary vascular endothelial cells and the 
endocardium [63]. 
4.4. Angiotensin I and II 
Many groups have reported on the presence of Ang I 
and II in cardiac tissue [24.32-34]. In most cases the tissue 
levels (expressed per g wet weight) were similar to or 
higher than the concomitant plasma levels (expressed per 
ml plasma). This. however, cannot be taken as definite 
evidence for angiotensin production at cardiac tissue sites. 
since both Aug I and Ang II may have been actively 
sequestered from the circulating blood. According to two 
studies [24.32]. cardiac angiotensin levels decreased to 
levels close to or below the detection limit following a 
bilateral nephrectomy. whereas a third study recently 
reported no change in cardiac angiotensin levels after 
nephrectomy [33]. The most likely explanation for these 
differences is that in the latter study cardiac angiotensin 
levels were measured in rats 24 h after nephrectomy. while 
the effects of nephrectomy on cardiac Ang II. at least in 
the rat. become apparent only at 48 h after nephrectomy 
[32]. Moreover. a bilateral nephrectomy is known to be 
accompanied by the release of large amounts of renin from 
the kidney. and this may have resulted in correspondingly 
high myocardial renin levels immediately during and after 
surgery [14.25]. 
What are the possible sources of Ang I and Ang II in 
cardiac tissue? Ang I in cardiac tissue might be derived 
from Ang I in the coronary artery. from Ang I generated in 
the coronary circulation by the reaction of circulating renin 
with circulating angiotensinogen ("plasma renin activity', 
PRA). or from Ang I synthesized in situ in cardiac tissue. 
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Cardiac Ang II might be derived from Ang II in the 
coronary artery and. via conversion. from the above three 
sources of Ang I. 
In order to quantify the contribution of each of these 
sources. we have measured the steady-state tissue and 
plasma levels of endogenous and radiolabelled Ang I and 
Ang II. as well as PRA. during infusions of 125I-labelled 
Ang I and Ang II [34]. Great care was taken to measure 
intact 125I-labelled and endogenous Ang I and Ang II 
rather than tissue radioactivity or immunoreactive an-
giotensin levels. The body does not distinguish between 
radiolabelled and endogenous angiotensins [64], and thus 
the steady-state levels of 1'l."il-labelled Ang I and Ang II 
present in cardiac tissue during the infusion of these 
radiolabelled peptides are a measure for the uptake of 
angiotensins from the circulation. The contribution of 
angiotensins generated in the coronary circulation by PRA 
can be calculated by assuming that PRA.-derived angioten-
sins are taken up by the heart in the same way as 
radiolabelled angiotensins. 
The results indicated that. under steady-state conditions, 
the cardiac 125I-Ang I concentrations are less than 5% of 
its levels in plasma. whereas the concentrations of cardiac 
1251-Ang II are approximately 90% of plasma 125I-Ang II. 
At the same time, the cardiac tissue concentration of 
endogenous Ang I was similar to the plasma concentration 
of endogenous Ang L while the cardiac tissue concen-
tration of endogenous Ang II was 4-5 times higher than 
the plasma concentration of endogenous Ang II (Fig. 1). 
Taking into consideration the small amounts of angioten-
sins generated by PRA. in the coronary circulation. it can 
be calculated that over 90% of the Ang I in tissue is 
synthesized in the tissue itself and not derived from the 
circulation. Moreover. more than 75% of the Ang II in 
tissue is also synthesized in the tissue and its source is 
in-situ synthesized Ang I rather than Ang I from the 
circulation. Interestingly, locally synthesized Ang L but 
not locally synthesized Ang II. was found to be released 
into the coronary circulation [65.66]. This suggests either 
that Ang I produced at tissue sites enters the blood at a 
level distal to the site where Ang I-to-II conversion occurs, 
or that Ang II produced in the tissue cannot leave the 
tissue. for instance because, following its formation. it 
rapidly binds to angiotensin receptors. 
Summarizing. the majority of cardiac Ang I and Ang II 
is synthesized at tissue sites by kidney-derived renin. 
Locally synthesized Ang II is kept in the tissue. whereas 
locally synthesized Ang I is capable of reaching the 
coronary circulation. 
5. Cardiac renin-, angiotensinogen- and ACE 
synthesis under pathological conclitions 
Although synthesis of renin and angiotensinogen at 
cardiac tissue sites does not appear to occur under normal 
circumstances, it is possible that the renin and angioten-
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Fig. 1. Pl:!sm:1 and cardiac tissue levels of angiotcn.~in (Ang) I and II in the pig. The rt~:~jority of cmdiac Ang I and II is synthe:.'izcd locally at cardiac ti.~e 
sites. The contribution of pla.~mu renin activity in the coronary vascular bed to the cardiac tissue levels of Ang I and II is too small to be shown. Data= 
taken from Ref. [34]. 
sinogen gene are switched on in response to pathological 
conditions. In addition. changes in ACE gene expression 
may occur. Most studies investigating the cardiac RAS 
under pathological conditions have determined changes at 
the mRNA level only. In view of the low to undetectable 
levels of renin and angiotensinogen mRNA in control 
hearts. as well as the uncertainties with regard to transcrip-
tional regulation. it is difficult to establish the value of 
increased mRNA levels in the diseased he::ut. Boer et al. 
[50] and Pieruzzi et al. [67] described increases in renin 
mRNA in the rat heart in response to volume overload. 
These increases could only be demonstrated after 37 and 
40 PCR cycles. and were not confirmed by lwai et al. [57]. 
No change in cardiac angiotensinogen mRNA was found 
in the volume overload model [50.57]. Passier et al. found 
increased renin mRNA levels in the infarct zone following 
coronary artery ligation. and no change in angiotensinogen 
mRNA levels in either the infarcted and noninfarcted zone 
[49]. In contrast. Lindpaintner et al. reported a transient 
activation of angiotensinogen mRNA in the noninfarcted 
left ventricle of rats after a coronary artery ligation [56]. 
Heller et al. studied myocardial renin-angiotensinogen 
dynamics during pressure-induced cardiac hypertrophy. 
and found cardiac renin to vary directly with plasma renin 
[14]. Similarly. the increases in plasma renin occurring in 
subjects with end-stage heart failure were found to be 
accompanied by parallel increases in cardiac renin [53]. 
Thus. on the basis of renin protein measurements in 
cardiac tissue no evidence was obtained for significant 
cardiac renin prOOuction under pathological conditions. As 
far as angiotensinogen is concerned. decreased rather than 
increased levels were found in failing hearts. suggesting 
local consumption by cordiac renin [53]. Thus. demonstra-
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don of significant angiotensinogen production in the heart 
under pathological conditions is difficult. since increased 
consumption may mask local production. Fmally, with 
regard to ACE. changes in its mRNA levels have been 
observed in diseased hearts that :rre supported by protein 
measurements. Both ACE protein and ACE mRNA in-
crease following myocardial infarction. as well as during 
pressure - and volume overload-induced left ventricular 
hypertrophy [45.57.59.60.67]. Under these conditions. the 
localization of ACE may no longer be limited to the 
endothelium. In humans. following myocardial inf:rrction. 
ACE can be detected in the remaining viable car-
diomyocytes near the infarct scar of the aneurysmal left 
ventricle, as well as in fibroblasts. vascular smooth muscle 
cells. and macrophages in the scor area itself [68]. In rats, 
following coronary occlusion. ACE was demonstrated in 
fibroblasts in the healthy hypertrophying part of the heart 
[69]. 
6. Site of tissue angiotensin generation 
Tissue angiotensin generation may occur in interstitial 
fluid. on the cell membrane. or within cells (Fig. 2). 
6.1. lnterstitialfluid 
According to our studies in the isolated rat heart. 
circulating renin and angiotensinogen arc able to reach the 
interstitial space [38]. This offers the possibility of an-
giotensin generation within this fluid. Indeed. during 
combined renin/angiotensinogen petfusion of the Langen-
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Fig. 2. Proposed scheme of angiotensin (Ang) I and II production in the heart [39]. Intruva.<ICI!lar and interstitial comprutments a.~ well a.~ blood vessel wall 
and cnrdinc cell~ (endothelial cell<;, myocyte;;, fibrobl:.lst<;, macroph:!ges) are depicted. Circulating renin and angioteru;inogen (Aog) both enter the interstitial 
fluid compartment Renin may also bind to the vascular wall and cnrdiac cclk ACE is present on cndothclinl cell~ and cardiac cclk Ang I and II are 
mel:lboli7.ed by peptid=s while passing through the V:!SCulM w:ill. AnJl': I and II in the inten:titi:ll fluid nrc mainly generated out,ide the vascular fluid 
compartment. TL'>..~ue Ang I and II generation may occur not only in the interstitial fluid or on the ce!l surface but aL'\0 within cells. for inst:lnce :iller renin 
uptake by the cell~. Binding of Ang Il to the AT, reteptor L~ followed by internaliz:.ltion of the AT, receptor-Ang II complex. 
dorff heart. we found the levels of Ang I and Ang IT in 
interstitial fluid to be two-three times higher than the 
levels measured simultaneously in the intravascular com-
partment [38.39]. Data from in~vivo studies in the dog also 
demoustrated that the cardiac interstitial angiotensin levels 
are higher than the plasma levels of these peptides [70]. 
Since diffusion of intact Ang I and II from the intravascu-
lar compartment to the interstitial compartment is marginal 
(most likely because of rapid metabolism of angiotensins 
in the vascular wall [38.39]). the high interstitial levels can 
be taken as evidence for interstitial angiotensin generation. 
6.2. Cell membrane 
In support of a role for membrane~bound renin in local 
angiotensin generation. we [38.65] and others [66] ob-
served that. both in vivo and in vitro. the amount of Ang I 
released by the heart via coronary effluent was too high to 
be explained by the renin-angiotensinogen reaction occur~ 
ring in intravascular fluid during coronary passage. More-
over. in the isolated Langendorff heart preparation per-
fused with renin and angiotensinogen. Ang I release via 
coronary effluent reached a steady-state level long nfter 
renin and angiotensinogen had reached a steady state in 
this fluid [38). and angiotensin release continued after 
discontinuation of the renin perfusion [40]. These dat:~. 
suggest that tissue~bound renin rather than extracellular 
fluid renin is responsible for the high Ang I levels in 
coronary effluent. Endothelial cells. vascular smooth mus-
cle cells. cardiomyocytes and cardiac fibroblasts may all be 
involved in the binding process. 
6.3. Intracellular compartment 
Direct evidence for intracellular angiotensin generation 
is not available. Renin dialysis into cultured car-
diomyocytes leads to a decrease in the conductance of the 
adjacent myocytes [71]. The reduction of conductance was 
amplified when renin was infused together with angioten-
sinogen and attenuated when a renin inhibitor was co-
administered. suggesting that these effects are mediated by 
renin-dependent angiotensin II formation within the cell, 
Our data on renin and prorenin internalization [16.41] 
might explain how renin nonnally enters the cell. When. 
concurrently with (pro)renin. angiotensinogen is taken up 
from the interstitial fluid via bulk fluid endocytosis, a 
scenario for intracellular angiotensin generation is pro-
vided (Fig. 3). Additional proof for intracellular angioten~ 
sin generation comes from studies where the extracellular 
and tissue levels of Ang II were measured during Ang II 
perfusion and during renin/angiotensinogen perfusion of 
the isolated rat Langendorff heart in the absence or 
presence of the AT 1 receptor antagonist losartan [39]. 
During these infusions the heart is exposed to arterially 
delivered and locally generated Ang II, respectively. 
Losartan did not affect the extracellular Ang II levels 
during both infusions. It did however reduce the tissue Ang 
II levels during Ang II perfusion to almost undetectable 
levels, whereas tissue Ang II during renin/ angiotensinogcn 
perfusion was not affected. It appears therefore that 
arterially delivered Ang II binds to AT 1 receptors at 
cardiac tissue sites and that losart:m interferes with this 
process. thereby reducing the tissue Ang II levels. Locally 
synthesized Ang II present at tissue sites is not affected by 
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Fig. 3. Binding and activation of prorenin by cardlomyocytes. After binding to the cell surfuce, the receptor-prorenin complex is inl:enml.i7.cd in a 
clathrin-coated pit, that pinches off to become :1 coated vesicle. The cl:!thrin CO!It then depolymeri7.cs, thereby leading to the formation of an cndooome. 
Prorenin L~ nctiv:~tcd to renin and dissociates from the receptor due to the acid environment in the endosome. The receptor return.~ to the ccll surf :lee. and 
the activated prorenin might participate in either intmcellular or exlr.!ccllular ;mgiotensin gcnerotion. 
losartnn. and thus may have been generated at a site that 
cannot be reached by losartan. i.e. the intracellul::rr com~ 
partment. 
7. Mannose 6-pbospbate receptors and cardiac 
(pro)renin binding 
In view of the absence of significant renin synthesis at 
cardiac tissue sites. one may speculate that the heart 
possesses specific mechanisms to sequester (pro)renin from 
the circulation. Several groups have reported on the 
existence of (pro)renin binding proteins and/or receptors 
[16.41.43.51-53.72-74]. An intracellular renin-binding 
protein (RnBP) wm: discovered in the early eighties in 
humans. mts and pigs [72-74]. Binding to this RnBP 
reduces the Aog I-generating activity of renin by >80%. 
Recently. this RnBP was found to be equal to the enzyme 
N-acyl-D-glucosaminc 2-epimerase, indicating that it might 
be involved in the intracellular processing of renin rather 
than renin uptlke [75]. Subsequently, using chemical 
cross-linking, two vascular RnBPs were identified by 
Campbell and colleagues in membranes isolated from rat 
mesenteric :uteries or cultured rat aortic smooth muscle 
cells [43]. Interestingly, binding to these RnBPs was 
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inhibited by a specific. active site-directed renin inhibitor. 
suggesting that the active site of the renin molecule might 
be involved in the binding process. Nguyen et al. and 
Sealey et al .. with the use of radiolabelled (pro)renin. 
demonstrated high-affinity renin binding sites/receptors 
(Ka."'" 1 nM) in hUlllan mesangial cells and in membranes 
prepared from rat tissues [51.52]. In the rat. these binding 
sites bound prorenin and renin equally well. which sug-
gests that neither the prosegmcnt nor the active site is 
involved in the binding process [51]. This contrasts with 
Campbell's findings. 
If binding does not involve the prosegment or the active 
site, a further possibility would be binding to the carbohy-
drate portions which both proteins contain. Renin and 
prorenin display isoelectric heterogeneity; up to five or six 
forms with different isoelectric points have been described 
in rats and humans [76-79]. This heterogeneity most likely 
results from differential glycosylation (glycoforms). The 
carbohydrate portion appears to be involved in the clear-
ance of renin by the liver. since deglycosylation greatly 
(>90%) reduced the hepatic uptlke of renin [80]. We 
recently observed that the mannose 6-phosphate signal. 
present on both renin and prorenin, determines (pro)renin 
binding and internalization by cardiac and endothelial cells 
[16.41]. Most likely therefore, it is the mannose 6-phos-
phate receptor (MPR) which is involved in this process. 
MPRs function in the process of intracellular lysosomal 
enzyme sorting [81.82]. At present. two different MPRs 
have been identified: a large MPR (mol. wt. 300 kDa), 
which binds ligand independent of divalent cations (cation~ 
independent or CI~MPR), and a small MPR (mol. wt. 46 
kDa), which requires divalent cations for optimal binding 
(cation-dependent or CD~MPR) [83,84]. In 1987. it was 
discovered that the CI~MPR and the insulin~like growth 
factor IT receptor are the same protein [85]. Thus, the 
CI~MPR is now also known as the M6P/IGFIT receptor. 
This receptor binds IGFIT. which is non~glycosylated. and 
phosphomannosylated proteins at distinct sites (Fig. 4) 
[86,87]. The M6P/IGFIT receptor is involved in the 
activation processes of seveml precursor proteins, such as 
procathepsin D and the latent form of tr.:ID.Sforming growth 
factor beta [88,89]. In view of the fact that we observed 
not only MPR-dependent binding and internalization of 
renin and prorenin. but also activation of prorenin to renin. 
it seems logical to assume that the MPR involved in these 
processes is the M6P/IGFll receptor. 
The M6P/IGFIT receptor consists of a large extracellular 
domain. containing 15 repeat regions. and a small cyto~ 
plasmic domain (Fig. 4). The extracytoplasmic domain of 
the CD~MPR is similar to each of the repeating units of the 
extracellular domain of the M6P/IGFII receptor. suggest~ 
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ing that the two receptors may be derived from a common 
ancestor [90]. The M6P/IGFIT receptor exists as a mono-
mer, whereas the CD~MPR exists as a monomer. dimer or 
tetramer [84,91]. MPRs cycle constitutively among the 
Golgi. endosomes. and the plasma membrane. The majori-
ty (90%) of the M6P/IGFII receptors is located in a late 
endosomal/prelysosomal compartment. with the rest being 
distributed over the plasma membrane. early endosomes. 
and the Golgi [92]. Extracellular lysosomal enzymes which 
bind to the cell surface M6P/IGFII receptor are internal-
ized via clathrin-coated pits. They dissociate from the 
receptor in acidified endosomal compartments and are 
subsequently delivered to lysosomes. The receptor is then 
reutilized; it can undergo many rounds of ligand delivery 
[92-95]. Binding and internalization of IGFIT to the M6P/ 
IGFIT receptor results in the lysosomal degradation of this 
ligand [96]. In addition, IGFIT mediates growth-stimulatory 
responses via this receptor [97]. At present it is not clear 
what the function of the M6P/IGFIT receptor with regard 
to (pro)renin is: clearance, coupling to second messengers 
[52]. or facilitation of local angiotensin production (Fig. 
3)? The idea of prorenin contributing to local angiotensin 
production is ann:tctive. in view of the fact that the 
prorenin concentrations in the circulation are tenfold 
higher than those of renin. 
COOH COOH 
cation-Dependent 
M-6-P Receptor-
Extr-acytosollc 
Cytosolic 
Fig. 4. Schenw.tic represent:ltion of the illlliliiOse 6-phosphate receptors. The two ligand.~ of the cation-independent llllliliiOSC 6-pho:;phate :1re depicted. 
Arginine residues at positions 435 and 1334 in domains 3 and 9, respectively,= essential for high-affinity binding of nw.nnosc 6-phospb.ate. Sequences in 
domain 11 :1re involved in binding in.~ulin-likc growth factor (lGF) n. Modified from Refs. [81.82]. 
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8. Role of alternative angiotensin generating 
pathways 
It bas been suggested. on the basis of in~vitro experi-
ments. that Ang II synthesis may occur independently of 
renin and ACE. The candidates that are generally assumed 
to replace renin and ACE are cathepsin D and chymase. 
respectively. Cathepsin D is a lysosomal enzyme that 
cleaves angiotensinogen. unlike renin. at low pH [98.99]. 
Consequently. measurement of Ang 1-genemting activity at 
acidic pH will yield results that are representative for 
lysosomal cathepsin D rather than renin. Studies in which 
Ang !-generating activity is quantitated as a measure for 
renin activity should therefore always be performed in the 
absence and presence of specific renin inhibitors to correct 
for non-renin-dependent Ang I generation. Evidence that 
cathepsin D is of importance in vivo is currently lacking. 
Under circumstances where cardiac angiotensinogen levels 
are high and cardiac renin levels are low or undetectable 
(e.g .• after nephrectomy). cardiac Ang I and II levels are 
close to or below the detection limit [2432]. Moreover, in 
human heart homogenates renin levels correlated nega~ 
tively with angiotensinogen levels, thereby suggesting 
angiotensinogen consumption by renin at cardiac tissue 
sites [53]. Studies in the isolated perfused heart also do not 
support a role for cathepsin D. since angiotensin generation 
in this preparation only occurred after the addition of renin 
to the perfusion buffer [37-40]. 
Chymase is a serine protease present in the cardiac 
interstitium. and cardiac mast cells and endothelial cells 
are sites of chymase biosynthesis and storage [100]. 
Remarkably. chymase is the main enzyme in human heart 
homogenates responsible for Ang I-ll conversion [101]. In 
contrast. Ang I-ll conversion in the coronary vascular bed 
of intact humans and pigs depends on ACE only 
[65.102,103]. This raises the question whether chymase is 
of importance in vivo. Kokkonen et al. [104] have sug~ 
gested that interstitial fluid contains an endogenous inhib~ 
itor of chymase. a 1 ~antitrypsin. which would normally 
suppress any chymase-depcndent Ang I-ll conversion. 
However. the inhibitory effect of ot 1 ~antitrypsin may be 
limited to tissue homogenates only. since it could not be 
demonstrated in an intact preparation [105]. Cardiac 
chymase mRNA levels are unaltered in subjects with heart 
failure [60]. More detailed knowledge on the in~vivo role 
of chymase will be obtained once specific chymase in~ 
hibitors are available. 
9. Regulation of cardiac angiotensin generation 
All RAS components arc present in cardiac tissue. and 
both Ang I and IT are generated in the heart. However, the 
renin responsible for this local angiotensin production 
originates from the circulation and is therefore lddney~ 
derived. Thus. a local RAS in the sense that all RAS 
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components are synthesized in situ does not appear to exist 
in the normal heart This does not mean that cardiac 
angiotensin synthesis occurs in parallel with angiotensin 
generation in the circulation. There still are many ways by 
which the heart may regulate its Ang I and IT con~ 
centrations independent of the circulating levels of these 
RAS components. Membrane binding could be a mecha~ 
nism by which renal renin is sequestered in the heart The 
density of the binding sites involved in the uptake process 
may vary. and this could modify the cardiac production of 
Ang I and IT. Interestingly. the inactive precursor of renin, 
prorcnin, also binds to these binding sites and becomes 
activated following internalization [16.41]. It is not yet 
known what enzyme(s) is/are responsible for the prorenin~ 
to-renin conversion step. Their concentration may decrease 
or increase under different circumstances. In addition. one 
has to keep in mind that normally the circulating levels of 
prorenin arc approximately 10~fold higher than those of 
renin. 
Cardiac ACE levels will also influence local Ang :a 
production. These are determined. at least in part. by the 
so-called insertion/deletion polymorphism [62]. Further~ 
more. enzymatic degradation of Ang IT and AT1 receptor-
mediated endocytosis could influence the Ang IT con~ 
centrations at the cellular and subcellular level. Finally. 
under certain pathological conditions renin and/ or an~ 
giotensinogen may be produced in the heart itself and this 
would create the possibility for the heart to regulate its 
own Ang IT production. independent of lddney and liver. 
More detailed knowledge on the actual sites of Ang :a 
production in the heart and on its regulation under 
pathological conditions will further illuminate the role of 
the RAS in cardiac function. growth, and remodelling. and 
will help us to understand the beneficial cardiac effects of 
ACE inhibitors, AT 1 receptor antagonists and renin in~ 
hibitors. 
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Chapter3 
Functional Importance of Angiotensin-Converting 
Enzyme-Dependent In Sitn Angiotensin ll Generation in 
the Human Forearm 
Jasper J. Saris, Marjan A. van Dijk, Ingrid Kroon, Maarten A.D.H. Schalekamp, A.H. Jan Danser 
Abstract-To assess the importance for vasoconstriction of in situ angiotensin (Ang) IT generation, as opposed to Ang II 
delivery via the circulation. we determined forearm vasoconstriction in response to Ang I (0.1 to 10 ng · kg- 1 • min-1) 
and Ang IT (0.1 to 5 ng • kg-1 • min-1) in 14 nonnotensive male volunteers (age 18 to 67 years). Changes in forearm 
blood flow (FBF) were registered with venous occlusion plethysmography. Arterial <J.Dd venous blood samples were 
collected under steady-state conditions to quantify forearm fractional Ang 1-to-II conversion. Ang I and II exerted the 
same maximal effect (mean±SEM 71±4% and 75±4% decrease in FBF. respectively), with similar potencies (mean 
EC:;0 [range] 5.6 [0.30 to 12.0] nmol/L for Ang I and 3.6 [0.37 to 7.1] nmol/L for Ang II). Forearm fractional Ang 1-to-II 
conversion was 36% (range 18% to 57%). The angiotensin-converting enzyme (ACE) inhibitor enalaprilat (80 ng • kg- 1 • 
min-1) inhibited the contractile effects of Ang I and reduced fractional conversion to 1% (0.1% to 8%). thereby 
excluding a role for Ang I~to-TI converting enzymes other than ACE (eg, cbymase). The Ang II type 1 receptor 
antagonist losartan (3 mg • kg-1 • min-1) inhibited the vasoconstrictor effects of Ang TI. In conclusion. the similar 
potencies of Ang I and n in the forearm. combined with the fact that only one third of arterially delivered Ang I is 
converted to Ang TI. suggest that in situ-generated Ang TI is more important for vasoconstriction than circulating Ang 
TI. Local Ang IT generation in the forearm depends. on ACE exclusively and results in vasoconstriction via Ang IT type 
1 receptors. (Hypernnswn. 2000;35:764-768.) 
Key Words: angiotensin • angiotensin-converting enzyme inhibitors • receptors. angiotensin IT • blood flow 
C ircula.ti.ng angiotensin (An g) I is converted to Ang II in many vascular beds.1..s The functional importance of this 
locally generated Ang II compared with arteri::illy delivered 
Ang II is currently unknown. Organ bath experiments in 
which the contractile responses of isolated human or porcine 
coronary arteries were recorded have shown that Ang I and 
Ang II display similar vasoconstrictor potencies,6.7 despite 
the fact that the levels of Ang II in the bath fluid during 
exposure to Ang I are <1% of those during exposure to Ang 
II,6 These in vitro experiments therefore suggest that locally 
generated rather than circulating Ang II mediates vasocon-
striction. A study of the local generation of Ang II and its 
vasoconstrictor effects in perfused rat hindquarters, in which 
the venous Ang II levels after the infusion of renin were 
compared with those after the infusion of Ang I or II, also 
indicated that vasoconstriction was caused by local Ang JI 
rather than by Ang II in the perfusion buffer.~ 
Two enzymes have been reported to contribute to Ang 
I-to-11 conversion: ACE and chymase. ACE is present both in 
circulating blood plasma and on the membrnne of vascular 
endothelial cells. whereas chymase is located in the adventi-
34 
tia. in the cytosol of mast cells.9•10 Although the results of in 
vitro studies in isolated human vessels6•7 and tissue homog-
enatesn.t~ support the contribution of chymase to Ang I-to-11 
conversion. in vivo studies do not support this view, because 
ACE inhibition suppressed Ang I-to-11 conversion in the 
human and porcine coronary vascular beds by >90%.3·1' 
However. coronary Ang I-to-II conversion in these latter 
studies was quantified with systemic or intracoronary infu-
sions of t:::sl-labeled Ang I. an approach that does not allow 
the detection of Ang II generation with chymase in the 
adventitia if such generation does not result in Ang II 
overflow into the blood compartment Moreover. contractile 
effects were not quantified in these studies. 
It was the aim of the present study to compare the in vivo 
potencies of Ang I and II to assess the functional importance 
of loc::illy generated Ang II. Ang I and Ang II were infused 
into the brachial artery, and forearm vasoconstriction was 
recorded under steady state conditions. Forearm Ang 1-to-II 
conversion was quantified with measurment of the venous 
Ang I and II levels at steady state. Infusions were made in the 
presence and absence of the ACE inhibitor enalaprilat and the 
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Ang IT type 1 (AT1) receptor antagonist losartan to investigate 
(I) whether enzymes other than ACE contribute to the local 
generation of Ang II and (2) whether Ang II mediates 
vascular effects through receptors other than the AT1 
receptor. 
Methods 
Subjects 
Fourteen whlte male volunteers (mean age 39 years, fll.Dge 18 to 67 
years: mean weight 83 kg, range 64 to 107 kg) were recruited via 
advertisement after the Medie::tl Ethics Committee of the Leiden 
University Medie::tl Center approved the protocol of the study. All 
participant.~ gave their informed CODSent. Medical hi~tory. physical 
examination. and routine laboratory tests did not reveal any abnor-
malities. All subject.~ were on a normal-sodium diet (-180 mmolld), 
and none of them received medie::ttion. Subjects did n01: smoke. and 
they refrained from the consumption of alcohol or caffeine-
containing substances for ~12 hours before the experiment 
Experimental Set-Up 
Each experiment wa.~ performed with the subject in the ~'Upine 
position in ::t quiet room at a constant temperature of 22° to 24°C, 
Forearm and hand volumes were mea.~ured with water di~'J)lacernent 
Onc-le:~d ECG wa.~ monitored continuously. After local anesthesia 
v.ith I% lidocaine, the brachial artery of the nondom.inant arm was 
cannulated. The cannula (1.0X45 mm) was connected to a Statham 
P"..3Id pressure transducer (Gould Inc). Dmgs were infused into the 
brachial anery v.ith Harvard Apparatus volumetric precision pumps 
(model 22). Both forearms were instrumented with mcrcury-in-
Silastic strain gauges. which were connected to a Hok:mson EC-2 
plethy~mograph. Both upper arms were connected to a Hokanson 
E-10 rapid cuff inflator. For the measurement of forearm blood flow 
(FBF), R wave-triggered cuff inflation (at 40 mm Hg) for venous 
occlusion plethysmography wa.~ controlled v.ith a personal comput-
er.14 FBF was mea.~ured 4 times per minute, and the final 6 
measurement~ at the end of each dose step. when a ste:~dy state had 
been reached, 1 ~ were used for further analysis. During e:~cb infu~ion 
experiment, the hands were continuously excluded from the circu-
lation v.ith the inflation of small wrist cuffs to a minimum of 
40 mm Hg above systolic blood pressure. Heart rate from the ECG, 
intra-arterial blood pressure, and left and right FBF values were 
recorded on ::t polygraph (Gould Inc) and on a personal computer 
v.ith an analog-to-digital conVt.:rter (model DT 2801: Data Transla-
tion Inc). 
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Study Protocol 
Figure 1. Schematic presentation of infu~ 
sion experiments. Top, Intra-arterial infu-
sion protocol. In experiments 2 and 4, 
continuous infusion 2 was started 3 min-
utes after start of continuous infusion 1. 
In all experiments, infusion 3 was started 
5 minutes after start of infusion 1; infu-
sion 3 consisted of 3 dose steps that 
lasted 5 minutes each. Blood sampling 
{BS) occurred under baseline conditions, 
before start of Infusions, and at end of 
each dose step of infusion 3, when a 
steady state had been reached. Bottom, 
Infusion rates in ng • kg-1 • min-1• SNP 
indicates sodium nitroprusside: Ang, an-
giotensin: anal, enalaprilat; and los, 
losartan • 
The infusion ~indies were started :?::60 minutes after the cannulation 
of the brachial artery. Between the various infusion experiments., the 
wrist cuffs were deflated. and sufficient time (minimum of 45 
minutes) wa.~ taken to allow the subjects to recover from hand 
ischemia and to allow FBF to return to baseline levels. The protocol 
is summarized in Figure I. Baseline arterial and venous blood 
samples were taken before the start of the infu:tions. Steady-state 
venous blood samples were obtained at the end of each Ang infusion. 
Sodium nitroprusside was used to predilate the vascular bed of the 
forearm to ... 5 mL • 100 mL-1 ·min-' because me:u."'l!ements of 
vasoconstrictor effects are more accurate when flow levels remain at 
>1 mL ·100 mL-1 • min-1• 10 
Blood Sampllllg 
Blood for Ang measurement~ was rapidly drawn with a plastic 
syringe containing the following inhibitors (0.25 mL inhibitor 
solution in 5 mL blood): 6.25 mmo1/L disodium EDT A. 
1.25 mmol/L 1.10-phenanthroline. and 0.01 mmol/L concentration 
of the renin inhibitor remikiren (Gnal concentrations in blood). The 
blood was tran~ferrcd into prechilled polystyrene tubes and centri-
fuged at 3000.;: for 10 minutes at 4°C. Plasma was stored at -70°C. 
Measurement of Ang I and IT 
Baseline arterial and venous Ang I and TI concentrations were 
measured with radioimmunoassay. after ScpPak extraction and 
hlgh-perfonnance liquid chromatographlc separation, as described 
previously.2.J The high Ang concentration.~ in the venous samples 
collected under ~ieady state condition.~ at the end of each infusion 
were measured without prior high-perfonnance liquid chromato-
graphic separation. 6 
Data Analysis 
Data were nonnally distributed and are expressed as mean:tSEM. The 
Ang-induced effect.~ are expressed as percentage change in FBF of the 
infu.o;ed fore:utn. The percentage change was calculated relative to the 
values mea.~-ured at baseline (ie, at the beginning of infu,ion 3) (Figure 
I). The steady state arterial Ang pl::tsma concentratioDS (in pmol/L) 
during the infu:.ions were calculated a.~ follows: [Ang].,_-..y ..... "" 
IRXBWXI0"/[(1-Ht)XFBFXFAVXMW]+[Ang].,_ ,_u.,. where IR 
is Ang I or D infusion rate (in ng • kg-1 • min- 1). BW is body weight (in 
kg). Ht is hematocrit, FA V is forearm volume. MW is molecular weight 
of Ang I or D. and [Ang].,._ _,,..is arterial Ang I or TI concentration at 
baseline. 
Fractional conversion and degradation of Ang I (ie, the percentage 
of arterially delivered Ang I that is converted to Ang U or degraded 
into other metabolites) and fractional degradation of Ang TI (ie. the 
35 
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Figure 2. Percent change of forearm blood flow (FBF) ln 
response to Ang I without {0) or with (e) enalaprilat and to Ang 
II without (0) or with (a) losartan. Data are mean:=SEM of 14 
experiments. 
percentage of arterially delivered Ang n that is degrnded) in the 
fore= were calculated as described previously.::..' 
EC-o values (ie. the arterial Ang I or II concentration at which 509'o 
of the maximal effect is :~chicved) were calculated from the arterial 
plasma concentrations :md the oorre..'q)Onding FBF Vlllues with 
4-panuncter logistic regression analysis (lnPJot 2.0; GraphPAD 
Softw=).1~.11 
Student's t test and AN OVA for repeated measures were used for 
statistical evaluation. Values of P<O.OS were considered statistically 
signifi=t. 
Results 
Baseline arterial Ang I and II levels (6.9:t::0.6 and 2.7±0.2 
fmollmL. respectively) were comparnble to baseline venous 
Ang I and II levels (10.8±2.3 and 3.0:::!:0.2 fmollmL. respec~ 
tively). Baseline Ang levels were unrelated to age or weight 
FBF did not change in the noninfused control arm during 
the infusions, nor did the Ang infusions affect heart rate and 
blood pressure (data not shown). 
Ang I and IT reduced FBF by a maximum of 71±4% and 
75±4%. respectively. with comparable potencies (EC,0 
5.6±1.0 and 3.6±0.5 nmol/L respectively; P=NS) (Figure 
2). En::tlaprilat virtually completely blocked the constrictor 
effects of Ang I. Los::trtan blocked the vasoconstrictor effects 
of Ang IT; in fact. a tendency for a vasodilator effect (P=NS) 
was observed at the 2 lowest doses of Ang IT in the presence 
of this drug. 
Fractional Ang I conversion was similar at all Ang I doses 
and was reduced to very low v::tlues in the presence of 
enalaprilat (Table). Fraction::tl Ang I and II degradations were 
higher at the high doses than .at the low doses of these 
pcptides. most likely because of the reduced FBF at these 
high doses. In support of this assumption. FBF correlated 
negatively with fraction::tl Ang I and II degradation (fractional 
Ang I degradation=-0.06XFBF+0.69 [r=0.56. P<0.05] 
and fractional Ang II degradation=-0.06XFBF+0.97 
[r=0.76, P<O.Ol]). The relationship between FBF and Ang 
degradation was unaltered with enalaprilat and losmtan (data 
not shown). 
Discussion 
The results of the present study provide in vivo evidence in 
humans that in situ-generated Ang II is more important for 
vasoconstriction than circulating Ang IT. This conclusion is 
based on 2 findings. First. Ang I and Ang II induced forearm 
vasoconstriction with similar potencie..'>. despite the fact that 
only one thlrd of Ang I was converted to Ang II in the 
forearm circulation. Second. the venous Ang II levels at the 
highest Ang I infusion rate in the presence of enalaprilat were 
comparable to the venous Ang II levels at a 50-fold lower 
Venous Angiotensin Levels, Fractional Ang I Conversion, and Fractional Ang I and II 
Degradation During Infusion of Ang 1 or II Wrth or Without Concomitant Infusion of ACE 
Inhibitor Enalaprilat (80 ng • kg-1 • min-1) or AT, Receptor Antagonist Losartan 
(3000 ng · kg-1 • min-1) 
lnfuslon Rate, ng • kg-1 • mln-1 
Aog I Ang I+ Enalaprilat 
Parameter 0.1 1.0 10 0.5 5.0 50 
Ang I, pmoi!L 43::'::6 304.:!::56 1691.:!::334 583::'::108 6583::'::1029 46161:!:6243 
Ang II, pmoVL 70.:!::5 544.:!::96 5307.:!::1037 29:!:5 103:!:30 662.:!::193 
Fractional Ang 1 41;!;3 32::!:3 34=2 2±1t 1±1t 1±ot 
conversion, % 
Fractional Ang I 48::!:2 62:!:2* 64::!:2* 38;!;7 48:!:8 68=5' 
degradation, % 
Ang II Ang II+Losartan 
0.1 
" 
5.0 0.1 OS 5.0 
Ang 1!, pmoVL 97:!:10 458:!:66 4283:!:627 97::!:7 443;!;62 3743:!:498 
Fractional Ang II 64.:!::4 78:!:3* 68::!:3" 48:!:4 58;!;4 76::!:3* 
degradatlon, % 
Data are mean±SEM (n-14). 
w P<0.01 vs lowest Infusion rate. 
tP<0.001 vs withol.lt enalaprHat 
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Ang I infusion rate without cnalaprilat. yet vasoconstriction 
was observed only in the latter case. These results conflllll 
previous in vitro observations of the importance of local Ang 
II in rats and huma.ns.6.s They are also in agreement with 
recent studies that show that despite the fact that ACE is 
present in the plasma of tissue ACE knockout mice, these 
a.nim:lls display the same hemodynamic :md vascular abnor-
malities as mice that are completely ACE deficient. 11'·1Q The 
potencies obtained for Ang I and IT in the present study were 
in the nanomolar r.mge. which is in agreement with the 
known affmity of AT receptors for Ang rr.:o.z1 It is therefore 
unlikely that vasoconstriction during Ang I infusion was 
mediated by Ang I. 
In contrast with fmdings in isolated human blood ves-
sels.6.7ZZ we did not obt:rin evidence for chymase-depeodent 
vasoconstriction in the human forearm. The ACE inhibitor 
enalaprib.t not only blocked forearm Ang I-to--IT conversion 
by >95% but also almost completely inhibited Ang !-in-
duced va.~oconstriction. It is unlikely that the absence of a 
cbymase-mediated effect in the present study is due to the 
inability of arterially infused Ang I to reach vascular chymase 
(ie. to diffuse into the adventiti.a10). It has been previously 
dcmonstr.ued that circulating Ang I and Ang IT both rapidly 
diffuse into the interstitial space.23.!4 Furthcnnore. studies in 
which the chymase-specifie substrate [Pro11.D-Ala1z]Ang I 
was administered intravenously to marmosets or hamsters 
showed clear dose-dependent pressor effects of this peptide 
that could not be blocked with an ACE inhibitor.:-.:s.z~ The 
discrepancy between in vitro and in vivo studies with regard 
to the importance of cbymase might be due to the presence of 
an endogenous chymase inhibitor. a:1-antitrypsin., in intersti-
tial fluid. Z7 However, such in vivo chymase inhibition is not 
in agreement with the vasoconstrictor effects obtained with 
[Pro11 .n-Ala1lAng 1.:1.!1.7.0 Moreover. a 1-antitrypsin appeared 
to inhibit chymase in tissue homogenatcs oolyP.m not in 
intact preparations.6.m A more likely explanation therefore is 
disruption of mast cells during tissue storage or preparation. 
which will result in chymase concentrations in vitro tha.t are 
far above those in vivo. 
The forearm Ang 1-to-II conversion rate obtained here is 
in agreement with previous studies in which forearm 
conversion was calculated during the infusion of 1:::sl-
labeled Ang F In those studies. the levels of 1:::si-Ang II 
that were obtained at steady state were too low to induce 
vasoconstriction. Remarkably. despite the clear dose-
dependent vasoconstriction that occurred in the present 
study. fractional forearm Ang 1-to-II conversion remained 
constant at all FBF values. In contrast. fractional forearm 
Ang I and II degradation correlated inversely with FBF. 
This latter finding is not surprising. because at lower flow 
rates. more time is available for metabolism. The fact that 
Ang I-to-II conversion was not related to FBF suggests that 
(1) it is a highly efficient process with a maximal result 
even at high flow rates and (2) conversion most likely 
precedes degradation (ie, that ACE might be located 
predominantly in the anerioles). 
In the present study. losartan. a competitive AT1 receptor 
antagonist,z9 fully prevented vasoconstriction at the 2 lowest 
Ang II doses and in l:u-ge part (>70%) inhibited vasocon-
striction at the highest dose of Ang II. These data are in 
agreement with the contention that Ang II induces vasocon-
striction in the human forearm through the activation of AT1 
receptors. 
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Abstract 
Objective: The hypertrophic response of cardiomyocytcs exposed to mechanical stretch is assumed to depend on the release of 
angiotensin (Ang) ll from these cells. Here we studied the synthesis of renin-angiotensin system (RAS) components by cardiac cells 
under basal conditions and after stretch. Methods: Myocytcs and fibroblasts were isolated by enzymatic clissoci:lti.on from hearts of 
1-J.d:l.y-old Wistar rat strain pups. grown for I day in serum-supplemented medium and then cultured in a chemically defined. serum-free 
medium. Medium and cell lysate were collected 5 days later or after exposure of the cells to cyclic stretch for 24 h. Proreni.n, renin and 
angiotensinogen were meusured by enzyme-lcinetic assay; Ang I and Ang II were measured by ra.dioimmuno:l.SS:ly after ScpPak elCtraction 
and HPLC separation. Results: Prorenin, but none of the other RAS components, could be detected in the medium of both cell types. 
However, its levels were low and the Ang 1-gener.:tting activity corresponding with these low prorenin levels could not be inhibited by the 
specific ra.t renin inhibitor CH-732. suggesting that it was most likely due to bovine and/or horse prorenin sequestered from the 
serum-containing medium to which the cells bad been exposed prior to the serum-free period. When incub:l!ed with Ang L both myocytcs 
and fibroblasts gcner.:ttcd Ang II in a captopril-inhibitable manner. Myocyte and fibrobla'>T. cell lysates did not contain prorcnin. renin. 
angiotcnsinogen. Ang I orAng II in detectable quantities. Stretch increased myocyte protein synthesis by 20%. but was not accompanied 
by Ang II release into the medium. Conclusion: Cardiac myocytcs and fibroblasts do not synthesize renin. prorenin or angiotensinogen in 
concentrations that are dctcct:lble or. if not detectable. high enough to result in Ang II concentrations of physiological relevance. These 
cells do synthesize ACE. thereby allowing the synthesis of Ang II at cardiac ti.<;.<;ue sites when renin and angiotcnsi.nogen are provided via 
the circulation. Ang II is not a prerequisite to observe a hypertrophic response of eardiomyocytes following stretch. © 1999 Elsevier 
Science B:V. All rights reserved. 
Keywords: Angiotens~ ACE inhibitor: Myocyt(!S; Renin-angiotensin ~)'Stem: Stretch 
1. Introduction 
The existence of a local renin-angiotensin system 
(RAS) in the heart. often invoked to explain the beneficial 
effects of ACE inhibitors in heart failure [1.2}. is sti.ll a 
controversial issue. The presence of RAS components in 
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cardiac tissue [3-5] cannot be taken as direct evidence for 
local production of these components. One or more 
components may have been sequestered from the circula-
tion. For instance. circulating renin may bind to cardiac 
cell receptors and to renin binding proteins in the heart 
[6-8]. and circulating Ang n is known to accumulate in 
cardiac tissue via AT 1 receptor-mediated endocytosis [9]. 
The levels of renin and angiotensinogen mRNA in the 
Renin-angiotensin system components in cardiac cells 
heart are low or undetectable [10-13]. thereby suggesting 
that the presence of these components in cardiac tissue 
may indeed depend on uptake rather than local production. 
The uncertainties concerning local synthesis arising from 
tissue measurements can be avoided when measurements 
are made in cells cultured in the absence of serum. The use 
of serum-free culture medium is necessary to exclude the 
uptake of RAS components present in serum. 
Most so--called renin-expressing extrarenal cells produce 
prorenin rather than renin. These cells do not store 
prorenin and secrete it in a constitutive manner [14-17]. 
With regard to cardiomyocytes, both Dzau andRe [18] and 
Dostal et al. [19] reported on the presence of renin in these 
cells. No distinction between renin and prorenin was made. 
nor did these authors determine (pro)renin release into the 
culture medium. Constitutive secretion of angiotensinogen 
bas also been described [20-22]. The single report on the 
synthesis of angiotensinogen by cardiac cells focuses on its 
presence in these cells [19]. ACE. a cell membrane-bound 
enzyme. has been demonstrated in cardiac cells by en-
zyme-kinetic and immunohistochemical methods [23-26]. 
According to seveml investigations. serum-deprived 
cardiac cells release angiotcnsins into the culture medium. 
The Ang I and II levels in the medium. however, show 
huge variations. from <10 fmol/ml to >1000 fmollml 
[23.26-29]. Ang II in the medium increased 100-fold after 
the induction of mechanical stretch [27]. possibly by 
release from intracellular storage sites [23.27]. and this 
cell-derived Ang II may play a role in the stretch-induced 
hypertrophic response of cardiomyocytes [26-29]. 
It was the aim of the present study to investigate the 
synthesis of RAS components by neonatal rat car-
diomyocytes and fibroblasts by measuring renin. prorenin., 
angiotensinogen. Ang I and Ang II in the medium and cell 
lysate of serum-deprived cells with the help of well-
established biochemical techniques. Cellular ACE activity 
was investigated by quantifying Ang 1-to-II conversion by 
intact cells in the presence and absence of captopril. 
Stretch-induced release of angiotensin II and its role in 
cellular hypertrophy were examined in cardiomyocytes 
exposed to cyclic. circular stretch for 24 h. For com-
parison, studies were also performed in cells cultured in 
the presence of serum. 
2. Materials and methods 
2.1. Reagents 
Fetal calf serum. horse serum, penicillin and strep-
tomycin were purchased from Boehringer Mannbeim 
(Mannbeim. Germany). Dulbecco's modified Eagle's 
medium (DMEM) and Medium 199 were from Gibco. Life 
Technologies (Middlesex. UK). Trypsin (type ill) and 
captopril were from Sigma (St Louis, MO. USA). Metha-
nol and ortho-phosphoric acid (both analytical grade) were 
from Merck (Dannstadt. Germany). Ang I was obtained 
from Bachem (Bubendorf. Switzerland). eHJ-leucine was 
from Amersham (Buckinghamshire. UK). The rat renin 
inhibitor CH-732 was a kind gift of Dr. M. Szelke. Ferring 
Research Institute. (Southampton. UK) [30]. Rat renin was 
prepared from rat kidneys as described before [31]. Human 
recombinant prorenin was a gift of Dr. W. FtSchli (Hoff-
mann-La Roche. Basel. Switzerland). Angiotensinogen 
was prepared from plasma of nephrectomized rats [31]. 
2.2. Cell culture 
All experiments were performed according to the regula-
tions of the Animal Care Committee of the Erasmus 
University, Rotterdam. The Netherlands, in accordance 
with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23. revised 1996). 
Primary cultures of neonatal ventricular cardiomyocytes 
and fibroblasts were prepared from 1-3-day-old Wistar 
strain rats as described before [32]. Briefly. ventricles from 
newborn 1-3-day-old WtStar rats were minced, and cells 
were isolated by eight subsequent trypsini.r..ation steps at 
30°C. Non-cardiomyocytes were separated from the car~ 
diomyocytes by differential preplati.ng. Cardiomyocytes 
were seeded in 20-cm2 culture dishes (Falcon. Becton & 
Dickinson, Plymouth. UK) at 1.5·105 eells/cm2, giving a 
confluent monolayer of spontaneously contracting cells 
after 24 h. The preplated cells (fibroblast fraction) were 
passaged after 4 days. using a 0.02% trypsin-0.05% 
EDTA solution. in 20-cm2 culture dishes at 0.75·105 cells/ 
cm2• The cells were maintained at 3rC and 5% C02-95% 
air in 5 ml culture medium consisting of DMEM and 
Medium 199 (4:1), supplemented with 5% fetal calf serum. 
5% horse serum. 100 U penicillin/ml and 100 ~g strep-
tomycin/ml. After incubation for 24 h. cells were either 
serum-deprived or maintained in serum-supplemented cul-
ture medium for 5 days. 
2.3. Collection of medium and cells for the measurement 
of RAS components 
Cardiomyocyte- and fibroblast-conditioned culture 
medium (5 ml} was collected for the measurement of RAS 
components after the cells had been maintained with or 
without serum for 5 days. The RAS component content of 
unconditioned medium. i.e. medium that had not been in 
contact with either cardiomyocytes or fibroblasts. was also 
studied. Medium for the measurement of prorenin, renin 
and angiotensinogen was frozen at -70"C without the 
addition of inhibitors. Medium for the measurement of 
Ang I and II was mixed with 250 ~ angiotensinase 
inhibitor solution (containing 125 mmol/l disodium EDTA 
and 25 mmolll1.1Q..phenanthrolinc) and frozen at -70°C. 
To measure RAS components in the cells, each well was 
washed three times with 6 ml ice-cold phosphate buffered 
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saline (PBS: 140 mmol/1 NaCL 2.6 mmol/1 KCL 1.4 
mmol/1 KH2P04• 8.1 mmol/1 Na2HP04, pH 7.4). After 
washing. cells used for the measurement of prorenln. renin 
and angiotensinogen were lysed in 0.5 ml ice-cold PBS 
containing 0.2% Triton X-100, and the celllysates were 
quickly frozen on dry ice. Cells used for the measurement 
of Ang I and IT were scraped with a rubber policeman in a 
volume of0.5 ml ice-cold PBS. The cell-PBS mixture was 
centrifuged at 1000 g at 4°C for 1 min. after which the 
pellet was homogenized in 0.5 ml 0.1 mol/1 HCI-80% 
ethanol using a hand-operated douncer. The ethanol was 
evaporated under vacuum rotation at 4°C using a Speed 
Vac Concentrator (Savant Instruments. Farmingdale. NY, 
USA). The concentrated homogenates were dissolved in 
0.5 ml 1% ortho-phosphoric acid and applied to SepPak 
columns (see Section 2.6). 
2.4. Angiotensin Mo-ll conversion by ACE 
To determine whether 5-day-old cardiomyocytes and 
fibroblasts contain ACE. Ang 1-to-.ll conversion by these 
cells was studied in the presence or absence of captopril 
(final concentration in the medium: 0.5 IJlD.Ol!ml). Ang I 
was added to the medium (final concentration: 1 pmol! 
ml). and 150 f.Ll samples were obtained over a period of 40 
min (from cells culrured in the presence of serum) or 120 
min (from cells culrured in the absence of serum). The 
samples were rapidly mixed with 10 f.Ll angiotensinase 
inhibitor solution and frozen at -70°C. No corrections 
were made for the small volume changes (approximately 
3% per sample) occurring as a consequence of fluid 
sampling. Ang I~to-IT conversion was also studied in 
unconditioned medium. 
2.5. Angiotensin II generation during stretch of 
cardiomyocytes 
To study the generation of Ang TI during prolonged 
stretch and its contribution to the increased protein syn~ 
thesis occurring under these conditions. cardiomyocytes 
were subjected to cyclic. circular stretch for 24 h. Follow~ 
ing isolation (see Section 2.2) the cells were seeded in 
fl.exible~bottomed 6-well culture plates (type I collagen~ 
coated. 5 em? /well: Flexcell. Hillsborough. NC. USA). 
They were maintained at 37°C and 5% C02-95% air in 1 
ml culture medium consisting of DMEM and Medium 199 
(4:1). supplemented with 5% fetal calf serum. 5% horse 
serum. 100 U penicillin/ml and 100 J,Lg streptomycin/ml. 
After 24 h the medium was replaced by DMEM and 
Medium 199 (4:1). supplemented with 4% horse serum. 
100 U penicillin/ml and 100 J,Lg streptomycin/ml. The 
stretch experiment was performed 4S h later under serum~ 
free conditions. The cells were preincubated for 30 min 
with 1.5 ml serum~free medium. The 6-well plates were 
then placed on a Flexcell Strain Unit (FX-2000. Flexcell). 
and the cells were stretched at 30 cycles per minute (1 s 
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strain. 1 s relaxation) at 20% elongation for 24 h. Control 
cells. grown on non~fl.exible~bottomed culture plates. were 
studied in parallel. For comparison. control cells cultured 
on non~fl.exible-bottomed culture plates were also incu-
bated for 24 h with endothelin-1 (ET-1; final concentration 
in the medium: 10-s molll). an agent known to induce 
protein synthesis in cardiomyoeytes [32.33]. 
The effect of stretch on protein synthesis was evaluated 
by adding em~leucine to the medium (final concentration: 
0.5 J,LCi/ml) of control-. stretched- and ET-1-treated cells 
2 h before the end of the 24 h study period. After 24 h. 
incorporated em-leucine was determined as described 
before [33]. Total cellular protein was measured after 24 h 
in control-. stretched- and BT-l-treated cells that had not 
been incubated with em-leucine, using the Bradford assay 
[34]. Cellular hyperplasia was investigated by measuring 
optical density after incubation of the cells for 2 h at 37°C 
with (3-[4,5dimethylthiazol~2-yl]-2.5-diphenyltetrazolium 
bromide (MTI), an agent which is converted to the 
colored product formazan via intact mitochondria. A 
change in optical density correlates directly with a change 
in cell number [35]. 
The effect of stretch on Ang I and II synthesis was 
studied by collecting 0.15 ml samples from the culture 
medium of each well of two 6-wcll plates after 1, 2. 6, and 
24 h. The twelve 0.15 ml samples obtained at each time 
point were added together and mixed with 0.1 ml angioten-
sinase inhibitor solution (final volume 1.9 ml). All samples 
were stored at -70°C. 
2.6. Biochemical measurements 
2.6.1. Renin and prorenin 
Renin was quantified in duplicate by measuring Ang I 
generation at pH 7.4 during incubation at 37'C for 2-4 h 
with a sarurati.ng concentration of rat angiotcnsinogen in 
the presence angiotensinase-. ACE- and serine protease-
inhibitors [4.7]. Two different inhibitor solutions were 
used. one with and one without the rat renin inhibitor 
CH-732 (final concentration in the incubation mixture: 5 
J.LIDOl/1). Inhibition of rat kidney renin is >95% at this 
concentration (Fig. 1). Ang I was measured with a 
sensitive radioimmunoassay [36]. The lowest renin level 
that could be detected was 1.0 fmol Ang 1/min per ml 
medium and 0.5 fmol Ang I/ min per 106 cells. 
Prorcnin was first converted into renin by proteolytic 
activation and then also measured with the above assay. 
Based upon our experience with the activation of prorenin 
in tissues [4.7]. two different activa.tion procedures were 
tested, i.e. acidification only or acidification followed by 
treatment with plasmin at neutral pH. Medium or cell 
lysate were acidified by dialysis at 4°C for 4S h against 
0.05 mol/1 glycine buffer. pH 3.3. containing 0.001 mol/1 
disodium EDTA and 0.095 mol/1 NaCl. This was followed 
by either 1) dialysis at 4°C for 24 h against 0.1 mol/1 
phosphate buffer. pH 7.4. containing 0.001 mol/1 disodium 
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Fig. L Dose-dependent inhibition of rat kidney renin by increasing 
concentrations of the mt renin inhibitor CH-732. 
EDTA and 0.075 mol/1 NaCl or 2) quick adjustment of 
pH to 7.4 with 1 mol/1 NaOH and the subsequent addition 
of 0.1 volume of a solution of human plasmin (final 
concentration: 0.5 casein units/ml) in 0.15 mol/1 NaO and 
incubation at 4°C for 48 h. Acid-treatment followed by 
restoration of pH to 7.4 and treatment with plasmin led to 
virtually complete activation of prorenin. as was demon-
strated by the >90% conversion and recovery of human 
recombinant prorenin that had been added to the samples 
before the activation procedure (n=3). Acid-treatment 
followed by restoration of pH to 7.4 without subsequent 
plasmin treatment led to less complete activation of 
prorenin; the recovery of added prorenin. measured as 
renin. was 45-55% (n=3). All samples were therefore 
activated by the combined acid~and~plasmin method. 
2.6.2. Angiotensirwgen 
The concentration of angiotensinogen was determined as 
the maximum quantity of Ang I that was generated during 
incubation for 1 hat 37'C and pH 7.4 with rat kidney renin 
in the presence of a mixture of angiotensinase~. ACE- and 
serine protease~inhibitors [431]. The lowest level of 
angiotensinogen that could be measured was 0.1 pmol per 
ml medium and 0.05 pmol/106 cells. 
2.6.3. Angiotensin I and II 
The Ang I and TI concentrations in medium collected 
during the measurement of ACE activity were measured 
directly with sensitive radioimmunoassays [36]. Measure~ 
ments were made in 50 Ml medium. The lowest measurable 
Ang I concentration was 15 fmollml. and the lowest 
measurable Ang TI concentration was 10 fmol!ml. 
In all other samples (medium and cell homogenates) 
Ang I and TI were measured by radioimmunoassay. after 
SepPak extraction and reversed~phase high-performance 
liquid chromotography (HPLC) separation (36]. 1z.s-I-
labeled Ang I was added to the samples before SepPak 
extraction. to determine the recovery of Ang I and TI. The 
recovery was better than 90%. and the Ang I and TI results 
were not corrected for incomplete recovery. The lower 
limit of detection for Ang I and Ang TI in the culture 
medium were 0.2 and 0.1 fmollml. respectively. In cell 
homogenates. it was 0.3 and 0.2 fmol/106 cells. 
2. 7. Calculations 
Ang I is eliminated by conversion to Ang TI by ACE. 
and by breakdown into small biologically inactive peptides 
by various other enzymes. The latter process is referred to 
as degradation of Ang I. The first order rate constants for 
Ang I degradation (k1} and conversion (k2 ) were calculated 
as described before (36]. The percent contribution of 
conversion to the total metabolism of Ang I is defined as 
follows: 
Contribution of conversion to metabolism(%} = 
[k,f(k, +k,)J X !00%. 
2.8. Statistical analysis 
Results are expressed as mean::!::SD. One~way analysis 
of variance (ANOVA) followed by appropriate post~hoc 
tests (Student's t~test for paired observations, with Bonfer-
roni correction) was used for comparison between groups. 
Values of P<O.OS were considered significant 
3. Results 
3.1. Renin, prorenin and angiotensirwgen 
Renin and prorenin were detectable in unconditioned 
fetal calf serum- and horse serum-supplemented medium 
(Fig. 2). The Ang !~generating activity corresponding with 
these renin and prorenin levels was not inhibited by the rat 
renin inhibitor CH-732 (5 ~ol/1). which suggests that 
CH~732. at this concentration. does not inhibit bovine or 
horse renin. Following 5 days of incubation with either 
cardiomyocytes or fibroblasts. the levels of renin and 
prorenin in serum-supplemented medium were unchanged. 
Renin was undetectable in cardiomyocyte. and fibroblast-
conditioned. serum-deprived medium. Low levels of 
prorenin were present in the cardiac cell-conditioned. 
serum~free media. but they were not inhibited by CH-732. 
indicating that the Ang I generation we measured after in 
vitro prorenin activation was not caused by rat renin. Both 
renin and prorenin were undetectable in cell lysates of 
serum-deprived cardiomyocytes and fibroblasts .. 
Low levels of angiotensinogen were detected in un-
conditioned. serum-supplemented medium. which did not 
change after 5 days of incubation with cardiac cells (Fig. 
2). These levels therefore most likely represent bovine and 
horse angiotensinogen. Angiotensinogen was undetectable 
in cardiomyocyte- and fibroblast-conditioned serum-free 
medium and in the lysates of these cells. 
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modi urn 
Fig. 2. Renin. prorcnin. nnd angiotensinogen levels in unc<~nclitioncd 
medium (n=3), cardiomyocyte-~.:onditioned medium (n=S), and fibro-
bla.o;t-conditioned medium (n=S) with (open bars) or without (hatched 
b:m;) senun. Addition of the specific mt renin inhibitor CH-732 (5 
fLillO!II) did not affect the outcome of the renin and prorcnin me<~.~ure­
menl'l (data not :ffiown). Data are me:m:!:S.D .. The dotted line represents 
the limit of detection. Renin :md :mgiotensinogen were below the 
dete<:tion limit in the cell.-conditioned serum-free media. 
3.2. Angiotensin 1-to·.Jl conversion by ACE 
Ang I added to unconditioned serum-supplemented 
medium was rapidly metabolized. Ang IT being a major 
metabolite (Fig. 3). Captopril prevented the formation of 
Ang IT completely. On the basis of the difference in Ang I 
metabolism with and without captopril it could be calcu-
lated that more than 90% of the Ang I metabolism in 
unconditioned serum-supplemented medium was due to 
ACE-dependent Ang I-to-II conversion (Table 1). During 
incubation with unconditioned serum-deprived medium. no 
significant Ang I metabolism could be demonstrated over a 
period of 2 h. 
Ang I metabolism in cardiomyocyte and fibroblast cell 
cultures that had been maintained for 5 days in the 
presence of serum tended to be more rapid than Ang I 
metabolism in unconditioned serum-supplemented medium 
(Fig. 3). Ang II was again a major metabolite, and 
captopril prevented its formation completely. In both cell 
cultures, approximately 80% of Ang I metabolism was due 
to ACE-dependent Ang 1-to-II conversion (Table 1). 
Ang I added to serum-deprived cardiomyocyte and 
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Fig. 3. Metabolism of :mgiotensin I added to unconditioned medium (top 
p:mel~. n=4), S~y-old cardiomyocytc culture.~ (middle p:mel~. n=6) 
:md 5-day-old fibrobla.~t cultures (bottom panel~. n =3) with (left panels) 
or without (right p:mels) serum. Data. which are exprcs.'led a.~ a pcrcentasc 
of the angiotensin I levels in the medium :ll t=O, are mcruJ~S.D.; where 
no S.D. is given. it wa.~ ml:lllcr than the ~)'lllbol. Oosed symbols 
represent Anf: L open ~ymbol~ represent Ang n. CAPT. experiment in the 
presence of c:tplopril (0.5 J,tmol/ml). 
fibroblast cell cultures was also converted to Ang IT. and 
captopril inhibited the formation of Ang II completely 
(Fig. 3). This indicates that. in the absence of serum. 
cardiomyocytes and fibroblasts contain detectable ACE 
activity. Approximately 60-70% of the Ang I metabolism 
was due to ACE (Table 1). 
3.3. Angiotensin I and II 
Low levels of Ang I and II were present in uncon-
ditioned serum-supplemented medium (Table 2). These 
levels remained low or decreased to levels below the 
detection limit after 5 days of incubation with car-
diomyocytes or fibroblasts. The cellular levels of Ang I 
and II at that time were also close to or below the detection 
limit of our assays (Table 2). Ang I and II were undetect-
able in cardiomyocyte- and fibroblast-conditioned serum-
deprived medium and could also not be demonstrated in 
cell homogenates of cardiomyocytes and fibroblasts that 
had been serum-deprived for 5 days (Table 2). 
Ang I and II were also undetectable in medium collected 
from cells that had been serum-deprived for 1 h (n = 3. data 
not shown). This excludes the possibility that Ang I and II 
are released by the cells at the start of the 5-day period and 
subsequently metabolized during further incubation. 
Renin-angiotensin system components in cardiac cells 
Table I 
Half-lives (1 11~) and notorder rote constantll for degradation (k,) and convenion (k::l of angiotensin I added to unconditioned culture medium, 5-day..old 
=diomyocytc cultures or 5-d:ly-old brobla.~tcultures in the absence or presence of 0.5 IL!llOlfml captoprila 
Unconditioned medium Cardiomyocytes Fibrobklsts 
(n=4) (n=6) (n=3) 
Wah serum 
t 11: without captopril (b) 0.63::!:0.35 0.27:!::0.03 0.30:!:0.02 
t ,, with c:1ptopril (h) 4.35::!::0.90• 1.53::!:0.37* 2.22::!:1.08'" 
k, (b"') 0.17:!::0.03 0.62:!:0.16 0.46::':0.15 
Is (h"') 1.69:!:0.77 2.13::!:0.22 1.92::!:0.09 
Conven~ion (%) 93::!:10 79::!:4 81:!:6 
Without scru.m 
t 1n without captopril (b) No mebboli.~m 1.42:!:0.33 3.22±0.10 
! 110 with captopril (b) No mct:lboli~m 4.15:!::1.52'" 14.0::!:1.97* 
k, (h"') 0.31::!:0.09 0.05:!::0.01§ 
k: (h"') 0.42::!:0.17§ 0.17:::0.01§ 
Conversion(%) 56::!:9 76::!:4 
nThe culture medium was either serum..deprivcd or conbined 5% fetal c;ili" = :md 5% bon;e l\e1"lllll. The percentage ofmebboli.~m due to angiotensin 
l-to-n conversion by ACE is given for each condition.Y:Ilues are me:m:!:S.D. *P<O.Ol without captopril vs. with captopril. §P<0.05 without serum vs. 
with serum. 
3.4. Angiotensin Il generation during stretch of 
cardiomyocytes 
Cyclic, citcular stretch of cardiomyocytes for 24 h led to 
the expected increase in protein synthesis rate and total 
cellular protein. although the effects were modest as 
compared to those observed after 24 h of exposure to ET -1 
(Table 3). Using the MIT assay, no change in cell number 
was observed following stretch (n=3. data not shown). 
This indicates that stretch induced cellular hypertrophy 
rather than cellular hyperplasia. Ang I in the medium of 
control cells and cells exposed to stretch was close to the 
detection limlt at 1 h after the start of the experiment 
( <0.2- 0.7 fmol/ml and <0.2- 0.8 fmol/ml. respectively; 
range of 3 experiments) and decreased to undetectable 
levels during prolongation of the experiment Ang [[ was 
undetectable at all time points. both in the medium of 
control cells and in the medium of stretched cells. Expo-
sure to ET-1 also did not result in Ang I orAng IT release 
(Table 3). 
T:lble 2 
4. Discussion 
This srudy indicates that cultured neonatal rat car-
diomyocytes and broblasts do not synthesize renin, 
T:lble 3 
['H)-Leucine incorporation. total cellular protein. and the angiotensin I 
and II level~ in the medium of untreated cardiomyoeytes (control), 
cardiomyocytes exposed to cyclic stretch for 24 h (stretch) and car-
diomyoeytes inculxlted with 10· ~mol/! endothelin-1 (ET-1) for 24 h" 
Control 
'"'"" 
ET·I 
Incorporated 19 5992:!:215 7300:!:283~ 9479:!:397~ 
['H)-leucine (dpm/well) 
Total cellular protein 19 0.15:!:0.01 0.17:!:0.01* 0.18:!:0.01* 
(mg/well) 
Aog I <0.2 <0.2 <0.2 
(fmol/ml medium) 
Aogll <0.1 <0.1 <0.1 
(fmollml medium) 
a Ang, angioten.~in. Value.~ are me:m:!:S.D. *P<0.05 vs. control 
Angioten.~in level~ in the medium were below the detection limit 
Angioten.~in I and II levels in unconditioned medium (n "'3), and in conditioned medium (n=5) and celllys:rtes (n =5) of 5-day-old cardiomyocyte..~ and 
5-d:l.y-old broblm;l.'! cultured in the p=nce or absence of serum" 
Medium Cells 
Unconditioned Cnrdiomyocyte- Fibrobln.~t- Cardiomyoeytes Fibroblns!s 
(fmollml) conditioned conditioned (fmol/106 cells) (fmol/10 cell~) 6 
(fmol!ml) (fmol/ml) 
With serum 
Aog I 1.3:!:0.3 2.1:!:1.2 <0.6:!:0.4 <0.5:!:0.2 <03 
Aogll 0.4:!:0.3 0.9:!:0.4 <0.1 <0.2 <0.2 
Without serum 
Aogl <02 <0.7:!:0.3 <0.6:!:0.3 <0.3 <0.3 
Aogll <0.1 <0.1 <0.1 <0.2 <0.2 
a Ang. :mgiotensin. Values are me:m:tS.D. If one or more values wru; below the detection limit, thi~ is denoted as <mean:!: S.D. If all values were below 
the detection limit thi~ is denoted n.~ Jes.~ than detection limit. 
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prorenin. or angiotensinogen in concentrations that are 
detectable or. if not detectable. high enough to result in 
Ang I or Ang II concentrations of physiological relevance. 
Both types of cardiac cells do appear to synthesize ACE. 
and thus are capable of converting Ang I into Ang II. 
Evidence for the presence of other enzymes capable of 
converting Ang I into Ang IT (e.g., chymase [37]) was not 
obtained. 
All RAS components are present in serum-containing 
medium. and will therefore be detected when measure. 
ments are made in the medium of cells cultured in the 
presence of serum. We used the specific rat renin inhibitor 
CH-732 [30.38] to distinguish Ang I generation by rnt 
renin from Ang I generation by other enzymes. such as 
bovine renin and/ or horse renin. The latter two are present 
in the fetal calf serum and horse serum applied in the 
present study to obtai.n cell adherence and conflueocy prior 
to serum-deprivation, and both renins are known to react 
with rat angiotcnsinogen [17.39]. 
No CH-732 inhibitable Ang !-generating activity could 
be detected in the medium of cells maintained in the 
presence of serum. whereas Ang I generation in medium of 
serum-deprived cells was below the detection limit A 
possible explanation for this lack of renin release from rat 
cardiac cells might be that extrarenal cells release prorenin 
rather than renin [14-17]. However. although the Ang 
1-genemting activity of medium obtained from cells cul-
tured with serum increased nearly 10-fold following 
prorenin activation. it could again not be inhibited by 
CH-732. Moreover. the levels of prorenin measured in 
serum-supplemented conditioned medium did not differ 
from those in serum-supplemented unconditioned medium. 
Thus. the increase in Ang !-generating activity following 
activation is most likely due to the activation of bovine 
and/ or horse prorenin. 
Interestingly, medium of cells cultured in the absence of 
serum also contained low levels of prorcnin. None of the 
Ang 1-generating activity corresponding with these 
prorenin levels could be inhibited by CH-732. nor did the 
prorcnin levels differ between cardiomyocytes and fibro-
blasts. Most likely therefore, this prorenin represents 
bovine and/or horse prorenin trapped or bound by the cells 
during their incubation in the presence of serum and 
released back into the medium during incubation under 
serum-deprived conditions. In support of this assumption. 
we have recently shown that neonatal rat cardiac cells. 
during incubation with prorenin. are capable of binding 
and internalizing prorenin. and that membrane-bound. non-
internalized prorenin is released back into the medium 
when the cells are subsequently incubated with fresh 
medium without prorenin [8]. Uptake of renin and/ or 
prorenin might also explain the presence of renin in rat 
cardiac cells described by others [18.19]. The lack of Ang 
1-generating activity in lysates of serum-deprived cells in 
the present study may be due to metabolism of (pro)renin 
following internalization. 
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The low levels of angiotensinogen present in uncon-
ditioned serum-supplemented medium (corresponding to 
<5% of the normal plasma angiotensinogen levels in the 
rat) did not change during incubation with cardiac cells. 
nor did the cells release angiotensinogen into the medium 
when incubated under serum-free conditions. All other 
cells described to synthesize angiotensinogen [20-22] 
release this substrate into the medium. without storing it 
intracellularly. In vivo. angiotensinogen also appears to be 
limited to the extracellular fluid compartment [45.31]. 
Therefore, our data do not support synthesis and/or release 
of angiotensinogen by neonatal rat cardiomyocytes or 
fibroblasts. 
In view of the absence of (pro)renin and angioten-
sinogen synthesis by cardiac cells. it is not surprising that 
Ang I and II were below the detection limit in medium 
samples obtained from cardiomyocytes and fibroblasts 
incubated in the absence of serum. This finding contrasts 
with data obtained by others [23.26-29]. who found 
angiotensin levels ranging from <10 to >1000 frnol!ml 
in medium of serum-deprived cardiomyocytes and fibro-
blasts. Part of this discrepancy may be due to the fact that 
angiotensins in other studies were measured directly by 
rndioimmunoassay, an approach which may result in an 
overestimation of the true angiotensin levels [40]. Further-
more. it must be kept in mind that in view of the levels 
measured in cardiac tissue in vivo (Ang I,""5 frnol/g: Ang 
IL""20 frnollg) (3.4.41.42] even levels of 5-10 fmol per 
ml medium are very high. since in most studies only 1 to 4 
million cells are incubated with a few milliliters of 
medium. 
Sadoshima et al. [27] found the Ang II concentration in 
the medium of serum-deprived neonatal rat car-
diomyocytes to increase nearly 100-fold upon stretch. This 
Ang II. which is assumed to be responsible for the 
hypertrophic response of cardiomyocytes after the induc-
tion of stretch [26-28], appeared to originate from in-
tracellular storage sites. Since neonatal mt cardiomyocyw; 
do not synthesize renin and angiotensinogen in detectable 
quantities, the Ang II in these storage sites may be derived. 
via AT1-receptor mediated endocytosis [9]. from the 
serum-containing medium used to culture the cells prior to 
stretch. We studied intracellular storage and stretch-in-
duced release of Ang II by measuring angiotensin levels in 
the cells after 5 days of incubation with serum and in the 
s-erum-free medium at various time points after the initia-
tion of stretch. Ang II was below the detection limit under 
all conditions. Yamazaki et al. reported that the con-
centration of exogenous Ang II needed to exert a similar 
hypertrophic response as stretch is ""10-s mol/1 [28]. In 
our cells. such concentrations of Ang II were found to 
induce near-maximal hypertrophic effects [33]. Although 
in the present study Ang II was undetectable (i.e .• < 10- 1 ~ 
mol/1). the well-known increase in cellular protein syn-
thesis did occur in response to stretch. It appears therefore 
that the stretch-induced hypertrophic response of car-
Renin-angiotensin system components in cardiac cells 
diomyocytes observed here was independent of Ang rr. In 
support of tbls conclusion. we could not inhibit the stretch~ 
induced hypertrophic response in cardiomyocytes with the 
AT1 receptor antagonist losartan (unpublished observa~ 
tions). Similarly. others observed hypertrophic responses in 
stretched cardiomyocytes obtained from angiotensinogen~ 
or AT1 receptor-deficient mice. and in isolated. buffer" 
perfused rat or guinea pig hearts (which do not contain 
renin [31]) exposed to increased systolic load [43-46]. 
The absence of Ang II release following stretch in the 
present study does not correspond with several earlier 
studies showing an upregulation. at the expression level, of 
renin [47], angiotensinogen [27.29.47-50]. and ACE 
[47,49]. Although differences in experimental conditions 
(presence/ absence of serum. static/ cyclic stretch) may 
have played a role, a more likely explanation for this 
discrepancy is that the increases in expression may not 
have been translated to the protein level. Indeed. despite 
the increases in ACE mRNA that have been described after 
stretch [47.49]. Miyata et al. [26] were unable to observe 
an increase in ACE activity in stretched cells. Possibly. the 
low mRNA levels of RAS components in cardiac cells. 
which in most cases can be detected only after>25 cycles 
of PCR. are the result of illegitimate transcription [51] 
and/ or do not play a physiological role [13]. 
Taken together, our data. obtained in neonatal rat 
cardiac cells. do not support the concept of cardiac 
angiotensin generation independent of kidney and liver. At 
present it is not known to what degree results obtained in 
neonatal cells can be extrapolated to adult cells [29]. Lack 
of renin synthesis by cardiac cells does not necessarily 
implicate that angiotensins are not generated locally in the 
heart. In fact. we have recently shown in pigs that the 
majority of cardiac Ang I and Ang II is synthesized at 
tissue sites by renal renin [4.42]. Possibly therefore, renin 
and/ or prorenin need to be taken up from the circulation in 
order to generate angiotensins locally in the heart IS]. 
Angiotensinogen diffuses freely from the blood into the 
interstitial fluid compartment, and may react with renin or 
activated prorenin on or in the cardiac cells [31]. ACE 
appears to be the only RAS component involved cardiac 
Ang II generation that does not have to be sequestered 
from the circulation. 
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Mannose-6-phosphate (man-6-P)(msulin-like growth fac-
tor-II (man-6-P/IgF-ID receptors are involved in the activa-
tion of recombinant hlllll3D. proreoin by cardiomyocytes. To 
investigate the kinetics of this process, the nature of activa-
tion, the existence of other prorenin receptors, and binding of 
native prorenin, neonatal rat cardiomyocytes were incubated 
with recombinant, renal, or amniotic fluid prorenin with or 
without man-S..P. Intact and activated prorenin were mea-
sured in cell lysates with prosegment- and renin-specific 
antibodies, respectively. The dissociation constant (Kd) and 
maximum number of binding sites (Bmnx) for prorenin bind-
ing to man-6-P/IGF-II receptors were 0.6 ± 0.1 nM: and 
3,840 ± 510 receptors/myocyte, respectively. The capacity for 
prorenin internalization was greater than 10 times Bmnx. 
Levels of internalized intact prorenin decreased rapidly 
(half-life "" 5 ± 3 min) indicating proteolytic prosegment 
removal. Prorenin subdivision into man-S..P-free and man-6-
P-containi.ng fractions revealed that only the latter was 
bound. Cells also bound and activated renal but not amniotic 
fluid prorenin. We concluded that cardiomyocytes display 
high-affinity binding of renal but not extrarenal prorenin 
exclusively via man-6-P/IGF-II receptors. Binding precedes 
internalization and proteolytic activation to renin thereby 
supporting the concept of cardiac angiotensin formation by 
renal prorenin. 
local renin-angiotensin system; cardiomyocytes; fibroblasts; 
heart; kidney 
THE BE};'EFJCIAL CARDIAC EFFECTS of angiotensin-convert-
ing enzyme (ACE) inhibitors in subjects with heart 
failure are usually attributed to interference of these 
drugs with ANG IT generation at cardiac tissue sites. 
Although initially it was thought that this generation 
depends on the de novo synthesis of renin in the heart, 
it is now well established that such synthesis does not 
occur either under normal circumstances (13, 24, 34, 
50 
35, 40, 56) or under pathological conditions (14, 31, 50). 
Therefore, the heart must sequester renin from the 
circulation to synthesize ANG IT locally. Renin may 
diffuse into the interstitial space (18, 28) or bind to 
renin receptors and/or renin-binding proteins (8, 46, 
53). Because renin in blood is predominantly present in 
the form of its inactive precursor prorenin (11), it is 
also conceivable that the heart sequesters prorenin 
instead of renin. This prorenin must then be activated 
locally. In support of this concept we recently demon-
strated that endothelial cells and cardiac myocytes and 
fibroblasts, which do not synthesize (pro )renin (1, 59), 
are capable of binding recombinant human prorenin to 
cell-surface mannose-6-phosphate (man-6-P)fmsulin-
like growth factor-IT (man-6-P/IGF -ID re<eptors (1, 58). 
Binding precedes rapid internalization and appear-
ance of renin-specific enzymatic activity. Furthermore, 
the receptors also bound and internalized recombinant 
human renin. It is well established that recombinant 
human prorenin produced in Chinese hamster ovary 
(CHO) cells contains the man~6-P signal that is re-
quired to bind to man-6-P/IGF-Il receptors (2, 25). This 
is not a unique property because many other prohor-
mones [e.g., latent transforming growth factor-13 (19), 
procathepsin D (29), and proliferin (39)] also cany the 
man-6-P recognition marker, and these prohormones 
(like prorenin) are activated after binding and inter-
nalization via man~6-PIIGF-II receptors. 
At present it is unlikely that the man-6-PIIGF-IT 
receptor is the only renin- and prorenin~binding recep-
tor, because excess man-6-P did not block prorenin 
binding to microsomal membrane fractions prepared 
from various rat tissues (53). In addition, it is not 
known whether intracellular prorenin activation oc-
curs proteolytically or nonproteolytically. Proteolytic 
activation involves the actual removal of the proseg-
ment by any of the known prorenin-renin convertases 
[e.g., cathepsin B (45),kallikrein (37), and prohormone 
convertases (51)]. Nonproteolytic activation implies 
transient unfolding of the prosegm.ent so that it no 
longer folds over the enzymatic cleft, thereby allowing 
prorenin to cleave angiotensinogen. In vitro, acid pH or 
cold storage favor the latter type of activation (21). 
Moreover, a recent study in mice has shown that non· 
proteolytically activated prorenin is capable of gener· 
ating ANG I at tissue sites in vivo (43). 
The aim of the present study was to investigate in 
neonatal rat cardiomyocytes and fibroblasts 1) the ki· 
netics of man·6·PIIGF .n receptor~dependent pro renin 
binding [dissociation constant (Kd), maximum number 
of binding sites (B=)] and activation; 2) the possibil· 
ity of prorenin binding independent of the man·6·P/ 
IGF·II receptor; 3) the nature of the prorenin activa~ 
tion (proteolytic or nonproteolytic) and, in case of 
proteolytic activation, the nature of the prorenin~acti­
vati.ng enzyme; and 4) possible differences between 
binding of recombinant human prorenin and binding of 
native human prorenin from renal and extrarenal 
sources. 
METHODS 
Cell culture. All experiments were performed according to 
the regulations of the Animal Care Committee of Erasmus 
University Rotterdam, Rotterdam, The Netherlands, and in 
accordance with the "Guiding Principles in the Care and Use 
of Laboratory Animals" as approved by the Council of the 
American Physiological Society. 
Primary cultures of rat neonatal cardiac cells were pre-
pared as previously described (57). Briefly, ventricles of 
WJ.Star strain rat pups (age 1-3 days) were minced and cells 
were dispersed by eight subsequent trypsmization steps. 
Nonmyocytes were separated from myocytes by differential 
preplating. Myocytes were seeded in noncoated 12·well 
plates (Corning Costar Europe; Badhoevedorp, The Nether-
lands) yielding a confluent monolayer of spontaneously beat-
ing cells at 1.5 X 105 cells/cm2 after 24 h. The preplated cells 
(fibroblast fraction) were passaged after 4 days to noncoated 
12·well plates yielding a confluent monolayer of 0. 75 X 105 
cells/cm2 after 2 days. The cells were maintained for 72 h in 
a humidified incubator at 37"C with 5% C02 in air and 1.5 ml 
of growth medium consisting of a 4:1 (vollvol) ratio ofDMEM 
(GffiCO Life Technologies; Breda, The Netherlands) and 
medium 199 (GffiCO) supplemented with 5% FCS (Roche 
Diagnostics; Almere, The Netherlands), 5% horse serum 
(Sigma-Aldrich; Zwijndrecht, The Netherlands), 100 U/ml of 
penicillin (Roche), and 100 mg/ml of streptomycin (Roche). 
The incubations with prorenin (see Incubation of cells with 
prorenin at 4 or 3'rC) were carried out under serum-free 
conditions. Before the start of each experiment, cells were 
washed with 1 ml of warm (37°C) PBS consisting of(in mM) 
140 NaCI, 2.6 KC!, 1.4 JaVO~ and 8.1 Na,HPO, (pH 7.4). 
The cells were then preincubated either at 4 or 37°C for 30 
min with 0.4 ml of incubation medium consisting of a 4:1 
(vollvol) ratio ofDMEM and medium 199 supplemented with 
1% (wtlvol) BSA (Sigma-Aldrich). 
Prorenin preparaticn. Recombinant human prorenin was a 
kind gift of Dr. S. Mathews (Hoffmann· LaRoche: Basel, Swit-
zerland). It was secreted by CHO cells transfected with a 
vector containing human prorenin eDNA To remove traces of 
renin, the prorenin was partially purified by Cibacron blue 
Sepharose affinity chromatography (Amersham. Pharmacia 
Biotech; Roosendaal, The Netherlands). The intrinsic renin 
activity of the prorenin preparation before proteolytic activa· 
tion was <2% of the activity after complete proteolytic acti· 
vation when the prorenin preparation contained -2 X 10:; 
un (4 eMJ renin. 
Prorenin uptake by cardiac cells 
Man-6-P receptor affinity chro11Udcgraphy. To separate 
prorenin into fractions that do or do not contain the man..S..P 
signal, recombinant human prorenin was applied to a 0.5-ml 
bovine liver man--6-P/IGF-ll receptor colw:on (kindly pro-
vided by Dr. S. Kornfeld, St. Louis, MO). The colw:on was 
equilibrated with colw:on buffer containing 50 mM imidazole 
at pH 6.5, 150 mM NaCl, 5 mM Na-~ycerophosphate, 0.1% 
(wtlvol) BSA, 6 ~ antipain, 8 ~ leupeptin, 6 ~ pepstatin 
A, 7 vM chym.ostatin (all from Sigma-Aldrich), and 10 kal-
likrein inhibitory U/ml of aprotinin (Bayer; MJjdrecht, The 
Netherlands) (26). All manipulations were performed at 4°C. 
After the application of recombinant human prorenin (500 
units in 0.1 ml of colw:on buffer), the colw:on was washed 
with colw:on buffer ("colw:on runthrough"). Subsequently, 10 
mM man-6-P was added to the colw:on buffer and man-6-P-
containing prorenin was eluted. Prorenin was measured in 
0.5-ml fractions. Fractions corresponding to colw:on run· 
through (ie., man-6-P·free prorenin) and man..S..P-contain· 
ing prorenin were separately pooled, concentrated, and ad-
justed to contain PBS (pH 7.4) by Centricon C-30 ultrafiltration 
(Amicon Bioseparations; Bedford, MA). 
lncubaticn of cells with prorenin at 4 or 3'rC. After prein· 
cubation at 4 or 37°C for 30 min under serum·free conditions 
(see Cell culture), experiments were started by replacing the 
incubation medium by 4 or 37°C incubation medium contain~ 
ing either recombinant human prorenin (final concentration 
3-1,000 Ull), man·6-P-free recombinant human prorenin (10 
Ull), orman..S..P-containingrecombinanthuman prorenin (10 
Ull). Incubations at 37°C were also performed with pools of 
human plasma and human amniotic fluid diluted to a 1:3 
ratio with incubation medium. Plasma was obtained from 
subjects with renal artery stenosis (one man and two women, 
age 41-66 yr). Amniotic fluid was obtained from three 
women (age 19-38 yr) after natural delivery. All incubations 
at 4 or 37°C lasted 4 h and were performed in both the 
presence and absence of 10 mM man-6-P to determine man· 
6-P/IGF-ll receptor-specific prorenin binding (58). To inves--
tigate the intracellular presence ofman..S..P/IGF·ll receptors 
in myocytes, incubations with recombinant human prorenin 
(1,000 Ull) at 4°C were also performed after prior penneabi· 
lization of the cells with PBS containing 0.2% saponin 
(Merck; Amsterdam. The Netherlands) (52). Finally, to de-
termine what proteases axe responsible for prorenin activa-
tion, incubations at 37°C were performed in the presence of 
the following five protease inhibitors: 0.04 mM 4-(2-aminoeth-
yl).bem.enesulfonyl:fl.uoride hydrochloride (AEBSF, Calbiochem; 
LaJolla, CA); 0.1 mM leupeptio.; 0.14 mM L-tro.ns-3-carboxyoxi.· 
ran-2-carbonyl·L-leucylagm.atine (E64, Sigma-Aldrich); 1.0 mM 
1,10-phenanthroline (Merck); or 0.1 mM pepstatin A 
At the end of the incubation period the culture medium 
was removed. Each well was washed three times with 1 ml of 
ice-cold PBS. Prorenin was not detectable in the last PBS 
wash. Cells were then lysed in 0.2 ml of ice-cold PBS con~ 
taining 0.2% Triton X-100 (Merck), and the celllysates were 
quickly frozen on dry ice. Celllysates were stored at -70°C 
until assays for total and cell-activated prorenin were per~ 
formed. 
To determine whether prorenin had been internalized, the 
acid·wash method was used (58). At low pH surface-bound 
prorenin dissociates from the cells; internalized prorenin, 
however, is acid resistant. Briefly, after the cells had been 
washed three times with ice-cold PBS, cells were incubated 
at 4°C with 0.4 ml of an acid solution containing 50 mM 
glycine and 150 mM NaCl at pH 3.0. After 10 min the acid 
solution was removed, the cells were washed and lysed as 
descn'bed above, and the celllysates were stored at -70°C 
until being assayed. 
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Incubation of cells at 4°C follawed by incubatian at 37°C, 
To study the kinetics of proren.in activation in more detail. 
cells cultured in six~well plates (Coming Costar) were loaded 
with 1 m1 of recombinant human proreni.n-containing incu-
bation medium (final C{)ncentrat:ion 100 Ull) for 2 h at 4°C. 
After this period, free prorenin was removed by washing the 
cells three times with 3 m1 of i~ld PBS. After the last 
wash, 1 ml of fresh incubation medium without prorenin at 
37°C was added, and the cells were incubated at 37°C. The 
incubation was ternllnated after 15, 30, 60, 120, 180, or 240 
min by removing the culture medium and subsequently 
washlng the cells three times with 3 ml of ice-cold PBS. The 
cells were then lysed in 0.5 ml of ic!X<lld PBS containing 
0.2% Triton X-100 as described above. Culture medium and 
cell lysate were stored at -70°C until assays for total prore-
nin. cell-activated prorenin, and intact propeptide-eontaining 
prorenin were performed. 
Prorenin 'fYU!aSurement. In the experiments with recombinant 
human prorenin in myocytes. cell-activated prorexrin and total 
prorellin (ie., cell-activated plus nonactivated proreniD) were 
measured by immunoradiometric assay (IRMA). The proteo-
lytic activation of recombinant human prorenin by myocytes 
was monitored with an mMA specific for intact prorenin, i.e., 
prorenin in which the propeptide was still bound to the renin 
part of the molecule. The IRMAs axe not sensitive enough to 
measure the low levels of cell·activated and total recombinant 
human proren.in in :fibroblasts. The prorenin measurements in 
these cells were therefore performed by enzyme-kinetic assay. 
The renin and prorenin me.asurements in the experiments with 
human plasma and human amniotic fluid were also performed 
by enzyme-kinetic assay. 
Enzyme·kinetic assay. Cell-activated recombinant prore-
nin and native renin were measured by incubating a 100·~ 
sample for 3 h with a saturating amount of sheep renin 
substrate at 37"C and pH 7.4 in the presence of serine 
protease and angiotensinase inhibitors (58). The generated 
ANG I was quantified by RIA. Results were expressed as 
microunits per 1,000,000 cells or microunits per milliliter 
medium u.sillg plasmin-activated recombinant human prore-
nin as a reference. The lower limit of detection was 1 fJ.U/10G 
cells or 1 J.l.U/ml of medium. To measure total recombinant 
prorenin and native prorenin, the samples were first incu-
bated for 48 hat 4"C with plasnlln (0.5 caseinolytic U/ml, 
obtained from Chromogenix; MOlndal, Sweden). This prein-
cubation with plasnlln causes complete proteolytic activation 
of prorenin. The serine protease inhibitor aprotinin (:6nal 
concentration 100 kallikrein-inhibiting U/ml) was added to 
the incubation medium of the ANG !..generating step to 
inactivate plasnlln. 
lmmunoradiametric assays. The monoclonal antibodies 
C:MAb) used in these assays were MAb R3-36-16 (Nichols 
Institute; Wychen, The Netherlands), which reacts equally 
well with activated and nonactivated prorenin (Kd = 0.6 pM) 
Fig. 1. Ptorouin isoforms and recognition sites of the 
monoclonul antibodies u..'!Cd in the present study. 
(30), MAh R1-20-5 (Nichols Institute), which recognizes the 
active site of renin (Kd = 250 nM) (60), andMAhF258--37-B1 
(a kmd gift of Dr. S. Mathews, Hoffmann-LaRoche), which is 
directed against the COOH-terminal part IP20-P43) of the 
pNpeptide (Fig. 1) and does not react (<0.1%) with renin 
(F. H. M. Derkx, unpublished observation). MAbs R1-20-5 
and F258-37-B1 do not react (<0.1%) with intact inactive 
prorenin. However, they do react with prorenin after the 
treatment of pro renin with the renin inhibitor remikiren (0.1 
mM; a kind gift of Dr. W. Fischli, Hoffmann-LaRoche; Basel, 
Switzerland) for 48 hat 4"C (16). The renin inhibitor enters 
the enzymatic cleft in which the active site is located, thereby 
inducing a slow conformational change of the inactive 
("closed~) form of the prorenin molecule into the active 
("open") form. This non proteolytic conformational change not 
only allows subsequent recognition of the active site by MAb 
R1-20-5, it also causes the propeptide to move to the surface 
of the molecule so that it can react with MAh F258-37-Bl. In 
the IRMA for cell-activated and total prorenin, 200 ~ of 
untreated and remikiren-treated sample (diluted to a 1:9 
ratio in heat-inactivated sheep serum, obtained from Bio-
trading; Mijdrecht, The Netherlands), respectively, were in-
cubated for 6 hat 37"C with biotinylated MAb R3-36-16, 
LUI-labeled R1-20-5 (250,000 counts/min), and an avidin-
coated bead as described (15). In the IRMA for intact propep-
tide-containing prorenin, 250 ~ ofremikiren-treated sample 
(diluted to a 1:4 ratio in heat-inactivated sheep serum) were 
incubated for 6 h at37°C with an avidin--coated bead to which 
1.6 !J.g ofbiotinylated MAb F258--37-B1 had been bound (1). 
The bead was then washed three times with 2 ml of PBS 
containing 0.1% (wtfvoD BSA and subsequently incubated 
with 100 ~ (250,000 counts/min) ofUGI-labeledMAb R1-20-
5 and 200 ~of heat-inactivated sheep serum containing 0.1 
mM remikiren for 24 h at room temperature. After the 6-h 
and 24-h incubation periods, the beads in both IRMAs were 
washed three times with 2 m1 of PBS containing 0.01% 
(vol/vol) Triton X-100, and bound radioactivity was measured 
in a gamma-counter. The results of these assays were ex-
pressed as microu.nits per 1,000,000 cells usillg intact recom-
binant human prorenin as a reference. The lower limit of 
detection was 5 fJ.U/106 cells. 
Statistical analysis. Results are expressed as means :!:: SE. 
Data were compared u.sillg Student's t-test for paired obser-
vations or ANOV A. A value of P < 0.05 was considered to be 
significant. Binding data were analyzed by nonlinear regres-
sion analysis u.sillg the GraphPad Prism (version 3) computer 
program (GrapbPad; San Diego, CA.). 
RESULTS 
Incubation of myocytes and fibroblasts with recombi-
nant human, prorenin at 4 or 3'rC. Myocytes (Fig. 2) 
and fibroblasts (Fig. 3) bound recombinant human pro-
native. inactive 
prorenin 
non-protcolytic:::illy 
llctivated prorenin 
proteolytically llttivatcd 
prorenin ("'renin) 
0 RJ..36-Hi • F258-37-Bl • Rl-26-S 
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renin in a concentration-dependent manner at both 4 
and 37°C. Cell-associated prorenin at 37°C but not at 
4°C was acid resistant (data not shown), indicating 
that prorenin internalization occurred at 37°C only. 
For a given prorenin concentration in the medium, the 
level of cell~associated total prorenin after 4 h of incu~ 
bation was 10-15 times higher at 37°C than at 4°C. 
Binding of recombinant human prorenin to man-6-
P!IGF-II receptors: Kd ond B_ Man-6-P significantly 
reduced recombinant human prorenin binding in both 
myocytes (Fig. 2A) and fibroblasts (Fig. 3A). The reduc-
tion was much smaller in fibroblasts than in myocytes, 
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suggesting that fibroblasts may contain a second pro-
renin binding site that cannot be blocked by man-6-P. 
However, because the levels of cell-associated prorenin 
after 4 h of incubation in the presence ofman-6-P were 
similar in myocytes and fibroblasts, a more likely ex-
planation is that non-man-6-P/IGF-11 receptor-medi-
ated prorenin binding represents nonspecific binding 
and that the man-6-P-induced reduction in prorenin 
binding is smaller in fibroblasts because these cells 
contain less cell-surface man-6-P/IGF~II receptors. In-
deed, Scatchard analysis revealed that binding of pro-
renin to man~-P/IGF-11 receptors occurred with simi-
0 
Fig. 3. A: levels of cell·nssociuted total 
prorenin after incubation of fibroblasts 
with recombirumt human prorcnin at 
4"C for 4 h in the absence (e) or pres-
ence (O) of 10 mM man-6-P. Mon-6-P/ 
IGF-II-receptor-specific binding (t.) was 
taken as the difference between lcvclB of 
cell-ossocinted prorcnin with and with-
out mn.n-6-P. Datu arc mcuns :t SE; n = 
4. ~ and B"""' were culcWatcd from a 
plot according to Scatchard (inset). B: 
levels of cell-associated total (e) and cell-
activated (O) proronin after incubation of 
fibroblasts with recombinant hlllllDll 
proronin at 37"0 for 4 h. Data are 
mcuns :':. SE; n "'- 4, 
30 100 300 1000 
Prorenin in Medium (UIL) Prorenin in Medium {UIL) 
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4'C lar affinity in both myocytes CK, = 0.6 ± 0.1 nM; n = 8) 
and fibroblasts CK, = 0.8 ± 0.2 nM; n = 4) and that A 
Bmnx was 3,840 ::!:: 510 sites/myocyte and 650 :!:: 150 
sites/fibroblast. Prior permeabilization of myocytes 
with saponin increased man~G~P/IGF-ll receptor-de-
pendent prorenin binding 7.7 :!: 0.4-fold (n = 4), indi-
cating that >85% of the man--6-P/IGF-II receptors is 
located intracellularly. Recycling of these intracellular 
receptors to the cell membrane most likely explains 
why the levels of cell-associated prorenin at 37°C are 
much higher than at 4°C. 
• 
37'C 
• 
Does prorenin binding occur independently of man-
6-P/IGF-II receptors? To investigate whether prorenin 
binding occurs independently ofman-6-PIIGF-II recep-
tors, recombinant human prorenin was separated into 
man-6-P-free and man-6-P-containing fractions with 
• i • 
the help of a bovine man-&.P/IGF-11 receptor-af.finity 
column (Fig. 4). The amount of recombinant human B 
prorenin (38 ::!:: 1 %; n = 3) that was not bound by this 
column (which did not contain the man-6-P signal) 
resembled the amount of prorenin (38 ::!:: 2%) that 
eluted only after the addition ofman~S..P to the elution 
buffer (which did contain the man-6-P signal). The 
remaining prorenin eluted shortly after the first 
nmthrough peak (before the addition ofman~6-P) and 
was not investigated further. 
mPR mPR ... ~ 
• 
Incubation of myocytes and fibroblasts with man~6-
P-containingprorenin resulted in cellular pro renin lev~ 
els that were ""'1.5-2.5 times higher than observed 
after incubation with nonfractionated prorenin (Fig. 5). 
Assuming that only man-6-P/IGF-TI receptors are in~ 
volved in prorenin binding, this is exactly what one 
would predict when exposing cardiac cells to a prorenin 
solution in wbich either all or only .... 40% of the prore-
nin molecules carry the man~6-P signal. 
Incubation with man-S..P-free prorenin resulted in 
cellular prorenin levels that were equal to or lower 
than the levels observed after incubation with nonfrac-
l5 +recombinant human 
t prorenin 
0 
Fraction 
+Man-6-P 
t 
" 
Fig. 4. Bovine liver man-6-PJIGF-II receptor-nffinity chromatogra-
phy of recombinant humnn prorcnin. Representative cx=plc is 
shown. After npplic::Ltion of prorelrin (500 units), the column was 
washed with column buffer (see METHODS). Man-6-P-eontaining pro-
rerun was eluted with 10 niM man..&-P in column buffer. 
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rhPR rhPR 
Fig. 5. Levels of cell-nssocintcd total prorcnin after incubation of 
myocytcs (A) or fibroblasts (B) with non£ro.ctionntcd recombinant 
human prorelrin (rhPR. 10 UJI; control), man-6-P-eontaining recom-
binant human prorenin ~tiP> 10 UJI), or man-6-P-frce recombi-
nant human prorenin (PR...m_.MIIl'> 10 UJI) nt 4 or 37"C for 4 h in the 
absence (open burs) or presence {filled burs) oflO m:Mman..&-P. Data 
arc means:!: SE (n "' 3) expressed ns n percentage of the cellular 
levels of control. ~p < 0.05 vs. control at4"C; #P < 0.05 vs. control at 
37"C. 
tionated prorenin in the presence of man-6-P (Fig. 5). 
Because the latter level was similar for myocytes and 
fibroblasts (Figs. 2A and 3A), this level most likely 
represents nonspecific prorenin binding. Thus our find-
ings do not provide evidence for prorenin binding to 
receptors other than the man-6-P/IGF-IT receptor. 
Activation of recombinant human pro renin: effect of 
protease inhibitors. Activation of recombinant human 
prorenin was detectable at 37°C only (Figs. 2B and 3B). 
Saturation of the activation process did not occur be-
cause the percentage of cell~associated prorenin that 
was activated was similar at all concentrations of pro-
renin to which the cells were exposed [ranging from 
88 :±: 15% at 3 U/1 to 78 :±: 8% at 1,000 U/1 in myocytes 
(n = 7) and from 83 :±: 9% at 3 U/1 to 75 :±: 9% at 1,000 
U/1 in fibroblasts (n = 4)]. The serine protease inhibitor 
AEBSF partially blocked the activation of prorenin in 
myocytes but had no effect in fibroblasts (Table 1). 
None of the other protease inhibitors that were tested 
Prorenin uptake by cardiac cells 
Table 1. Effect of protease inhibitors on cellular levels of total (i.e., cell-activated and nonactivated) pro renin 
and cell-activated prorenin after incubating myocytes and fibroblasts for 4 hat 37"'C with 100 U/l 
recombinant human prorenin 
My- Fibroblast!! 
Typo Proteru<c Totnl prorcnin. Activntcd pw'<.'niD. Total prorenin, Activntcd Jmrcnin. 
Protcuse Jnhibit:Qr Inhibited %of Control % ofTotnl prorecin 
" 
%of Control % of Total prorecin 
Non~ 7 100:!: 18 75:!:6 5 100::!:24 77:!:.6 
PepstD.tinA Aspartic 4 109± 12 87:t3 4 115±10 87:=.7 
Loupcptin Serine und cysteine 5 143:!:5~ 85:!:8 4 179:!:18t 85±6 
AEBSF Serine 5 118::17 52:!:4* 4 73::6 71::10 
E64 Cysteine 5 136:': 10 70:!:11 3 136:!: 15 82:!:12 
1,10-Phenanthrolinc Metallo 5 111:!:17 69:!:9 4 72:!:20 64::!:6 
Data arc mellill:l:!: SE; n., no. ofmye>cytes or fibroblasts. AEBSF, 4-(2-nminoctbyl}-bcnzCD.osulfonyl£.uorido hydrochloride; E64. r..-trans..S.. 
cnrboxyo:ciron-2-c:ll'bonyl-L-loucylagmatino. *P < 0.05 vs. eontrol; tP < 0.01 vs. control. 
blocked pro renin activation in either myocytes or fibro-
blasts. The cysteine protease inhibitor E64 and the 
mixed serine--cysteine protease inhibitor leupeptin in~ 
creased the level of cell-associated total prorenin by 
40-50% in myocytes and by 40-80% in fibroblasts, 
thereby indicating that cysteine proteases contribute 
to (pro)renin degradation in cardiac cells. 
Proteolytic or nonproteolytic activation ofproren.in in 
myocytes. After 2 h of incubation at 4°C with 100 U/1 
prorenin and repeated washing with ice-cold PBS, the 
level of cell-associated total prorenin was 350 ::!: 45 
p..U/106 cells (n = 7). Acid wash confirmed that at that 
time, all cell~associated prorenin was located on the 
cell surface. Im.m.ediately after the temperature was 
raised to 37°C, the level of cell~associated intact (i.e., 
prosegment-containing) prorenin started to decrease. 
The decrease followed a biphasic pattern (Fig. 6). The 
first phase [half-life (t,,.) = 5 ::!: 3 min] corresponds with 
~ 80 
. 
c 
c 
' ~ 60 
• 
• ~ 40 
.! 
~ 20 0 
• 
minutes 
Fig. 6. Time course of internalization and proteolytic activation of 
proreni.n by myocytes. Cells were preineubaUld with rocombin.:mt 
human prorenin (100 Ull) fer 2 h at 4"C and were washed with 
ice-eold PBS. Fresh cultul'e medium free of prorenin was added and 
the incubation wns continued at 37"C. Data are means :!:: SE (n = 7) 
expressed ns o. percentage of the cellular levels of proreni.n at the 
end of the 2-h prcincubo.tion period (t = 0). Total proreni.n (•), 
cell-activated proreni.n (O), and intact proscgmcnt-containing prore-
nin (•l are shown. 
the release of cell-surface-bound intact prorenin into 
the medium and did not differ from the first phase that 
was observed for total prorenin (t,,.. = 4 ::!: 1 min). This 
phase is determined by the rapidity of the internaliza~ 
tion process. The second phase represents the proteo-
lytic removal of the prosegment from internalized pro-
renin (t,.., = 21 ± 4 min), because a rise in the cellular 
levels of activated prorenin was simultaneously ob-
served. These levels reached a maximum after 60 min 
and then started to decrease, with at,,., (67 ± 8 min) 
similar to that of the second phase of total prorenin 
(t,.., = 74 ± 5 min). Release of activated prorenin into 
the medium could not be demonstrated during the 6-h 
observation period (data not shown). Taken together, 
these findings suggest that prorenin, after its internal-
ization, is rapidly activated by proteolytic cleavage of 
the prosegm.ent and that activated prorenin is subse-
quently metabolized by degrading enzymes without 
being released into the medium. 
Incubation of myocytes with native hUTYIJln (pro)renin 
at 37'C. To verify man-6-P/IGF-11 receptor-dependent 
binding, internalization, and activation of native human 
prorenin of renal and nonrenal origin, myocytes were 
incubated at 37"C during 4 h with human plasma or 
human amniotic fluid (diluted to a 1:3 ratio with incuba~ 
tion medium) in the presence or absence of man~&-P . 
Expressed as a percentage of the sum of renin and pro-
renin, plasma and amniotic fluid contained 79 ::!:: 10% and 
94 ::!: 3% prorenin, respectively (Fig. 7). Incubation with 
plasma resulted in man-6-P/IGF~II receptor-mediated 
(pro)renin uptake by myocytes. After incubation with 
plasma, myocytes contained predominantly (>75%) re-
nin (Fig. 7). Because man-6-P/IGF-11 receptors bind and 
internalize man-6-P-containing renin and prorenin 
equally well (58), this is not due to selective uptake of 
plasma renin. The increased renin-to-prorenin ratio in 
celllysates therefore suggests that internalized plasma 
prorenin, like internalized recombinant human prorenin, 
is activated to renin by myocytes. The cellular (pro)renin 
levels after incubation with amniotic fluid were close to 
the detection limit and did not dilfer with or without 
man~6-P (Fig. 7). Thus amniotic fluid does not contain 
prorenin that carries the man-6-P signal. 
55 
ChapterS 
"' ~ 
E 
~ 
~ 
E 
c 
.. 
• ~ 
~ 
+IIGP 
Rocomblnont 
Human Prorvnln 
~ 
i 
~ [ 
~ , ,. 
"' §
'" ~~ 
Plasma Amnloticnuld 
Fig. 7. Levels of totnl prorciDn in medium and cell lysate after 
incubation of myocytcs with rceombinunt humun prorenin, humun 
plasma (diluted to 1:3 ratio in incubation medium), or humun ::unni.-
otic fluid (diluted to 1:3 rntio in incubation medium) nt 37"0 for 4 h 
in the absence or presence of 10 mM man-6-P, Solid region repre-
sents activated prcrcnin (i.e., renin). Dntn m'<l means ::!: SE ( n = 4). 
•p < 0.05 vs, without mun-6-P; #P < 0.05 vs. rceombirumt humun 
prorcn.in; tP < 0.01 vs. plasmn. 
DISCUSSION 
The data of the present study show that man-6-P-
contai.n.ing prorenin binds with high affinity to man-6-
P/IGF-II receptors on neonatal rat myocytes and fibro-
blasts. Binding is followed by internalization and 
subsequent proteolytic activation to renin, possibly by 
a serine protease. Internalization is greatly enhanced 
by receptor recycling. Obtained with recombinant hu-
man prorenin, these results could be fully reproduced 
with native human prorenin of renal origin (ie., pro-
renin in human plasma) but not with native human 
prorenin of extrarenal origin (i.e., prorenin in human 
amniotic fluid), suggesting that local angiotensin pro-
duction by nonrenin-producing cells such as myocytes 
and fibroblasts (59) depends on renin of renal origin. 
Evidence for prorenin binding to receptors other 
than the man-6-P/IGF-IT receptor was not obtained. 
First, man-6-P significantly reduced prorenin binding 
in myocytes and fibroblasts. Although the reduction 
was more modest in fibroblasts, prorenin binding in the 
presence of man-6-P (i.e., "nonspecific" prorenin bind-
ing) was similar in myocytes and fibroblasts and did 
not differ from prorenin binding to human umbilical 
vein endothelial cells in the presence ofman-6-P (data 
not shown). These findings may point to the eJcistence 
of a second unidentified prorenin receptor. However, in 
view of the similarity of the non-man-6-P/IGF-II recep-
tor-mediated prorenin binding in cardiac and endothe--
lial cells, a more likely explanation is that binding in 
the presence of man-6-P represents nonspecific bind-
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ing. Second, when exposing cardiac cells to a recombi-
nant human prorenin fraction in which all molecules 
contain the man-6-P signal (as opposed to only 40% of 
the molecules in the nonfractionated recombinant hu-
man prorenin preparation), binding and internaliza-
tion increased 1.5- to 2.5-fold. This is within the range 
expected when increasing the level ofman-6-P-contain-
ing prorenin ""'2.5-fold and also indicates that the true 
Ko. is -2.5-fold lower than the values reported here. 
The increases were somewhat smaller in fibroblasts, 
which is most likely due to the fact that man-6-P/ 
IGF-IT receptor-specific prorenin binding in these cells 
was comparable to prorenin binding not mediated via 
man-6-P/IGF-ll receptors (i.e., nonspeci£c prorenin 
binding). A low number of cell-surface man-6-P/IGF-IT 
receptors also explains why the decrease in prorenin 
binding in the presence of excess man-6-P was more 
modest in fibroblasts than in myocytes. 
Binding ofprorenin to man-6-P/IGF-II receptors oc-
curred with high affinity (K, < 1 nM), which suggests 
that prorenin occupies both man-6-P binding sites of 
this receptor (22, 38). In both fibroblasts and myocytes, 
the levels of cell-associated prorenin increased 10-15-
fold when the cells were incubated with prorenin at 
37°C instead of 4°C. This can be explained on the basis 
of the internalization and continuous recycling ofman-
6-P/IGF-II receptors among the cell surface and intra-
cellular compartments (e.g., Golgi and endosomes) that 
are known to occur at 37°C but not at 4°C (10). In 
myocytes, >85% of the man-6-P/IGF-IT receptors were 
found to be located in the cells. Internalization of the 
receptor-prorenin complex appeared to occur rapidly 
with a half-life of <5 min and was followed by activa-
tion of prorenin. The rapid decline in the levels of 
prorenin still containing the carboxy terminal part of 
its prosegment [as measured with monoclonal antibody 
F258-37-B1 (Fig. 6)] con£r:ms that prorenin activation 
was a proteolytic process and that cleavage occurred in 
the correct manner. The cells did not release proteo-. 
lytically activated prorenin (i.e., renin) into the me--
dium. Instead, renin was degraded intracellularlywith 
a half-life of -1 h. This raises the possibility that the 
man-6-P/IGF-TI receptor is involved in (pro)renin clear-
ance. Alternatively and perhaps more likely in view of 
the rapid activation process, cell-activated prorenin 
may contribute to intracellular angiotensin generation 
before its destruction. Several studies have provided 
evidence for intracellular angiotensin generation (17, 
32, 42), and ANG II is known to activate intracellular 
AT 1 receptors in the cytosol and nucleus (23, 27). In the 
absence of local renin synthesis, such intracellular 
angiotensin generation will depend on the uptake of 
circulating renin or prorenin. Moreover, because in 
previous studies we were unable to demonstrate angio-
tensinogen synthesis in neonatal rat cardiac myocytes 
and fibroblasts (59), it seems that renin substrate also 
has to be internalized to allow intracellular angioten-
sin generation in the neonatal heart. This may be 
different in the adult heart or under pathological con~ 
ditions (40). In addition, age as well as pathological 
conditions may affect the density of cardiac man-6-P/ 
IGF-II receptors and/or give rise to the appearance of 
alternative (pro)renin receptors or uptake mechanisms 
(4, 8, 46, 48, 53). 
At present it cannot be concluded what enzymes ar-e 
responsible for the intracellular prorenin activation. 
With the exception of the serine protease inhibitor 
AEBSF, none of the protease inhibitors used in this 
study exerted an inhibitory effect on prorenin activa-
tion. This is not due to the inability of these blockers to 
reach the proper intracellular compartment because 
others have demonstrated efficacy in the same setup 
(7, 44). Moreover, the mixed serine-cysteine protease 
inhibitor leupeptin and the cysteine protease inhibitor 
E64 increased the levels of cell-associated prorenin by 
>40%, indicating that cysteine proteases contribute to 
(pro)renin degradation and that exogenous inhibitors 
apparently are capable of reaching the intracellular 
sites where degradation occurs. Possible candidates for 
the prorenin-activating enzyme are kallikrein (37), 
prohormone convertases (51), and cathepsin B (45), 
although the latter seems unlikely in view of the ab-
sence of an inhibitory effect of E64. These enzymes 
have been demonstrated in the heart (6, 41, 49, 55). 
Furthermore, Baba and colleagues (3) described a 
serine protease (mol mass 26 kDa) capable of activat-
ing prorenin in rat adrenal explant cultures. The pH 
optimum for prorenin activation by this enzyme was 
6.5. The rapid activation of prorenin in the present 
study, which is indicative for early endosomal (i.e., at 
pH 6.5) removal of the prosegment, as well as the 
inhibitory effects of AEBSF on prorenin activation in 
myocytes, is in agreement with the existence of a sim-
ilar serine protease in the heart. 
Finally, our results are not limited to recombinant 
human prorenin but also apply to native human 
plasma prorenin. Plasma prorenin is predominantly of 
renal origin (11), although extrarenal prorenin sources 
such as the eye (12), ovary (20), placenta (33), and 
testis (54) are also known to contribute to circulating 
levels ofprorenin. When incubated at 37°C for 4 h with 
plasma containing prorenin (and low levels of renin), 
myocytes were found to contain predominantly renin. 
It is unlikely that this is due to selective uptake of 
plasma renin because man-6-P/IGF -II receptors do not 
make a distinction between man-6-P-containing renin 
and prorenin (58). Therefore, these :findings suggest 
that plasma prorenin, like recombinant prorenin, is 
activated intracellularly to renin. In absolute terms, 
the levels of cell-associated renin and prorenin after 
incubation with plasma were two to three times lower 
than after incubation with equal amounts of recombi-
nant prorenin (Fig. 7). This may have at least two 
explanations. First, the percentage of plasma prorenin 
carrying the man-6-P signal may be lower than the 
percentage of recombinant human prorenin carrying 
this signal. Second, the high (in the nanomolar range) 
levels of soluble man-6-P/IGF-II receptors that have 
been reported in plasma (9) may affect prorenin bind-
ing to cellular man-6-P/IGF-II receptors, especially be-
cause the density of the latter (expressed per million 
cells) is in the femtomole range. Studies reporting on 
Prorenin uptake by cardiac cells 
the presence of high-molecular-weight forms of prore-
nin in plasma (5, 47) are in agreement with the con-
tention that plasma prorenin is in part bound to solu-
ble man-6-P/IGF -II receptors. Further experiments are 
required to resolve this issue. Interestingly, prorenin 
present in human amniotic fluid did not bind to myo-
cytes, which suggests that this prorenin does not con-
tain the man-6-P signal. Amniotic fluid prorenin is 
derived primarily from the placental chorion laeve (33) 
(i.e., is synthesized extrarenally), and its isoelectric 
focusing pattern differs from that of plasma prorenin 
(36). The levels of soluble man-6-P/IGF-II receptors in 
amniotic fluid are -100 times lower than in plasma (9). 
Whether prorenin from other eA"trarenal sources also 
lacks the man-6-P signal is currently unknown, but if 
so, this would imply that only pro renin of renal origin 
is meant to be taken up by the heart and thus that 
cardiac angiotensin generation is regulated by the kid~ 
ney and not by other (pro)renin-producing tissues. 
Consequently, the release of large amounts of prorenin 
from extrarenal sources [e.g., during pregnancy (33)] 
would not necessarily result in increased cardiac an-
giotensin generation. 
In conclusion, our data support the concept of cardiac 
angiotensin generation by renal (pro)renin. Prorenin is 
sequestered from the circulation by cardiac cells 
through binding to man-6~PIIGF-II receptors. Binding 
occurs with high affinity and is limited to prorenin 
containing the man-6-P signal. After binding, the pro-
renin-man-6-P/IGF-II receptor comple.x is internalized 
and prorenin is activated to renin, possibly by a serine 
protease in an early endosomal compartment. The re-
ceptor then returns to the cell surface to repeat the 
binding and internalization process. Activated prore-
nin may participate in intracellular ANG I production 
before its destruction by cysteine proteases in lyso-
somes. 
This study was supported by The N etberlunds Heart Foundation 
Research Grant NHS96-019. 
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Chapter6 
Prorenin Accumulation and Activation in 
Human Endothelial Cells 
Importance of Mannose 6-Phosphate Receptors 
Mark M.E.D. van den Eijnden, Jasper J. Saris, Rene J.A. de Bruin, Elly de Wit, Wim Sluiter, 
Timothy L. Reudelhuber, Maarten A.D.H. Schalekarnp, Frans H.M. Derkx, A.H. Jan Danser 
Abstract-ACE inhibitors improve endothelial dysfunction. possibly by blocking endothelial angiotensin production. 
Prorcnin. through its binding and activation by endothelial mannosc 6-phosphate (M6P) receptors. may contribute to this 
production. Here, we investigated this possibility as well as prorenin activation kinetics. the nature of the 
prorenin-activating enzyme, and M6P receptor-independent prorenin binding. Human umbilical vein endothelial cells 
(HUVECs} were incubated with wild-type prorenin. KJA-2 prorcnin (in which Lys42 is mutated to Ala. thereby 
preventing cleavage by known proteases), M6P-free prorenin, and nonglycosylatcd prorenin. with or without M6P. 
protease inhibitors, or angiotensinogcn. HUVECs bound only M6P..containing prorenin (~ 0.9::!:0.1 nmol!L. maximum 
number of binding sites [Bma.J 1010±50 receptors/cell). At 37°C, because of M6P receptor recycling. the amount of 
prorenin internalized via M6P receptors was >25 times B....,.. Inside the cells. wild-type and K/A-2 prorenin were 
proteolytically activated to renin. Renin was subsequently degraded. Protease inhibitors interfered with the latter but not 
with prorcnin activation. thereby indicating that the activating enzyme is different from any of the lmown 
prorenin-activating enzymes. Incubation with angiotensinogen did not lead to endothelial angiotensin generation. 
inasmuch as HUVECs were unable to internalize angiotensinogen. Most likely. therefore. in the absence of 
angiotensinogen synthesis or endocytosis. M6P receptor-mediated prorenin internalization by endothelial cells 
represents prorcnin clearance. (Arterioscler Thromb Vase BioL 2001;21:911-916.) 
Key Words: human umbilical vein endothelial cells • mannose 6-phosphate receptors • prorenin 
• renin • angiotensin 
V ascular angiotensin II (Ang II). through stimulation of Ang II type 1 (AT1) receptors, induces the generation 
of superoxide anions, thereby resulting in endothelial 
dysfunction.1 Blockade of this process. with ACE inhibi-
tors or AT1 receptor antagonists. reverses endothelial 
dysfunction in human atherosclerosis.1 At present, it is still 
being debated whether vascular Ang II generation depends 
on locally synthesized or circulating kidney-derived renin. 
In support of the latter. angiotensins cannot be demon-
strated in the perfusate of vascular preparations obtained 
from nephrectomized animals, unless renin is added to the 
perfusion buffer.3 Because renin in circulating blood 
plasma is predominantly present in the form of its inactive 
precursor. prorenin.4 it is also conceivable tha.t kidney-
derived prorenin. after its local activation. contributes to 
vascular angiotensin generation. 
Renin and/or prorenin may enter the vascular wall through 
binding to (pro)renin receptors. Indeed. we have recently 
demonstrated that human umbilicul vein endothelial cells 
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(HUVECs) bind renin and prorenin to cell surface mannose 
6-phosphate (M6P) receptors.~ Binding was followed by 
internalization and proteolytic activation of prorenin. The 
latter process is not unique. inasmuch as M6P receptors are 
known to be involved in the activation of several other 
prohonnones carrying the M6P recognition marker. such as 
thyroglobulin.6 Moreover. M6P receptor-mediated prorenin 
activation also occurs in cardiac cells.7 The enzyme respon-
sible for prorenin activation is currently not known. Possible 
candidates include cathepsin B. glandular kallikreins. and 
members of the prohonnone convertase family.M-JO Further-
more. receptors other than the M6P receptor may also 
contribute to (pro)renin binding.u.12 
It was the aim of the present study to investigate the 
kinetics of prorenin binding and activation in HUVECs. the 
nature of the proreWn-activating enzyme in these cells. 
endothelial prorenin binding independent of M6P receptors, 
and whether endothelial prorenin binding and activation 
result in angiotensin generation. 
Prorenin uptake and angiotensin generation by endothelial cells 
Methods 
Human Prorenin Preparations 
Recombinant human prorenin (wild-type prorenin), produced in 
Chinese hamster ovary cells transfected with n vector containing 
human prorenin eDNA, was kindly provided by Dr S. Mathews 
(Hoffm:lnn-I....:tRochc, Basel, Switzerland).~ To remove tmces of 
renin. it was parti.ally purified by Cibacron blue Sepb.arose affmity 
chromatography (Pharm.acia).~·7 Wild-type prorenin wa.-: ~"toted at 
-sooc in nliquors containing -2XIO' U!L (4 ~oi/L) in 0.1% 
BSA It was also separated into an M6P-containing and an M6P-free 
fraction by use of a bovine M6P receptor affmity column. provided 
by DrS. Kornfeld (WashingtO!l University School of Medicine, St. 
Louis, Mo).', In short, 1 U recombinant wild-type prorenin W<lS 
applied to a 0.5-mL bovine M6P receptor affinity column. The 
column was washed with column buffer,D and M6P-containing 
prorenin wa.~ eluted by adding lO mmol/L M6P to the column buffer. 
Fractions corresponding to the column run-through material (ie, 
M6P-free prorenin) and to M6P-eluted material (ie, M6P-containing 
prorenin) were separately pooled and stored at -80°C in aliquot_~ 
containing ... 100 UIL. 
K/A-2 prorcnin. ic. prorenin thnt c;mnot be cleaved by known 
pretenses. wa.~ produced in GH4 cells trnnsfected with a vector 
containing human prorcnin eDNA in which Lys42 is mutated to 
Ala. '4 Nonglycosylated prorenin wa.~ produced in GH4 cell~ trans-
fected with a vector containing human prorenin eDNA in which Asn 
at positions 5 and 75 of renin is mutated to Ser.'~ The KJA-2 and 
nonglycosylatcd prorenin mutant.~ were stored at -80°C in aliquot.~ 
containing -700 and 30 UIL. respectively. in DMEM with 5% FCS. 
Cell Culture 
HUVECs were isolated from umbilical cord~. cultured to confluence. 
trypsinizcd. and stored in liquid nitrogen us described earlier.3 For an 
experiment. an aliquot of HUVECs (p:ls&age!i 2 to 5) wa.~ thawed. 
The cells were cultured to confluence in a 75-cm: ti.'>.we culture fla.~k 
coated with fibroncctin (10 p.g/cm~ in modified medium 199 
containing 10% newborn calf serum. 10% human serum, 150 p.glmL 
endothelial cell growth factor.~ IS UlmL heparin. 50 U/mL penicil-
lin, and 5 p.g/mL streptomycin at 37°C in a humid 5% CO: 
atmosphere. Cells were trypsinized and seeded in 12-wdl plates. 
Studies were carried out -1 day after confluence (eom:..~ponding to 
a den.'iity of 4X tif cell"-' em:) had been reached. Before the ~tnt of 
each experiment, the cell~ were wa.-.hed 3 time:'> with 2 mL warm 
(37°C) PBS (140 mmoi/L NaCI. 2.6 mmoi/L KCl. 1.4 mmol!L 
KH:P04, and 8.1 mmoi/L N:1:1HP04 • pH 7.4). The cell~ were then 
prcincubated either nt 37°C or 4°C for 30 minutes with 0.5 mL 
incubation medium consisting of modified medium 199 without 
newborn calf serum or human serum but supplemented with 1% 
human serum albumin. 
Incubation With Prorenin at 4°C or 37°C 
After preincubation at 3rC or4°C for 30 minutes.. experiments were 
st:lrted by replacing the incubation medium by incubation medium of 
37°C or 4°C containing wild-type prorenin (final concentration 3 to 
300 UIL). M6P-containing wild-type prorcnin (10 UIL). M6P-free 
wild-type prorenin (10 U/L), K/A-2 prorcnin (100 UIL). or nongly-
cosylated prorenin (10 UIL) with or without 10 mmoi/L M6P. Cell~ 
were then incubated at 37°C or 4°C for maximally 4 hours. To 
investigate the nature of the prorenin-renin-converting enzyme. 
incubation_~ at 37°C with wild-type prorenin (100 UIL) were also 
performed in the presence of the serine protease inhibitors 4-(2-
aminoethyl)benzencsulfonyl fluoride hydrochloride (AEBSF, 
0.5 mmoi/L. Calbiochem). aprotinin (0.001 mmol!L, Hoffmann-
LaRoche). and chymostatin (0.1 mmoi/L, Hoffmann-LaRoche). the 
cysteine protease inhibitor L-trnns-3-carboxyoximn-2-carbonyl-L-
leucylagmati.ne (E-64, 0.1 mmol!L. Sigma Chemical Co), the mixed 
serine/cysteine protease inhibitor leupcptin (0.1 mmoi/L, Sigma). the 
mctalloprotc!lSe inhibitors EDTA (1 mmoi/L), phenanthrolinc 
(I mmol!L. Merck), and phosphor:unidon (0.5 mmoi/L. Sigma). and 
the Mpartic protease inhibitor pepstatin A (0.1 mmol!L. Sigma). At 
the end of the incubation period. the culture medium wus removed. 
The cell~ were w.1shed 3 times with 2 mL ice-cold PBS and lysed in 
0.2 mL ice-cold PBS containing 0.2% Triton X-100. Subsequently. 
the cell lysate wus frozen on dry ice. Cell lysntes were stored at 
-sooc. 
To distinguish cell surface-bound from internalized prorenin. the 
acid-wa.-.h method was used.7 Cells were then lysed us described 
above. 
Incubation With Prorenin at 4°C Followed by 
Incubation at 37°C 
The kinetics of prorenin internali7.ation and activation were studied 
by incubating HUVEC.--. which were cultured in 6-well plates. with 
1 mL wild-type prorcnin-containing incubation medium (fmal con-
centration !00 U/L) for 2 hours at 4°C. Thereafter, the cells were 
wa.~hed 3 times with 3 mL ice-cold PBS and further incubated at 
37°C with prorenin-frce incubation medium The incubation wa." 
t=inatcd after variou.~ times (ranging from 10 to 360 minutes) by 
washing the cells 3 times with 3 mL ice-cold PBS. The cell~ were 
then lysed in 0.5 mL icc-cold PBS containing 0.2% Triton X-100 as 
de.~cribed above. Celllysates were stored at -80°C. 
Angiotensin Generation During Incubation With 
Prorenin at 37°C 
To study prorenin-induced endothelial angioten.<cin generation, 
HUVECs. which were cultured in 6-wcll plates. were incubated at 
37°C for 4 hours with 1 mL incubation medium containing 10 UIL 
wild-type prorenin and/or 150 nmol/L human angioten.'iinogen (Sig-
ma). HUVEC.~ incubated without prorenin or angiotensinogcn served 
a.~ the control. After 4 hours of incubation. the medium wa.~ rapidly 
mixed with 50 ,J.L inhibitor solution (containing 0.1 mmoi/L 
remikiren. 200 mmoi/L di..oo.ium EDT A. and 0.2 mrnoi/L lisinopril) 
and frozen at -70°C. Cell~ u."!:d for the measurement of angioten-
sinogen were washed 3 time.~ with 3 mL ice-cold PBS and lysed in 
0.2 mL ice-cold PBS containing 0.2% Triton X-100 a.~ described 
above. Cell~ used for the measurement of angiotensin I (Ang I) and 
Ang ll were scraped with a rubber policeman in a volume of 0.5 mL 
ice-cold PBS. The cell-PBS mixture wa.~ centrifuged at 1000g at 4°C 
for I minute, after which the pellet wa.~ homogenized in 0.5 mL 0.1 
moi/L HCI!SO% eth.:lnol by using a hand-operated Dounce homog-
enizer. 1 ~1-Ang I wa.~ added to the samples before the homogeniza-
tion procedure to determine angiotensin recovery. Ethanol wa.~ 
evaporated under vacuum rotation at 4°C by using a Speed Vac 
Concentrator. The concentrated homogenate.~ were dissolved in 0.5 
mL 1% onbopho~-phoric acid and applied to Sep-Pak column.~ (see 
below). 
In view of the purtial catalytic activity of prorenin.,l'• Ang I wus 
also measured in incubation medium containing 10 UIL wild-type 
prorenin a.nd/or 150 nmol/L angioten.~inogen that had been incubated 
without HUVECs for 4 hours :u 37°C. 
Finally. HUVEC-mediatcd Ang l-Ang ll conversion a.nd Ang I 
degradation wus studied by incubating HUVEC..~ for up to 4 hours at 
37°C with 1 nmoi/L Ang I in the presence or absence of 10 ;.unoliL 
quinaprila.t. &unples (0.1 mL) for the measurement of Ang I and ll 
were taken at 0, 0.5. I. 2, and 4 hours.. rapidly mixed with 10 ,J.L 
inhibitor solution, and frozen at -70°C. 
Biochemical Measurements 
Total prorenin (ic. cell-activated plu.~ nonactivated) and cell-acti-
vated prorenin in the celllysates obtained from the 3rC experiments 
were measured by immunorndiomctric a.%:\y (IRMA).'' Proteolytic 
activation of prorenin in these experiment.~ was verified with an 
IRMA specific for intact prorcnin.. ie. prorcnin in which the 
C-terminal part of the prosegment i.~ still attached to the renin pan of 
the molecule.~ The re.~'Ults of the.'iC IRMA..~ arc expressed a.~ mi-
crounits per 10" cell~ with intact recombinant human prorcnin used 
a.~ a reference. The lower limit of detection wus 5 !J.U/1 0" cells. The 
IRMAs arc not sen.'iitive enough to measure the low leveL~ of 
prorcnin that were present in the celllysates at 4°C. Therefore. the 
prorenin mea..~urements in these cxpcri.ments were performed by 
enzyme-kinetic a.'>.~y.7 The results of this ussay arc expressed a.~ 
microunit.~ per IO' cells with piasm.in-activated recombinant human 
prorenin used a.~ a reference. The lower limit of detection was 1 
!J.U/10' cell~. 
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Figure 1. Cell-associated prorenln after lncub:;rtlon of HUVECs 
with wild-type prorenin at 4"C Oeft) or 37"C (right) for 4 hours. 
The open and closed circles represent the cellular levels of cell-
actlvateo' and total (cell-activated plus nonactivated) prorenln, 
respectively. Data are mean=SEM (n"'S). 
The concentration of aogiotensinogen in the cell lysates was 
determined n.~ the maximum quantity of Ang I that was gencrotcd 
during incubation at 37"C and pH 7.4 with excess recombinant 
h= renin in the prc~cc of a mixture of angiotensinase, ACE. 
and serine prote:.tsc inhibitors. '7-1? The lowest level that could be 
IDC;J.Sured w:tS 20 fmol/1 0' CCJl~. 
Ang I and II levels in medium and in cell homogcnates were 
measured by radioimmunoassay :lftcr Scp-Pak extraction and 
reversed-ph= higb-pcrfo=cc liquid chromatography SCP=-
tion.',.,19 Recovery was better than 65%, and result.~ were corrected 
for incomplete recovery. The lower limits of detection for Ang I and 
II were 2 aod I fmol per milliliter medium or per 10" cells, 
respectively. 
Statistical Analysis 
All data are expressed ns mcao::!:SEM. Differences between the 
cellulnr prorcnin levels at 37°C aod 4°C and between the cellular 
levels of total prorenin aod cell-actiwted prorcnin in the presence or 
absence of protease inhibitors were evaluated for statistical signifi-
cance by ANOV A. Statistical significance wns accepted at P<O.OS. 
Results 
Incubation With Prorenin at 4°C or 37°C 
HUVECs bound wild-type prorenin in a concentration-
dependent manner at 4°C and at 37°C (Figure 1). Cell-
associated prorenin at 37°C, but not at 4°C, was acid resistant 
(data not shown), indicating that prorenin internalization 
occurred at 37°C only. For a given prorenin concentration in 
the medium, the level of cell-associated prorenin after 4 hours 
of incubation was 10 times higher at 37°C than at 4°C. 
Prorenin activation was detectable at 37°C only. Saturation of 
the activation process did not occw-. inasmuch as the percent-
age of cell-associated prorenin that was activated was similar 
at all concentrations of prorenin to which the cells were 
exposed (ranging from 82±5% at 3 UIL to 76:!:6% at 300 
UIL. n=6; P=NS). None of the protease inhibitors that were 
tested (n=5 for each inhibitor) blocked the activation of 
prorenin (ranging from 68:!:5% [with AEBSF] to 81:!:9% 
[with EDTA]). although some inhibitors affected the amount 
of cell-associated total prorenin. E64,leupeptin. and pepstatin 
A increased the levels of cell-associated total prorenin to 
135:!:9%, 138±11%, and 126±7% of control (?<0.05 ver-
sus control), respectively. thereby indicating that cysteine and 
aspartic proteases contribute to (pro)renin degradation in 
endothelial cells. AEBSF and phenanthroline reduced the 
levels of cell-associated total prorenin to 49±7% and 39:!:7% 
64 
~' 'i 100 j 
' ~ st 80 ~ ·~ 
£ [i! 
~ ~· 60 Oi~
~ ~· ~ z[ 40 
1 I I t)~ 20 ii • ~ ~ u 0 
wlldtypco ~ .. 0 60 120 180 240 
pro,.nln ~nln Tfmo (mlrtutw) 
Figure 2. Left, Cellular levels of cell-activated (open bars) and 
Intact prosegment-contalnlng (closed bars) prorenln after Incu-
bation of HUVECs for 4 hours at 37"C with wild~ type or K/A-2 
prorenln. Levels (mean±SEM. no::4) are expressed as a percent-
age of the cellular levels of total (cell-activated plus nonacti-
vated) prorenln after 4 hours of Incubation. Right, Time-
dependent Increase In the cellular levels of activated prorenln 
during Incubation of HUVECs at 37"C with wild~type prorenln 
(open circles) or KIA-2 prorenln (clOSed circles). Levels 
(mean::!::SEM, n=4) are expressed as a percentage of the cellu-
lar levels of total proronln after 4 hours of incubation. 
of control, respectively (P<0.05). This was not due to 
interference with the internalization process. because the 
percentage of cell-associated prorenin that was acid resistant 
was similar in the presence and absence of these inhibitors 
(data not shown). Aprotinin (96±9% of control), chyrnostatin 
(119±6%), EDTA (85:!:8%), and phospboramidon (94:!:9%) 
did not affect the levels of cell-associated total prorenin. 
K/A-2 prorenin was bound and internalized by HUVECs to 
the same degree as wild-type prorenin (Figure 2. left). 
Moreover, after 4 hours of incubation with K/A-2 prorenin at 
37°C, 80:!:2% of cell-associated total prorenin was in the 
activated form. The activation was due to proteolytic cleav-
age of the prosegment. inasmuch as <30% of cell-associated 
total prorenin still contained the C-tcnninal part of the 
prosegment. Furthermore. the rate of prorenin activation over 
the 4-hour incubation period was identical for wild-type and 
K/A-2 prorenin (Figure 2. right). Taken together, therefore, 
HUVECs activated K/A~2 prorenin in a manner indistin-
guishable from the activation of wild-type prorenin, thereby 
supporting the idea that activation was not mediated by any of 
the known prorenin-renin convertases. 
M6P significantly inhibited native prorenin binding at 
37°C and at 4°C (Figure 3). In the presence ofM6P. prorenin 
binding was observed only at prorenin concentrations >10 
UIL. and the levels of cell-associated prorenin were identical 
at 37°C and at 4°C. Scatchard analysis of the results obtained 
at 4°C revealed that M6P receptor-specific binding of prore-
nin occurred with high affinity (}(, 0.9:!:0.1 nmol/L). The 
number of prorenin-binding M6P receptors on the cell surface 
(B,.J was 1010±50 sites per cell. 
Binding studies after the separation of wild-type prorenin 
into an M6P-free and an M6P-contai.ning fraction. with the 
help of a bovine M6P receptor affinity column, revealed that 
only M6P-containing prorenin and not M6P-free prorenin 
was bound by HUVECs (Figure 4). In agreement with this 
finding, the cells did not bind or internalize nonglycosylated 
prorenin (n=4. data not shown). 
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Figure 3. Cell-associated prorenin after incubation of HUVECs 
with wild-type prorenln In the absence {closed circles) or pres--
ence (closed squares) of 10 mmoVL M6P at 4"C Oeft) or 37"C 
(right) for 4 hours. M6P receptor-specific binding (open trian-
gles) was taken as the difference between levels of cell-
associated prorenln wlth and without M6P. Data are 
mean::!:SEM (n""6). 8/F Indicates bound-to-free ratio: B. bound 
prorenln, K~ and B,.. were calculated from a plot according to 
Scatchard Onsert). 
Incubation With Prorenin at 4°C Followed by 
Incubation at 37°C 
After 2 hours of incubation at 4°C with 100 U/L wild-type 
prorenin, followed by repeated washing with ice-cold PBS. 
the level of cell-associated tot:J.l prorenin W:lS I97:t26 
,u.U/10~ cells (n=S). Acid wash coofumed that all cell-
associated prorenin at that time was located on the cell 
surface. Immediately after elevating the temperature to 37°C. 
the level of cell-associated total prorenin started to decrease. 
The decrease followed a biphasic pattern (Figure 5). The 
rapid phase (half-time [tl/2]7:!:.1 minutes) corresponds with 
the release of cell-associated prorenin into the medium, 
whereas the slow phase (tl/2 405:!:.72 minutes) represents 
intracellular degradation after internalization. A$ soon a." 
,., 
3~C 
Figure 4. Cell-associated prorenin after incubation of HUVECs 
with nonfractionated wild-type prorenin (1 0 U!L), M6P-
contalning wild-type prorenin (10 U/L), and M6P-free wild-type 
prorenin (10 UIL) at 4"C (top) or 37"C (bottom) for 4 hours in the-
absence (open bars) or presence (closed bars) of 10 mmolll 
M6P. Data (mean~SEM, n:S) are expressed as a percentage of 
the cellular levels of control (16:±:9 _u.U/106 cells and 158:!:51 
~U/1 ~ cells at 4"C and 37"C, respectively). 
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Figure S.. Time course of Internalization and cellular actlvatlon of 
wild-type prorenln by HUVECs. Cells were preincubated with 
prorenln (100 U!L) for 2 hours at 4"C. They were then washed 
with Ice-cold PBS, fresh culture medium free of prorenln was 
added, and the Incubation was continued at 37"C. The cellular 
level of total prorenln (cell-activated plus nonactivated) at the 
end of the preincubation at 4"C (0 minutes) was 197:!:26 .u.l)/106 
cells {1 00%). The open and closed circles represent the cellular 
levels of cell-activated and total prorenin, respectively. Data are 
mean:!:SEM (n=S). 
prorenin release into the medium no longer occurred (ie, at 
the time :ill remnining cell surface-bound prorenin had been 
internalized. after -40 minutes). the cellular levels of acti-
vated prorenin started to rise rapidly. reaching a maximum 
after 60 minutes. Thereafter, these leveL~ decreased with a 
half-life (tl/2 305:!:.33 minutes) si.rnil.ar to that of the degra-
dation of cell-associated total prorenin, Taken together. these 
findings suggest that activation precedes degradation and that 
the half-lives of both processes differ 40- to 60-fold. 
Angiotensin Generation During Incubation With 
Prorenin at 37°C 
HUVECs that had been incubated under serum-free condi-
tions for 4 hours in the absence of prorenin and angioten~ 
sinogen did not contain detectable levels of angiotensinogen. 
Ang I. or Ang II (n=4). nor could these renin-angiotensin 
system components be demonstrated in the medium (n=4) of 
these cells. Cellular angiotensinogen and angiotensin levels 
remained undetect:lb1e after a 4-hour incubation with 10 UJL 
wild-type prorenin and/or 150 nmolJL angiotensinogen (n=4 
for each condition). Medium of HUVECs that had been 
incubated for 4 hours with 10 UJL wild~type prorenin plus 
150 nmolJL angiotensinogen contained 569:!:.85 pmolJL Ang 
I and 125:!:.26 pmolJL Ang II (n=4), A 4-bour incubation of 
medium containing the s:u:oe amount of wild-type prorenin 
and angiotensinogen in the absence of HUVECs also resulted 
in the appearance of Ang I (2520±130 pmolJL. n=4) but not 
Ang II. Medium containing either prorenin or angioten-
sinogen. after incubation with or without HUVECs. did not 
contain angiotensins (n=4 for each condition). 
HUVECs metabolized Ang I (tl/2 1.0:!:.0.1 hour, n=4), 
and this resulted in the appearance of Ang II in the medium. 
which reached a peak level (191:!:.24 pmolJL) after 2 hours. 
Quina.prilat fully prevented the generation of Ang II. On the 
basis of the half-life of Ang I in the presence of the ACE 
inhibitor (t1/2 1.7:!:.0.2 hours. n=4: P<O.Ol versus control). 
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calculati.ons19 revealed that 42±7% of the Ang I met:J.bolism 
by HUVECs was due to conversion by ACE. 
Discussion 
With the use of prorenin mutants as well as wild~type 
prorenin. the present study shows that endothelial internal-
ization and activation of prorenin are mediated exclusively 
via M6P receptors. We have demonstrated earlier that these 
receptors also bind and internalize renin. in a manner indis-
tinguishable from that of prorenin.~ Thus. despite evidence of 
the presence of other M6P-independent (pro)renin receptors 
in vascular preparations, 11 our data do not support the idea 
that such receptors are locali7..ed on human endothelial cells. 
M6P receptor-dependent (pro)renin binding to endothelial 
cells also provides an explanation for the selective endothelial 
staining of renin in hum:m arterics.::o 
At present. 2 different M6P receptors have been identified: 
the cation-independent type (also known as insulin-like 
growth factor II [IGFll] receptor) and the cation-dependent 
type. These receptors contain 2 M6P binding sites and 1 M6P 
binding site. respectively.21 The high-affinity binding of 
prorenin in the present study resembles the high~affut.ity 
binding of diphosphorylated oligosaccharides that occupy 2 
M6P binding sitcs.22 Most likely. therefore. the endothelial 
prorenin~binding receptor is the cation~independent M6P 
receptor. In this respect. prorenin resembles other M6P~ 
carrying prohonnones that are internalized and activated after 
binding to cell surface cation~independent M6P receptors.6 
Intem:ili.zed prorenin was rapidly activated to renin. and 
the activation occurred proteolytically. as evidenced by the 
use of an :mtibody directed against the C~tennin::U part of the 
prosegment Inhibitors of known proteases did not prevent 
cleavage. although some inhibitors interfered with the subse~ 
quent renin degrada.tion by cysteine and aspartic proteases. 
The latter shows that protease inhibitors do enter endothelial 
cell~ and thus confirms that their lack of effect on prorenin 
activation is not due to their inability to get into the cells. 
Unexpectedly. K/A~2 prorenin. a prorenin mutant that is not 
cleaved in vitro in isolated cells or in vivo in rat pituitary 
glands.l0·14Zl was also cleaved to renin. Remarkably. its 
activation occurred as rapidly as that of wild~type prorenin. 
although in vitro we found that plasmin activated K/A-2 
prorenin 4 to 5 times as slowly as it did wild~type prorenin 
(authors' unpublished data. 2000). T:lken together. therefore. 
endothelial cells contain an as-yet~unidentified protease that 
is capable of cleaving prorenin at or near its natuntl cleavage 
site. The rapidity of this process after internalization suggests 
that this enzyme is located in endosomes. 
Activated intracellular prorenin may contribute to endothe-
lial :mgiotensin generation. This would require the simulta-
neous uptake or endothelial synthesis of :mgiotensinogen. 
The demonstration of Ang II in the cytoplasm of rat endo-
thelial cells~ and of the release of intracellularly generated 
Ang II from bovine endothelial cells::s supports this concept 
However. we were unable to demonstrate intracellular endo~ 
thelial angiotensin generation during the incubation of 
HUVECs with prorcnin and angiotensinogen. Although Ang 
I :md II could be detected in the medium during these 
experiments. it is important to note that Ang I generation also 
occurred during the incubation of prorenin and angioten~ 
sinogen in the absence of HUVECs and that the addition of 
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Ang I to HUVECs resulted in the immediate appear.mce of 
Ang II in the medium. T:lken together, therefore. the presence 
of Ang I :md II in the medium of cells incubated with prorenin 
and angioten.~inogen most likely reflects the partial catalytic 
activity of prorenin that is due to the temporal unfolding of its 
pro:;cgment16 :rather than endothelial activation of prorenin. 
On the basis of the Ang I level measured after 4 hours of 
prorenin plus :mgiotensinogen incubation in the absence of 
HUVECs. it can be estimated that <2% of prorenin is 
catalytically active; ie. it exists in an .. open" form. 
The absence of intracellular angiotensin generation. despite 
the prorenin internalization (and subsequent activation) that 
occurred at 37°C. is most likely due to the fact that HUVECs 
did not sequester angiotensinogen. Although this does not 
necessarily apply to all endothelial cells in the human body. 
it suggests that intracndothelial angiotensin generation will 
occur only in endothelial cells that synthesize angioten-
sinogen. Evidence for the latter is currently not available. 
In the absence of intracellular angiotensin generation. the 
high vascular levels of Ang JT'-6 can be explained only on the 
basis of AT1 receptor-mediated internalization of Ang IT after 
its extracellular generation.27.zs Such extracellular angioten-
sin generation most likely involves interstitial renin::? or renin 
bound to the surface of vascular cells via receptors other than 
the M6P receptor.ll.J2.3o 
Fmolly. in view of the intracellular degradation of activated 
prorenin. it is conceivable that M6P receptors function as 
clearance receptors of (pro)renin and that prosegment cleav-
age is a first step toward intracellular destruction. For 
instance. binding and internalization of IGFII to M6P/IGFII 
receptors results in the lysosomal degradation of this ligand. 6 
An argument against this concept is the large difference in 
half~life between prorenin activation :md degrada.tion. This 
difference would leave activated prorenin ample time to 
contribute to intracellular :mgiotensin generation. However, 
even if M6P receptors serve as clearance receptors for 
(pro)renin. this would still allow these receptors to affect 
V:lScular angiotensin generation. 
In conclusion. prorenin internali7..ation by HUVECs is 
mediated exclusively via high~affinity M6P receptors :md is 
greatly enh:mced by receptor recycling. Internalized prorenin 
is rapidly activated to renin by a protease that is different 
from any of the Jmown prorenin-activati.ng enzymes. Activa-
tion is followed by degradation and/or. if :mgiotensinogen is 
present. may result in intracellular angiotensin generation. 
Both possibilities support the regulation of vascular angio-
tensin generation by M6P receptors. 
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Native human prorenin uptake by cardiac cells 
Reprinted from: 
Cardiomyocytes bind and activate native human prorenin: role of 
soluble man nose 6-phosphate receptors. 
Saris J.J., Derkx F.H.M., Lamers J.M.J., Saxena P.R., Schalekamp M.A.D.H. and 
Danser A.H.J. Hypertension. 2001; 37:p710-715. 
Chapter 7 
Cardiomyocytes Bind and Activate Native Human Prorenin 
Role of Soluble Mannose 6-Phosphate Receptors 
Jasper J. Saris, Frans H.M. Derkx, Jos M.J. Lamers, Pramod R. Saxena, 
Maarten A.D.H. Schalekamp, A.H. Jan Danser 
Abstract---Cardiomyocytes bind. internalize, and activate recombinant human prorenin through mannose 6-phosphate/ 
insulin-like growth factor II (M6P/IGFII) receptors. To investigate whether this also applies to native human prorenin. 
neonatal rat myocytes were incubated for 4 hours at 37°C with various prorenin-containing human body fluids. Uptake 
and activation by M6P/IGFJI receptors were observed for plasma prorenin from subjects with renal artery stenosis and/or 
hypertension and for follicular fluid prorenin. The total amount of cellular renin and prorenin (expressed as percentage 
of the levels of renin and prorcnin in the medium) after 4 hours of incubation was 4 to 10 times lower than after 
incubation with recombinant human prorenin. Although plasma contains alkaline phosphatases capable of inactivating 
the M6P label as well as soluble M6PIIGFll receptors that block prorenin binding in a competitive manner and proteins 
(eg. insulin. IGFJJ) that increase the number of cell-surface M6P/IGFTI receptors. these factors were not responsible for 
the modest uptake of native human prorenin. Uptake did not occur during incubation of myocytes with plasma prorenin 
from anephric subjects or with amniotic fluid prorenin. and this was not due to the presence of excessively bigh levels 
of M6P/IGFTI receptors and/or phosphatase activity in these fluids. In conclusion. myocytes are capable of binding, 
internalizing, and activating native human prorenin of renal and ovarian origin through M6P/IGFTI receptors. 
Differences in prorenin glycosylation and/or phosphorylation as well as the concentration of soluble M6PIIGFTI 
receptors and growth factors affecting cell-surface M6P/IGFTI receptor density determine the amount of prorenin 
entering the heart and thus cardiac angiotensin ll production. (Hypertension. 2001;37[part 2]:710-715.) 
Key Words: myocytes • receptors, angiotensin ll • insulin growth factor • renin 
The beneficial effects of ACE inhibitors on postinfarct remodeling and in subjects with heurt failure arc gener-
ally attributed to interference with cardiac angiotensin (Ang) 
IT production.1 Initially, it was thought that the renin required 
for cardiac Ang II generation is synthesized de novo in the 
heart. However. it is now well esta.blished that cardiac renin 
is largely if not completely derived from the circulation. both 
under normal and pathological conditions.~ Circulating 
renin and/or its inactive precursor, prorenin. diffuse into the 
cardiac interstitial spacCS.6 or bind to (pro )renin receptors. 7 ,II 
We recently reported that one of these receptors is identical to 
the mannosc 6-phosphate!J.O.Sulin-like growth factor IT (M6P/ 
IGFIT) receptor,?.to M6P/IGFIT receptors not only have bind-
ing domains for M6P-containing ligands such as renin and 
prorenin but also for IGFIT and retinoic acict.tt.tz Interest-
ingly. prorenin binding to M6P/IGFIT receptors is followed 
by rapid internalization and activation.?,to This is not a unique 
property because it also applies to other M6P-containing 
prohormones (eg, latent transforming growth factor-,B).n 
In our studies on M6PJIGFTI receptor-mediated prorenin bind-
ing, we made use of recombinant human prorenin. This prorenin 
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may differ from native human renal prorenin with reg:m:i to its 
gl.ycosylation and/or phosphorylation. t4-l(> Simil::tr differences exist 
between prorenin of renal ::wd extrarenal origin.16.17 In fact. the 
absence of the M6P label on extrarenal prorenin could explain why 
Ang n is virtually undetectable in the heart after a bila1eral 
nephrectomyZ.ts despite the fact that prorenin. unlike renin. is still 
present in circulating blood of nephrectomized subjects. sometimes 
at levels as high as those in nonnal individuals. N-21 
In this study. we set out to investigate whelher cardiomyocytcs 
bind. internalize. and activate native human prorenin of renal and 
extrarenal origin through M6PJIGFTI receptors. taking into consid-
erntion the fact that plasma and other prorenin-containing human 
body fluids (eg. amniotic fluid) contain factors that may interfere 
with proreain binding, such as soluble M6PJIGFJI receptors. phos-
phatases. and proteins that increase the number of cell"sutface 
M6PJIGFII receptors (eg. insulin and IGFII).n.Z:: 
Methods 
Cell Culture 
All experiment.~ were performed according to the regulations of the 
Anim:tl Care Comminee of Erasmus University Rotterdam (The 
Netherlands), in accord:lnce with the "Guiding Principles in the Care 
and Use of Laboratory Animals~ as approved by the Council of the 
American Physiological Society. 
Primary cultures of rat neonatal cardiac cells were prepared as 
described bcfore.9 Briefly, ventricles of newborn 1· to 3-<!ay--old 
Wb1::lr strain rat pups were minced. and cells were dispersed by 
trypsinization. Myocytes were separated from nonmyocytes by 
differential preplating and seeded in noncoated 12-wcll plates 
(Corning Costar), giving a confluent monolayer of ~-pontanoously 
beating cell~ at 1.5 X I ()!i celL'\/cm~ :llter 24 hours. Cells were 
m:Untained at 37"C in a humidified 5% C02 incubator in 1.5 mL 
medium consisting of DMEM and Medium 199 (4:1) (Gibco Life 
Technologies) and supplemented with 100 U penicillin/mi.. (Roche). 
100 mg streptomycin/mi.. (Roche), 5% fctnl calf serum (Roche). and 
5% horse serum (Sigma). Before the start of each experiment. cell" 
were washed 3 times with 1 mL warm (37°C) PBS (consisting of 
140 mmoliL NaCI. 2.6 mmoliL KCI. 1.4 mmoliL KHlPO., and 
8.1 mmoliL Na:HP04, pH 7.4). They were then preincubated at 4°C 
or 37°C for 30 minute.~ with 0.4 mL medium supplemented with 1% 
(wt/vol) BSA (Sigma). 
At 4°C, prorcnin bind.-. to cell-surface receptors without being 
internalized. wherea." at 37°C, prorcnin binding M6P!IGFII receptors 
is followed by intcrnaliz.ation and intr:lcellular activation to renin. 9.1(1 
Moreover, at the latter tcmper:lture, M6P/IGFII receptors continu-
ously recycle between the cell surface and intracellular 
compartment.'>..'' 
Binding and Activation of Native Prorenin 
To study binding and activation of native human prorcnin. cell" were 
incubated at 37"C with 0.4 rnL incubation medium containing 30% 
(vol/vol) blood plasm:l., amniotic fluid. or follicular fluid. Plasma 
wa." obtained from 3 subject" with renal anery steno~is (1 man. 2 
women: age, 41 to 66 years). 3 subjects with essential hypertension 
treated with the ACE inhibitor captopril (2 men. I woman: age. 51 
to 67 years), and 4 anephric subjects (1 man. 3 women: age, 33 to 61 
years) who had been ancphric for 1 to 11 years. Amniotic fluid wos 
obtained from 3 women (age, 19 to 38 years) after naturni delivery. 
Follicular fluid wa.-. obtained from 3 women (age, 30 to 39) during an 
in vitro fertilization program. All incubations lasted 4 hours and were 
performed with and without 10 mmoliL M6P to determine M6P/ 
IGFTI receptor-specific binding. For comparison. incubations were 
also performed with recombinant human prorenin (a kind gift of Dr 
S. Mathews, Hoffmann*LoRoche) diluted in incubation medium to a 
concentration comp;trable to the lowest concentration in the native 
prorenin samples. At the end of the incubation period. the medium 
wa." removed. Each well was wa."hcd 3 times with 1 rnL ice-cold 
PBS. Cells were then lysed in 0.2 mL icc-cold PBS containing 0.2% 
Triton X-100 (Merck), and the cell lysate.~ were quickly frozen on 
dry ice. Media and celllysates were stored at -70°C. 
Recombinant Prorenin Binding and Internalization 
in the Presence of Plasma or Amniotic Fluid 
To study whether the soluble M6P/IGFII receptors and growth 
factors that arc present in pla.~ma and amniotic fluid affect prorenin 
binding and internalization by myocytes.. cell" were incubated at 4°C 
or 37°C with 0.4 rnL incubation medium containing 100 mU/mL 
recombinant human prorcnin in the presence of 0%, I%. 3%, IO%. 
or 30% (voVvol) plasmn (obtained from 6 healthy men: age, 26 to 64 
years) or amniotic fluid (obtained from 3 women. see above). On the 
basis of the leveL~ of endogenous renin plus prorcnin in plasma and 
amniotic fluid (240 and 5200 JLU/mL, fe!>-pcctivdy). it can be 
estimated that the addition of plasma or amniotic fluid to medium 
containing IOO mU/rnL recombinant human prorenin m;uginally 
(<2%) affected the levels of immunoreactive totnl renin. For 
comparison. incubations were alo;o performed with pla.~ma that had 
been incubated at 56°C for I hour to denature soluble M6P/IGFTI 
receptors, Incubations lasted 4 hours, and media and celllysates were 
collected and stored as described above. 
Native human prorenin uptake by cardiac cells 
Effect of Preincubation of Myocytes With Plasma 
on Reeombinant Prorenin Binding 
To study whether incubation with pla.~ma affects the number of 
cell-surface M6P/IGFII receptors, cell" were prcincubatcd at 37°C 
for maximally 2 hours with 0%, 3%, or 30% (vol/vol) plasma 
(obtained from 6 healthy men, see above) or plasma that bad been 
incubated ot 56°C for I hour. The cell" were then wa.'lbcd 3 times 
with I rnL ice-cold PBS and incubated at 4°C for 4 hours with 100 
mU/rnL recombinant human prorenin. Thereafter, media. and cell 
Jysates were collected and ~1:ored as described above. 
Effect of Preincubation of Recombinant Prorenin 
With Plasma or Amniotic Fluid 
To study whether plasma or amniotic fluid contain.." pbospbotasc 
activity toward the M6P label, 1 U recombinant human prorenin was 
incubated for 24 hours at4°C or 37°C in 1 mL 100 =oliL HEPES 
buffer (pH 7.4, Sigma). 0.5 mL HEPES buffer+0.5 mL plasmn 
(obtained from 6 healthy men.. see above), or 0.5 rnL HEPES 
buffer+0.5 mL amniotic fluid (obtained from 3 women.. see above) 
in the presence or absence of the pbosphatasc*inb.ibitors imidozolc 
(25 mmol/L, fmol concentration) (Sigma), Na ,B-glycerophosphate 
(5 mmoliL) (Sigma). and Na o-vnnadotc (2 mmoliL) (BDH Chem-
icals). Next, the pretreated recombinant human prorcnin (diluted in 
incubation medium to a fino.J. concentration of 100 mU/rnL) wa." 
incubated with myocyte.~ for 4 hours at 4°C. Media. and cell Jysates 
were collected and stored os described above. 
Renin and Prorenin Measurements 
In the experiment~ with recombinant human prorcnin. cell-activated 
prorcnin (ic, renin) and toto.l prorcnin (ie. cell-activated plus noDOc-
tivated prorcnin) were mea.wred by immunoradiometrie :1."--:ay. a." 
described beforc.' 0~ The results of this a."say arc expressed as 
mill.iunit~ per million cells or per milliliter of medium. with recom-
binant human prorenin used as a reference. The lower limit of 
detection wa." 5 JLV per million cells or per milliliter of medium. The 
immunoradiomctric a."--:ay is not sen.~itivc enough to allow the 
detection of the cellular renin and prorcnin leveL" in the experiments 
with plasma. amniotic fluid. and follicular fluid. The renin and 
prorenin mea."urcments in these experiment" were therefore per· 
formed by enzyme-kinetic assay.9 The results of thi~ :l."--:ay arc 
expressed a." milliunits per million celh or per milliliter of medium. 
with plasmin-activated recombinant human prorenin used a." o 
reference. The lower limit of detection wa.~ 1 JLU per million cell" or 
per milliliter of medium. 
Statistical Analysis 
Re:ults arc expressed as mean:!: SEM Data were compared by 
means of a Student's t test for paired observations or ANOVA A 
value of P<0.05 was considered to be ~i.gnificant 
Results 
Binding and Activation of Native Prorenin 
All samples of human origin (plasma. amniotic fluid. and 
follicular fluid) contained predominantly prorenin. As a 
result. the level of prorenin (expressed as a percentage of the 
sum of renin and prorcnin) in the media containing these 
smnples was 2:80% (Figure I. top). 
Incubation at 37°C with plasma from subjects with renal 
artery stenosis or plasma from hypertensive subjects treated 
with captopril. as well as incubation with follicular fluid, 
resulted in uptake of renin and prorenin by myocytes (Figure 
1. bottom). The uptake of plasma and follicular (pro)renin 
was M6P/IGFTI receptor mediated: it was abolished when 
M6P was added to the medium. However. the mnount of 
(pro )renin present in the cells after 4 hours of incubation with 
plasma or follicular fluid. expressed as a percentage of the 
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Figure 1. Binding and activation of native and recombinant 
human prorenin by myocytes. Top, Renin {black bars) and pro-
renin (white bars) levels in medium, Bottom, Levels of cell-
associated renin {black bars) and prorenln {white bars) after 4 
hours of incubation at 3'rC In presence or absence of 
10 mmoi/L M6P. rhPR indicates recombinant human prorenin; 
RAS, plasma from subjects with renal artery stenosis: CAP, 
plasma from hypertensive subjects treated with captoprll: Nx, 
plasma from nephrectomized subjects; /'F, amniotic fluid; and 
FF, follicular fluid. Data are mean::!:SEM of 4 experiments.. 
*P<0.05 vs without M6P. 
renin and prorenin levels in the medium. was 4 to 10 times 
lower than after incubation of the cells with recombinant 
human prorenin (Figure 1). 
At the end of the incubation period. the cells contained 
predominantly (>75%) renin. indicating that the internalized 
prorenin had been activated. 
Incubation with plasma from nephrectomized subjects. or 
with amniotic fluid. did not result in M6PIIGFII receptor-
mediated accumulation of renin or proreoin. despite the fact 
that the prorenin levels in the medium containing these 
samples were comparable to or much higher than the levels of 
recombinant human prorenin that did result in cellular o.ccu~ 
mulation of prorenin (Figure 1). 
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Figure 2. Cellular prorenin levels after Incubation of myocytes 
for 4 hours with 100 mU/mL recombinant human prorenin in 
presence of nonlnactivated plasma (8), heat·inactlvated plasma 
(o), or amniotic fluid (•) at 4°C Qeft) or 3rC (right). Levels 
(mean±SEM; n=6 to 8) are expressed as percentage of levels 
measured In absence of plasma or amniotic fluid. ·P<O.OS vs 
100%. 
Recombinant Prorenin Binding and Internalization 
in the Presence of Plasma or Amniotic Fluid 
Plasma from healthy men as well as amniotic fluid inhibited 
recombinant human prorenin binding at 4°C in a 
concentration~dcpendent manner (Figure 2. left). Heat inac· 
tivation. which denatures soluble M6PIIGFII receptors. abo!· 
ished this effect. Similar data were obtained with plasma from 
anephric subjects (n==3. data not shown). Remarkably. at 
37°C. heat·inactivated plasma from healthy men enhanced 
recombinant human proreoin uptake in a concentration· 
dependent manner (Figure 2. right). This effect was not 
observed during incubation with noninactivated plasma at 
37°C. Activation of recombinant human prorenin by myo-
cytes (after 4 hours of incubation at 37°C, 85::!::5% of total 
cell-associated prorenin was activated. n==6) was not affected 
by coincubation with noninactivated or heat-inactivated 
plasma (data not shown). 
Effect of Preincubation of Myocytes With Plasma 
on Recombinant Prorenin Binding 
A 30-minute preincubation of myocytes with plasma of 
healthy men increased recombinant human prorenin binding 
by ""'100% (Figure 3. left). This effect was diminished on 
}Qnger preincubation with plasma and occurred in a 
concentration-dependent manner (Figure 3. right). Preincuba-
tion with heat·inactivated plasma yielded similar results. 
Effect of Preincubation of Recombinant Prorenin 
With Plasma or Amniotic Fluid 
Preincubation of recombinant human prorenin with plasma or 
amniotic fluid. with or without phosphatase inhibitors. did not 
affect its binding to myocytes (Figure 4). 
Discussion 
This study shows that neonatal rat cardiomyocytes bind 
native human prorenin through M6PIIGFII receptors. Binding 
is limited to prorenin of renal and follicular origin and is 
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prolneublrtlon tlmo '}'.plasma 
"'""' Figure 3. Cellular prorenin levels after Incubation of myocytes 
for 4 hours with 100 mU/mL recombinant human prorenin after 
prelncubatlon of celts with 30% plasma for 0.5, 1, or 2 hours 
~eft) or wlth 3% or 30% noninactlvated (0) or heot~lnactlvated 
{o) plasma for 2 hours (rlght), Levels (mean::!::SEM; n"'6) are 
expressed as percentage of levels measured without preincuba-
tion of cells. 
followed at 37°C by intemal.i7..ation and activation to renin. 
Preincubation of myocytes with plasma at 37°C increases the 
number of cell-swface M6P/IGFII receptors. thereby enhanc-
ing subsequent prorenin binding, whereas coincubati.on with 
soluble M6P!IGFIT receptors containing bumun body fluids 
reduces prorenin binding to myocytes. 
In previous studies. we demonstrated that myocytes bind 
M6P-containing recombinant human renin and prorenin ex-
clusively through M6PIIGFJI receptors.Z4 No evidence was 
obtained for the presence of other (pro)renin receptors on 
myocytes. Our current cb.u, showing M6P/IGFIT receptor-
media.ted binding and activation of plasma prorenin. support 
the concept of circulating. kidney-derived prorenin connib-
uting to cardiac Ang II production. Our inability to demon-
Str:lte uptake of circulating prorenin of anepbric subjects 
suggests that extrarenally produced prorenin Lacks the M6P 
signal. This might explain why C:ll'diac tissue levels of Ang II 
in anepbric ani.mals are close to or below the detection 
lim.it,2.1N despite the continuous presence of prorenin in the 
"' 
buffw anu>lo!lc fluid 
37"C 37"C :J:I"C <t'C 
Figure 4. Cellular prorenin levels after Incubation of myocytes 
for 4 hours at 4QC with 100 mU/mL recombinant human prore-
nln after preincubation of recombinant human prorenln for 24 
hours at 4QC or 3'rC with HEPES buffer, plasma, or amniotic 
fluid in presence or absence of phosphatase Inhibitors. Levels 
(mean±SEM; n:3 to 6) are expressed as percentage of levels 
obtained with nonpreincubated recombinant human prorenln. 
Native human prorenin uptake by cardiac cells 
circulation of anepbrics.19-21 Glycosylation differences be-
tween prorenin of renal and extrarenal origin are in full 
agreement with the isoelectric heterogeneity of prorenin in 
human body fluids.16.17.ZS 
However, not all extrarenal prorenin lacks the M6P signal; 
we did observe M6PJIGFli receptor-mediated binding and 
activation of ovary-derived prorenin. Ovarian prorenin is 
produced and secreted by the mature follicle and by the 
corpus luteum26 and is largely responsible for the rise in 
plasma prorenin that normally occurs during pregnancy.~6.27 
The function of ovarian prorenin in plasma is currently 
unknown. On the basis of our data. it appears that ovarian 
prorenin may p:lrti.cipate in C:ll'diac and vascular Ang II 
production. Chorionic prorenin. in contr::LS.t with ovarian 
prorenin. does not enter the circulation in significant 
amounts,n nor did we observe M6PJIGFli receptor-mediated 
uptake of this prorenin by myocytes. The latter is not due to 
the presence of pbo~-pbatase activity in amniotic fluid (Figure 
4). Moreover. in agreement with our findings. the isoelectric 
focusing profile of chorionic prorenin is different from that of 
renal prorenin. 17 
All prorenin-containing human body fluid samples that 
were applied in the present study also contained small 
amounts of renin ( <20% of total renin). After 4 hours of 
incubation at 37"'C with plasma or ovarian prorenin. the 
myocytes. however, were found to contain predominantly 
(>75%) renin. Because M6PJIGFli receptors do not make a 
distinction between M6P-containing renin or prorenin.'~· 10 the 
high cellular levels of renin cannot be explained on the basis 
of selective uptake of renin. A more likely explanation is 
therefore that native human prorenin. like recombinant hu-
man prorenin. is proteolytically activated after it" binding to 
M6PIIGFli receptors. Such activation occurs intracellularly. 
as demonstrated previously with the acidwwasb metbod. 10 
M6PIIGFII receptors recycle between the cell surface and 
intr::Lcellular compartments. and the majority of the cellular 
M6PJIGFII receptors is located intracellularly.11 Because of 
this continuous recycling. the cellular prorenin levels are 
higher after incubation at 37"'C than after incubation at 4"'C 
and increase proportionally with the levels of prorenin in the 
medium.:M In the present study, the cellular leveL" of native 
renin+prorenin (expressed as a percentage of the 
renin+prorenin levels in the medium). measured after 4 hours 
of incubation at 37"'C with plasma.. were several times lower 
than after incubation with recombinant human prorcnin. This 
may have several reasons. FII'St. the percentage of plasma 
(pro)renin molecules containing the M6P signal may be lower 
than the percentage of recombinant human prorenin mole-
cules ( -40%):M carrying this signal. If so. this is not due to 
phosphatase activity in plasma (Figure 4). 
Second. plasma contains high levels (-3.5 nmol/L)22 of 
soluble M6PIIGFli receptors, which. through competition. 
will prevent M6P-containing prorenin from binding to cellu-
lar M6PIIGFli receptors. Under the conditions of our incu-
bation experiments (0.6 million cells exposed to 0.4 mL 
medium containing 30% plasma). the number of soluble 
receptors in the medium will exceed the number of cell-
surface receptors (-4000/cell):M by a factor of 100. Indeed. in 
agreement with the presence of soluble M6PJIGFII receptors. 
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we observed that coincubation of recombinant human prore· 
nin with 30% plasma at 4°C decreased recombinant human 
prorenin binding to myocytes by ... 50%. This effect disap-
peared after heat inactivation of soluble plasma M6PIIGFII 
receptors. Similar data were obtained with amniotic fluid and 
plasma of anephric subjects. thereby indicating that the 
absence of prorenin binding during incubation with these 
fluids is not due to the presence of exceptionally high soluble 
M6PIIGFTI receptors in anephric plasma or amniotic fluid. In 
fact. the levels of soluble M6P/IGFIT receptors in amniotic 
fluid are lower than in plasma.z:: No data are currently 
available on the presence of these receptors in follicular fluid. 
The function of soluble M6P/IGFII receptors is not yet 
known but may involve transport ofiGFII.zz Intere.."tingly. the 
levels of soluble M6PIIGFIT receptors are highest in circul:J.t. 
ing blood plasma of pregnant women and diabetics. two 
groups of subjects with high plasma prorenin levels.23.2l:! 
Finally. several growth factors in plasma. including insulin 
and IGFII. decrease the rate of M6P/IGFII receptor intemal-
ization through induction of receptor dephosphorylation. 
thereby increasing the steady-state cell-surface M6P/IGFII 
receptor number.ll Indeed. preincubation of myocytes with 
plasma at 37°C enhanced binding of recombinant human 
prorenin by the cells during subsequent incubation at 4°C. 
The increase in cell-surface receptor number occurred rapidly 
and appeared to diminish on longer incubation with plasma. 
Coincubation of cells with recombinant human prorenin 
and heat-inactivated plasma at 37°C also resulted in higher 
levels of cell-associated prorenin than incubation with recom-
binant human prorenin alone. This confirms that heat inacti-
vation at 56°C does not result in the destruction of growth 
factors. Enhanced prorcnin binding was not observed when 
coincubating noninactivated plasma with recombinant human 
prorenin. demonstrating that the growth factor-induced up-
regulation of cell-surface M6P/IGFII receptors may compen-
sate for the decrease in prorcnin binding caused by the 
·presence of soluble M6P/IGFII receptors. Taken together. 
therefore. the most likely explanation for the 4- to 10-fold-
lower uptake of plasma and follicular fluid prorenin as 
compared with recombinant human prorenin is a difference in 
glycosylation and/or phosphorylation between native and 
recombinant prorenin. 
Conclusions 
Myocytes bind and activate native human prorenin through 
M6P/IGFII receptors. This process depends on the presence 
of the M6P signal on prorenin and is affected by the presence 
of soluble M6P/IGFII receptors and growth factors in human 
body fluids. These data show the complexity of cardiac 
prorenin uptake, which. eventually. determines the degree of 
Ang IT generation in the heart. 
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ChapterS 
Prorenin-Induced Myocyte Proliferation 
No Role for Intracellular Angiotensin II 
Jasper J. Saris. Mark M.E.D. van den Eijnden, Jos M.J. Lamers, Pramod R. Saxena, 
Maarten A.D.H. Schalekarnp, A.H. Jan Danser 
Abstract---Cardiomyocytes bind. internalize. and activate prorenin. the inactive precursor of renin. via a mannose 
6-phosphate receptor (M6PR}-dependent mechanism. M6PRs couple directly to GMproteins. To investigate whether 
prorenin binding to cardiomyocytes elicits a response. and if so. whether this response depends on angiotensin (Ang) 
II. we incubated neonatal rat cardiomyocytes with 2 nmol/L prorenin and/or 150 nmol/L angiotensinogen. with or 
without 10 mmoiJL M6P, I ,umol/L eprosartan. or 1 p.mol!L PD123319 to block M6P and AT1 and AT2 receptors. 
respectively. Protein and DNA synthesis were studied by quantifying eHJ-leucine and eHJ-thymid.ine incorporation. For 
comparison. studies with 100 nmol/L Ang II were also performed. Neither prorcnin alone, nor angiotensinogen alone. 
affected protein or DNA synthesis. Prorenin plus angiotensinogen increased [3H]~leucine incorporation (+21:±:5%. 
mean±SEM, P<0.01). eHJ-thymidine incorporation (+29:±:6%. P<0.01), and total cellular protein (+14±3%. 
P<O.OI). whereas Ang IT increased DNA synthesis only (+34:±:7%. P<O.Ol). Eprosartan. but not PD123319 or M6P. 
blocked the effects of prorenin plus angiotensinogen as well as the effects of Ang IT. Medium Ang IT levels during 
prorenin and angiotensinogen incubation were <1 nmoJJL. In conclusion. prorenin binding to M6PRs on cardiomyo-
cytes per se does not result in enhanced protein or DNA synthesis. However. through Ang IT generation. prorenin is 
capable of inducing myocyte hypertrophy and proliferation. Because this generation occurs independently of M6PRs. 
it most likely depends on the catalytic activity of intact prorcnin in the medium (because of temporal prosegment 
unfolding) rather than its intracellular activation. Taken together. our results do not support the concept of Ang II 
generation in cardiomyocytes following intracellular prorenin activation. (Hypertension. 2002;39[part 2]:573-577.) 
Key Words: myocytes • renin • insulin growth factor • receptors. angiotensin 
Cardiac angiotensin synthesis depends on renin of renal origin. both under normal and pathological condi-
tions.1-4 Circulating kidney-derived renin diffuses into the 
cardiac interstitial space.5•6 and/or may bind to renin recep-
tors.?-9 In addition. the heart may sequester prorenin. the 
precursor of renin. from the circulation, Prorenin could 
contribute to angiotensin generation at cardiac tissue sites. 
either because of its inherent catalytic activity. which is the 
consequence of temporal prosegment unfolding,to.tt or fol· 
lowing its local conversion to renin. In support of this 
concept, we have recently demonstrated that cardiac myo-
cytes and fibroblasts are capable of binding and internalizing 
recombinant human renin and prorenin via mannose 
6-phosphatefmsulin-like growth factor II (M6PJIGFIT) recep-
tors. and that prorenin following its internali7..ation is rapidly 
activated to renin by proteolytic cleavage of the 
prosegment t Z.B 
Recombinant as well as native human renin and prorenin 
contain the M6P signal that is required to bind to M6PJIGFII 
receptors.t4-16 These receptors also contain binding domains 
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for IGFII and retinoic acid.17,ts and binding of the latter 
agonists to M6PJIGFII receptors results in second messenger 
activation and growth inhibition. respectively.l9.2o Moreover, 
proliferin. which, similar to (pro)renin., binds to M6PJIGFII 
receptors via its M6P group.21 has been reported to induce 
endothelial cell chemotaxis via these receptors in a G-protein-
and mitogen-activated protein kinase-dependent manner,zz In 
this respect, it is of interest to note that renin binding to 
mesangial cells resulted in enhanced 3H-thymidine incorpo-
ration and plasminogen-activator inhibitor-! (PAI-l) release. 
without intermediate angiotensin generation.9 
M6PIIGFIT receptor-mediated accumulation of renin and 
activated prorenin in cardiac cells may result in intracellular 
angiotensin generation. ::md such intracellular angiotensin 
synthesis could underlie the stretch-mediated release of an-
giotensin IT (Ang II) that has been demonstrated in myo-
cytes.n.24 However. to allow intracellular Ang II synthesis. 
the intracellular presence of angiotensinogen and ACE is also 
required. and in previous studies we were unable to detect 
.angiotensinogen synthesis by cardiomyocytes.2:5 
In the present study. we set out to investigate whether 
prorenin binding. internalization. and activation by neonatal 
rat cardiomyocytes results in a cellubr response. either 
directly (without intermediate Aog n generation). via binding 
to M6P/IGFII receptors. or indirectly. via the generation of 
Ang II and subsequent AT receptor activ::ttion. We meosured 
protein and DNA synthesis following incubation of cells with 
recombinant human prorenin with or without angiotensino-
gen. Experiments were repeated in the presence of M6P. 
eprosartan. and PD123319. to antagonize M6P/IGFII -. AT1 -. 
and AT2 receptors. respectively. For comparison. we also 
studied the effect of Ang IT in the presence and absence of 
these antagonists. Fl.ll3lly. we investigated Ang I and TI 
generation during incubation of myocytes with prorenin and 
angiotensinogen, t:Jki.ng into consideration that prorenin itself 
displays catalytic activity (ie, without prosegment cleavage). 
Methods 
Cell Culture 
All experiment~ were perfonned according to the regulations of the 
Animal Care Committee of the Era.~mus University Medical Center 
Rotterdam. in accordance with the MGuiding Principles" of the 
American Physiological Society. 
Prim.ary cultures of neon:1tal Wistar rat (Harlan) cardiomyocytes 
were prepared as previously described. ttl~ Cells were seeded in 
nonco:ltcd 24-well plates (Corning Costar), giving a confluent 
monolayer of spontaneously beating myocytes at l.SX I!Ji cellsfcmZ 
after a 24-hour incubation in 1.5 mL medium (consisting of DMEM 
and Medium 199 [4:1], ~-upplemented with 5% fetal calf serum [Life 
Technologies], 5% horse serum [Sigma], 100 U/mL penicillin, and 
100 mg/mL streptomycin [Roche]). Thereafter. cells were incubated 
for 48 hours in medium supplemented with 5% horse serum and for 
24 hours in serum-free medium. Before the start of each experiment. 
cells were rinsed 3 times with 1 mL warm (37°C) phosphate-
buffered saline. Next. myocytes were incubated for 24 hours at 37°C 
with 250 pL serum-free medium. supplemented with 1% bovine 
serum albumin (BSA), and containing 100 U!L (""'2 nmol!L) 
recombinant human prorenin (a kind gift of Dr S. Mathews., 
Hoffmann-LaRoche, Basel, Switt..erland) and/or 150 nmol/L human 
angiotcnsinogcn (Sigma) in the presence or absence of 10 mmol!L 
M6P. 1 p..mol!L eprosartan, or I p..mol/L PD1233\9. For comparison. 
experiments with 100 nmol!LAng D (Bachem) were also pcrfonned. 
Celb incubated without prorenin. angiotensinogen, orAng II served 
a.~ control. 
Protein and DNA Synthesis 
Protein and DNA synthesis rates were determined in triplicate by 
quantifying [lH]-lcucine and rHJ-thymidine incorporation during 
the last 6 hours of the above 24-hour incubation period in the 
presence of Ang II or prorenin and/or angiotensinogen.~~ Total 
cellular protein and DNA were quantified after solubilization as 
descn'bed previously using BSA and salmon spenn a.~ standard. 
respectively.::.. 
Angiotensin Generation 
To measure angiotensin generation, myocytes were cultured in 
6-well plates, and incubated at 37°C for 4 hours with 1 mL medium 
containing 10 or 100 U!L recombinant human prorenin and/or ISO 
nmol/L angiotensinogen. Cells incubated without prorenin or angio-
tensinogen served as control. After 1 hour and 4 hours of incubation., 
75 pL medium was rapidly mixed with 6 pL inhibitor solution27 and 
frozen at -70°C. Cells were collected after 4 hours (when the 
cellular levels of activated prorenin arc maximal';:.',) a.~ described 
bcfore.27 Ang I and Ang II levels in medium were measured by 
radioimmunoas:>ay (detection limit 40 and 20 fmoVmL. respective-
ly).~.27 Ang I and D leveL~ in cell homogenmes were measured by 
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Figure 1. Effect of 2 nmoVL prorenln, 150 nmoVL anglotensino-
gen, 2 nmoVL prorenln plus 150 nmoVL angiotenslnogen, and 
100 nmoVL angiotensin (Ang) II on total cellular protein content, 
total cellular DNA content. f!HHeuclne Incorporation. and 
f!HJ-thymidlne incorporation in cardiomyocytes. Data are 
expressed as percentage change from control (mean±SEM of 
8-16 ex:perlments). PR indicates prorenin; Aog, anglotenslno-
gen. "P<0.01 versus control. 
radioimmunoassay after SepPak extraction and reversed-phase high-
performance liquid chromatography separation (detection limit 0.4 
and 0.2 fmolfto• cells).~.27 For comparison, cellular angiotensin 
levels following a 4-bour incubation with 100 nmol!L Ang II were 
al.~o meru.1l!Cd. 
Statistical Analysis 
Data arc expressed a.~ me:m±SEM. Statistical analysi.~ was by 
ANOV A, followed by post-hoc evaluation according to Dunnett 
where appropriate. Statistical significance was accepted at P<O.OS. 
Results 
Protein and DNA Synthesis 
The total cellular protein and DNA contents of myocytes, 
following a 24-hour incubation with vehicle. were 147:!: 14 and 
8.3:!:1.0 ,u.g!well (n=I5-16). respectively. Incorporation of 
3H-leucine and 3H-thymidine during the last 6 hours of the 
24-hour incubation period amounted to 27901:!:3707 and 
57403:!:6262 dpmlwell (n=16), respectively. None of the re-
ceptor blockers affected protein or DNA content or incorpora~ 
tion of 3H~leucine and 3H~thymidine (n=S for each blocker. data 
not shown). Prorenin alone and angiotensinogen alone were 
without effect (Figure 1). Prorecin (2 nmol/L) combined with 
:mgiotensinogen increased total cellular protein (P<O.OI). >H~ 
leucine incorporation (P<O.Ol). ::md 3H~thymidine incorporation 
(P<O.Ol), whereas Ang II increased the htter (P<O.Ol) only. 
The effects of prorecin combined with angiotensinogen were not 
observed at a prorenin concentration of 0.2 nmol/L (n=IO. data 
not shown). All effects of prorecin combined with ::mgioten~ 
sinogen as well as the effect of Ang TI on 3H-thymidine 
incorporation were blocked by eprosartan but not PD123319 or 
M6P (Figures 2 and 3). PD123319 tended to enhance the effects 
of Ang II on total cellular protein. but the difference wa.~ not 
~ignificant (Figure 3). 
Angiotensin Generation 
Ang I and Ang TI were undetectable in medium or cells under 
control conditions and following incubations with either 
prorenin alone or angiotensinogen alone. At 1 hour after the 
addition of 2 nmol/L prorenin combined with 150 nmol/L 
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Figure 2. Effect of 2 nmoVL prorenln plus 150 nmoVL angloten-
sinogen on total cellular protein content, total cellular DNA con-
tent, fHHeucine incorporation, and fHJ-thymldine incorporation 
in cardiomyocytes in the presence of vehicle (none), the AT, 
receptor antagonist eprosartan (Epro: 1 ~oLIL). the AT2 recep-
tor antagonist PD123319 (1 ;.unoi/L), or the M6PIIGFI! receptor 
antagonist M6P (10 mmoLIL). Data are expressed as percentage 
change from control (mean:!:SEM of 8 experiments). #P<O.OS 
versus none. 
o.ngiotensinogen to the cells. Ang I and Ang II levels in the 
medium were 4278::!::207 and 372:::!:23 pmol/L (n=3). and 
after 4 hours these levels nmountcd to 4704::!:::462 o.nd 
795±102 pmol/L, When using 0.2 nmol/L prorcnin in com-
bin:rti.on with 150 nmol/L o.ngiotensinogen. the Ang I and 
Ang II levels in the medium were 656::!::161 and 85::!::14 
pmol/L after 1 hour (n=3), and 876::!::43 and 129::!::18 pmol/L 
after 4 hours. Cellular Ang I levels measured after 4 hours of 
incubation with prorcnin and angiotensinogen or 100 nmol/L 
Ang n were below the detection limit (n=3 for ca.ch 
condition). Cellular Ang IT levels were also undetectable 
following a 4-hour incubation with 0.2 nmol/L prorenin 
combined with 150 nmol/L angiotensinogcn. However. at a 
10-fold higher prorenin concentration. as well as following a 
4-hour incubation with 100 nmol/L Ang n. cellular Ang II 
levels amounted to 1.3::!::0.5 and 1.9::!::0.3 fmol/W cells. 
Angiotensin 11 
Figure 3. Effect of 100 nmoVL Ang II on total cellular protein 
content, total cellular DNA content fH]·Ieuclne incorporation, 
and fH]-thymldlne Incorporation in cardlomyocytes in the pres-
ence of vehicle (none), the AT, receptor antagonist eprosartan 
(Epro: 1 ttmoi/L), the AT~ receptor antagonist PD1233i9 (1 
ttmoi!L), or the M6PIIGFII receptor antagonist M6P (1 0 mmoi!L). 
Data are expressed as percentage change from control 
(mean::tSEM of 8 experiments). #P<O.OS, "P<0.01 versus none. 
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respectively (n=3 for each condition). These levels represent 
<0.5% of the levels in the medium. 
Discussion 
Prorenin binding to M6P/IGFII receptors located on the cell 
surface of neonatal rat cardiomyocytes does not result in 
enhanced protcin or DNA synthesis. Enhanced protein and 
DNA synthesis were observed however when exposing the 
cells to prorenin combined with angiotensinogcn. suggesting 
that these effects depend on angiotensin generation. Because 
prorenin binding to M6PIIGFII receptors is followed by 
intemal.i.7..ation and rapid intracellular activation to renin. 
without subsequent release of renin to the medium,12.13 we 
reasoned that intracellular angiotensin synthesis might under-
lie these fmdings. Such intracellular angiotensin genemtion 
will not occur in the absence of prorcnin, because neonatal mt 
-cardiomyocytes do not synthesi7.e renin in detectable 
.amounts.::-..:; However, the addition of 10 mmol/L M6P to the 
medium, which fully blocks prorenin internilization and 
.activation,12.13 did not block the prorenin plus angioten-
sinogcn-induced effects on DNA and protein synthesis. Re-
markably. blockade was observed with the AT1 receptor 
antagoirist eprosartan.. while the AT2 receptor antagonist 
PD123319. like M6P. was without effect In view of the 
virtual lack of internalization of receptor antagoiristsP the 
most likely explanation for these findings is that the inherent 
catalytic activity of prorenin. caused by temporal unfolding of 
the prosegment. results in extracellular A.ng TI generation and 
subsequent AT1 receptor stimulation. In support of this 
concept. Ang I and Ang II could be detected in nanomolar 
concentrations in the medium during incubation of the cells 
with 2 nrnol/L prorenin and 150 nmol/L angiotensinogen. 
The lack of effect of prorenin binding per sc was unex-
pected. because several groups have reported that binding of 
M6P-containing glycoproteins to M6P!IGFII receptors results 
in a cellular response in a G-protein-dependent manner. eg. 
chemotaxis or increased c-fos expression. 19.:Z Moreover. 
binding of renin to human mesangial cells was found to 
enhance 0H~thymidine incorporation and PAl~ 1 release. inde-
pendent of angiotensin genemtion.9 The receptor mediating 
the latter effect has not yet been identified and is not 
necess::uily the M6P/IGFII rcceptor.9 Furthermore. the IGFII 
analog [Lcu27]1GFII, which binds to the M6P/IGFII receptor 
with equal affinity as IGFII. induced chemotaxis but not 
DNA synthesis.29.;1° Therefore, taken together, it is still very 
well possible that prorenin binding to M6PJIGFIT receptors 
elicits other cellular responses than protein and DNA 
synthesis. 
The addition of human angiotcnsinogen to the medium did 
not result in protein or DNA synthesis. This suggests that 
neonatal rat cardiomyocytes. like mouse cardiomyocytcs,31 
do not posses enzymes (eg. cathepsins) capable of cleaving 
human angiotensinogen into Ang I and des-angiotensinogcn. 
Ang I generation only occurred when combining human 
prorenin with human angiotensinogen. and this generation 
was limited to the extracellular compartment The absence of 
intracellular Ang I. despite the proteolytic cleavage of prore-
nin to renin in myocytes. is in agreement with previous 
studies showing neither binding of angiotensinogen to cardiac 
and va...;.cular membrane :fractions.t,ll nor angiotensinogen 
intem:ilization.27 Apparently. the intracellular presence of 
Ang IT in myocytes must be explained on the basis of AT1 
receptor~mediated endocytosis,3~34 rather than intracellular 
Ang IT generation. In support of this contention. Ang n W:lS 
also detected in cell lys:ues following a 4-hour incubation 
with 100 nmol/L Ang IT. Furthermore. the low cellular Ang IT 
levels during incubation with prorenin plus angiotensinogen 
( <0.5% of the levels in the medium) al~o argue against 
synthesis and/or storage of Ang IT in myocytesP 
In the present study. extracellular Ang I generation oc-
curred in a prorcnin concentration-<lcpcndent manner. At the 
highest prorenin concentration tested (2 nmoJJL). the Ang I 
levels in the medium reached a steady state within 4 hours. 
The leveL~ were in the order of 5 nmol/L, which is within the 
range expected based on the concept that <2% of prorenin i..<; 
catalytically active.27 We previously reported that. in the 
absence of serum. Ang I-IT conversion by ACE on myocytes 
is responsible for approximately 50% of Ang I metabolism by 
neonatal rat cardiomyocytes.. and that the Ang I half life under 
these conditions is 1 hour.Z!; The Ang ll half life is much 
longcr,Z<> and this may explain why the medium Ang IT levels 
in the present study continued to rise between 1 and 4 hours. 
Importantly however. the Ang IT levels in the medium after 4 
hours of prorenin plus angiotensinogen incubation were less 
than 1 nmol!L. and it is unlikely. in view of the stcady~statc 
Ang I levels, that these levels would have become much 
higher on longer incuixt.tion. Yet. despite these relatively low 
Ang IT levels.. the effects of prorenin combined with angio-
tensinogen on protein and DNA synthesis were equal to or 
stronger than those of 100 nmolJL Ang IT. There are seveml 
explanations for this apparent discrepancy. First. Ang I-II 
conversion by ACE may occur in close prox:imlty of AT1 
receptors and may thus result in higher Ang IT levels in the 
microenvironment of these receptors than in the medium. 35 
Second. long-term exposure to low levels of Ang II (as a 
consequence of continuous Ang IT generation) might be more 
efficient to induce cellular responses than short-term expo-
sure to high levels of Ang II. for instance because the latter 
results in rapid downregulation of AT1 receptors.36 Fmally. 
because neonatal rat cardiomyocytes possess both AT1 and 
AT: receptors. Ang II may al~o stimulate AT2 receptors. and 
this could counteract the AT1 receptor-induced effect.~.Z<>.J7 It 
is possible that ACE-dependent local Ang IT generation 
predominantly leads to AT1 receptor activation, because ACE 
is located in close proximity of AT1 receptors,J8 whereas 
exogenous Ang IT results in equal AT1 and AT2 receptor 
activ:J.tion. In agreement with this concept. as in our previous 
study,26 the Ang IT-mediated effect on total cellular protein 
increased in the presence of PD123319 (Figure 3). 
The effects of locally generated and exogenous Ang IT on 
protein and DNA synthesis rate were of modest proportion 
and exceeded those on total cellular protein and DNA 
content. suggesting that they may have been counterbalanced. 
at least in part. by protein and DNA degradation. 
In conclusion, the partial catalytic activity of prorenin is 
responsible for the enhanced protein and DNA synthesis 
observed in eardiomyocytes during their incubation with 
prorenin and angiotensinogen. We found no evidence for 
Does prorenin induce cellular effects? 
intracellular angiotensin generation in these cells.. nor did 
prorenin binding to M6PIIGFJI receptors per sc result in cell 
proliferation. 
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Summary and concluding remarks 
Chapter 1 & 2- Introduction 
The renin-angiotensin system (RAS) was originally seen as an endocrine system 
regulating blood pressure and Na+ excretion. According to this concept, its active 
endproduct, angiotensin II, is generated in the circulation by the enzymes renin 
(released from the kidneys) and angiotensin-converting enzyme (ACE) from the liver-
derived substrate angiotensinogen. Angiotensin II activates angiotensin II (AT) 
receptors, resulting in vascular contraction and renal Na+ and H20 retention. 
To explain the success of ACE inhibitors and AT receptor blockers in the treatment 
of cardiovascular diseases the concept of local or tissue RAS was developed, 
separate from the circulating RAS.1"2 This concept implies in situ generation of 
angiotensin II, rather than delivery of circulating angiotensin II to tissues.' 
At first it was thought that the renin and angiotensinogen required for such in situ 
angiotensin II generation are synthesized de novo at tissue sites. Although this may 
be the case in some organs, in the heart the mRNA levels for renin and 
angiotensinogen are low or undetectable:·• Moreover, renin activity disappeared 
from the heart following a bilateral nephrectomy and the perfusate of isolated 
perfused hearts does not contain renin or angiotensinogen.""7 Both proteins, 
however, can be detected in the heart under normal as well as pathological 
conditions ... " Presumably therefore, most of cardiac renin and angiotensinogen, if 
not all, is taken up from the circulation. As the levels in the circulation of prorenin, the 
inactive precursor of renin, are much higher than the levels of renin, it is also 
conceivable that prorenin is sequestered and, following activation, contributes to 
cardiac angiotensin formation. Inhibition of cardiac uptake and/or activation of 
kidney-derived prorenin might reduce local angiotensin II generation in the heart. 
It was the aim of the present thesis to study the functional importance of local 
angiotensin II generation and the possible role of (pro)renin in this process. 
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Chapter3 
To assess the importance of in situ angiotensin II formation in the arterial wall, as 
opposed to angiotensin II delivery via the circulation, we determined forearm 
vasoconstriction in response to infusion of angiotensin I or angiotensin II in 14 
normotensive male volunteers. 
Both angiotensins reduced forearm blood flow by maximally 70-75% with equal 
potency (4 nmoi/L). Forearm fractional angiotensin I-ll conversion was 36% (range 
18% to 57%). The ACE inhibitor enalaprilat inhibited the contractile effects of 
angiotensin I and reduced fractional conversion to 1% (range 0.1% to 8%), thereby 
excluding a role for converting enzymes other than ACE. Blockade of AT1 receptors 
with losartan inhibited the vasoconstrictor effect of angiotensin II. In conclusion, the 
equal potencies of angiotensin I and angiotensin II, combined with the limited 
conversion of angiotensin I, suggests that in situ generation of angiotensin II is more 
important for vasoconstriction than circulating angiotensin II. 
Chapter4 
To study angiotensin II synthesis by cardiac cells, independently of renal renin and 
liver derived angiotensinogen, we measured renin, prorenin, angiotensinogen, ACE, 
angiotensin I and angiotensin II in cell lysates and conditioned media of neonatal rat 
cardiac myocytes and fibroblasts cultured under serum-free conditions for 5 days. 
Measurements were also made in the unconditioned horse serum- and fetal calf 
serum-containing medium used for isolation and adherence of the cells, and in the 
conditioned serum-free medium of myocytes exposed to cyclic stretch, since stretch-
induced hypertrophy of myocytes is believed to depend on the release of 
angiotensin II by these cells.12•15 
All RAS components were detectable in unconditioned serum-containing medium. In 
serum-free conditioned medium low levels of prorenin, but none of the other RAS 
components, could be detected. The angiotensin !-generating activity corresponding 
with these low prorenin levels was not of rat origin, as the activity could not be 
inhibited by the rat renin-specific inhibitor CH-732. Most likely therefore, this prorenin 
is bovine and/or horse prorenin that is sequestered from the serum-containing 
medium used for the isolation and adherence of the cells, prior to the serum-free 
incubation period. 
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Both myocytes and fibroblasts converted angiotensin I to angiotensin II and this was 
completely inhibited by captopril. Renin, prorenin, angiotensinogen, angiotensin I or 
angiotensin II were not detected in the lysates of serum-deprived myocytes or 
fibroblasts. The application of stretch to myocytes under serum-free conditions 
increased protein synthesis by 20%, but this was not accompanied by angiotensin II 
secretion. 
In conclusion, cultured cardiac myocytes and fibroblasts do not synthesize (pro)renin 
and angiotensinogen in amounts that are high enough to result in angiotensin II 
concentrations of physiological relevance. Myocytes and fibroblasts do express ACE 
on the cell surface, thereby allowing the synthesis of angiotensin II at cardiac tissue 
sites when renin and angiotensinogen, or angiotensin I, are provided from the 
circulation. ACE is the only angiotensin !-converting enzyme on cardiac cells. 
Angiotensin II release is not a prerequisite for the hypertrophic response, following 
stretch, of cardiomyocytes. 
Chapter 5 and 6 
Earlier reports have suggested that mannose 6-phosphate!lnsulin-like growth factor II 
(IGFII) receptors are involved in the binding and activation of recombinant human 
prorenin by cardiac and endothelial cells.16"17 To investigate the kinetics of this 
process, the nature of activation, and the existence of other prorenin receptors, 
neonatal rat cardiac myocytes and fibroblasts or human umbilical vein endothelial cells 
(HUVECs) were incubated with recombinant wild-type prorenin, K/A-2 prorenin (in 
which Lys42 is mutated to Ala42, thereby preventing cleavage by known proteases), 
man nose 6-phosphate-free prorenin and non-glycosylated prorenin, with or without 
mannose 6-phosphate, protease inhibitors or angiotensinogen. Intact and activated 
prorenin were measured in cell lysates with prosegment- and renin-specific antibodies, 
respectively. Cardiac cells, as well as HUVECs, only bound mannose 6-phosphate-
containing prorenin. The dissociation constant (Ko) for prorenin binding to mannose 6-
phosphate/IGFII receptors was approximately 1 nmoi!L for either cell type. The 
maximum number of binding sites (Bmoxl was highest in cardiomyocytes. At 37°C, due 
to mannose 6-phosphate/IGFII receptor recycling, the amount of prorenin internalized 
via man nose 6-phosphate/IGFII receptors was >1 0 times Bmax· The levels of 
internalized intact prorenin decreased rapidly, indicating proteolytic prosegment 
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removal. Renin was subsequently degraded. Protease inhibitors added to the culture 
medium marginally affected prorenin activation in cardiomyocytes, and were without 
effect on prorenin activation in fibroblasts and HUVECs. Moreover, the proteolytic 
activation of K/A-2 prorenin in HUVECs was indistinguishable from wild-type prorenin 
activation. These data indicate that the prorenin-activating enzyme most likely is 
different from any of the previously known prorenin-activating enzymes. Incubation of 
HUVECs with prorenin and angiotensinogen did neither led to internalization of 
angiotensinogen, nor, to intracellular angiotensin generation. In conclusion, cardiac 
myocytes, cardiac fibroblasts and endothelial cells display high affinity binding of 
prorenin exclusively via mannose 6-phosphate/IGFII receptors. Binding is followed by 
internalization and proteolytic activation to renin. Although this process may underlie 
intracellular angiotensin synthesis, our data in HUVECs do not support this concept, 
and suggest that prorenin internalization represents prorenin clearance. 
Chapter7 
Since recombinant human prorenin may differ from native human pro renin with 
regard to its glycosylation and/or phosphorylation,18"19 we repeated the studies 
regarding (pro)renin binding to mannose 6-phoshate/IGFII receptors with cardiac 
cells using various prorenin-containing body fluids. 
Uptake and activation via mannose 6-phosphate/IGFII receptors were observed for 
plasma prorenin from subjects with renal artery stenosis and/or hypertension, and for 
ovarian follicular fluid prorenin. The total amount of cellular renin and prorenin 
(expressed as percentage of the levels of renin and pro renin in the medium) after 4 
hours of incubation was 4-10 times lower than after incubation with recombinant 
human prorenin. Although plasma contains alkaline phosphatases capable of 
inactivating the mannose 6-phosphate label, as well as soluble mannose 6-
phosphate/IGFII receptors that block prorenin binding in a competitive manner, and 
proteins (e.g., insulin, IGFII) that increase the number of cell surface mannose 6-
phosphate/IGFII receptors, these factors were not responsible for the modest uptake 
of native human prorenin. Uptake did not occur during incubation of myocytes with 
plasma prorenin from anephric subjects or with amniotic fluid prorenin, and this was 
not due to the presence of excessively high levels of mannose 6-phosphate/IGFII 
receptors and/or phosphatase activity in these fluids. In conclusion, myocytes are 
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capable of binding, internalizing and activating native human prorenin of renal and 
ovarian origin via mannose 6-phosphate/IGFII receptors. Differences in prorenin 
glycosylation and/or phosphorylation, as well as the concentration of soluble 
mannose 6-phosphate/IGFII receptors and growth factors affecting the cell surface 
density of mannose 6-phosphate/IGFII receptors, may determine the amount of 
blood-derived prorenin in the heart, and, thereby influence cardiac angiotensin II 
production. 
ChapterS 
Mannose 6-phoshate/IGFII receptors on the cell surface couple to intracellular 
second messenger systems, and renin binding to renal glomerular mesangial cells 
increases 3H-thymidine incorporation directly (i.e., independent of angiotensin II 
formation).20•22 Therefore, to investigate whether prorenin binding to cardiac 
myocytes elicits a response, and if so, whether this response depends on intra- or 
extracellular angiotensin II generation (Figure 1), we incubated neonatal rat 
cardiomyocytes with 2 nmoi/L prorenin and/or 150 nmoi/L angiotensinogen, with or 
without mannose 6-phosphate, eprosartan or PD123319 to block mannose 6-
phosphate/IGFII-, AT1- and AT2-receptors, respectively. Protein and DNA synthesis 
were studied by quantifying 3H-Ieucine and 3H-thymidine incorporation. For 
comparison, studies with 1 00 nmoi/L angiotensin II were also performed. 
{€~-~-~~~~;: 
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Figure 1: Mechanisms for prorenin-induced effects on myocytes. Binding to mannose 6-
phosphate/-IGFII receptors directly confers a cellular effect (top left), or following intracellular 
activation and angiotensin II formation (top right). Alternatively, angiotensin II is generated 
extracellularly independent of prorenin binding, as a consequence of the partial activity of 
prorenin (bottom). 
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Neither prorenin alone, nor angiotensinogen alone affected protein or DNA 
synthesis. Prorenin plus angiotensinogen increased 3H-Ieucine incorporation by 
=20%, 3H-thymidine incorporation by =30% and total cellular protein by =15%, 
whereas angiotensin II increased DNA synthesis only (by =35%). Eprosartan, but not 
PD123319 or mannose 6-phosphate, blocked the effects of prorenin plus 
angiotensinogen as well as the effects of angiotensin II. Angiotensin II levels in the 
medium during prorenin and angiotensinogen incubation were very low(< 1 nmoi/L) 
with respect to its levels (100 nmoi/L) in incubations in which angiotensin II was 
added for comparison. 
In conclusion, prorenin binding to mannose 6-phoshate/IGFII receptors on 
cardiomyocytes per se does not result in enhanced protein or DNA synthesis. 
However, through angiotensin II generation, prorenin is capable of inducing myocyte 
hypertrophy and proliferation. Since this generation occurs independently of 
mannose 6-phoshate/IGFII receptors, it most likely depends on the catalytic activity 
of intact prorenin in the medium (due to temporal prosegment unfolding) rather than 
its intracellular activation. Local generation of angiotensin II results in more efficient 
AT1 receptor activation and/or second messenger generation. Taken together, the 
results described in this chapter do not support the concept of angiotensin II 
generation in cardiomyocytes following intracellular prorenin activation. 
Concluding Remarks 
Local angiotensin II generation and receptor-dependent prorenin binding 
The experiments described in this thesis focus on the cardiac generation of RAS 
components and the possible contribution of prorenin to angiotensin II generation in 
the heart. 
Despite many reports in the literature on the generation of angiotensin II by cultured 
. 12·15 
card1ac cells, we were unable to show that these cells are capable of 
synthesizing (pro)renin or angiotensinogen. Our data are in agreement with the 
concept that ACE and AT receptors are present on cardiac cells, and that 
angiotensin II mediates its hypertrophic effect via these receptors. Thus, either renin 
is not involved in the generation of angiotensin II by cultured cardiac cells, or the 
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renin (and angiotensinogen) required for angiotensin II synthesis are derived from 
the media used to culture the cells. A role for enzymes other than renin in the 
generation of angiotensins in the heart seems unlikely in view of the absence of 
angiotensin 11-mediated effects following angiotensinogen application to 
cardiomyocytes. Cardiac cells may sequester circulating (pro)renin via binding to cell 
surface mannose 6-phoshate/IGFII receptors. However. non-mannose 6-
phoshate/IGFII receptor (pro)renin binding sites (or receptors) have also been 
demonstrated in membrane preparations from various rat tissues 2324 and in human 
glomerular mesangial cells.22 The gene encoding the latter receptor has recently 
25 
been cloned and characterized. Expression of the receptor in a SV40-immortalized 
human mesangial cell line revealed high-affinity renin-binding properties with 
concurrent more efficacious angiotensin I formation. Renin binding to this receptor 
within minutes also led to an increase in phosphorylation of the cytosolic 
serine/threonine kinases ERK1 and ERK2, which are both involved in intracellular 
signal transduction.25 Localization studies with antibodies against several domains of 
the receptor revealed that its expression is restricted to vascular smooth muscle cells 
and mesangial cells. It appeared to be absent in endothelial and cardiac cells.25 
These results agree with ours as prorenin binding sites other than man nose 6-
phoshate/IGFII receptors could not be demonstrated in rat cardiac myocytes and 
fibroblasts, or human umbilical cord endothelial cells. 
Binding of mannose 6-phoshate-labeled prorenin to cardiac and endothelial cells is 
perhaps somewhat unexpected, since the mannose 6-phoshate label classically 
confers lysosomal targeting of proteins that are either generated de novo in the 
endoplasmatic reticulum or endocytosed from the cell surface. In this regard, 
mannose 6-phosphate labeling of prorenin might be due to evolutionary 
conservation, since prorenin's homologue, the aspartic protease cathepsin D, is 
normally present in lysosomes only. Prorenin also contains signal motifs for storage 
and activation in secretory vesicles, and the presence of multiple signal motifs might 
explain why part of prorenin, including mannose 6-phosphate-labeled prorenin, 
'escapes' into the circulation:s-28 Furthermore, the mannose 6-phosphate label has 
additional functions, as in some cases (e.g., latent-TGF~29 and leukemia inhibitory 
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factor"") man nose 6-phosphate is required to dock a protein on the cell surface, prior 
to its internalization and transportion to lysosomes. Another example of the versatility 
of the mannose 6-phosphate label is its role in the sorting and secretion of the 
apoptosis-inducing enzymes granzyme A and B by cytotoxic T cells, and in the 
subsequent internalization of these enzymes by target cells.31 "32 Finally, prorenin of 
non-renal origin does not always contain the mannose 6-phosphate signal.18"
19 
Irrespective of (pro)renin binding to mannose 6-phosphate/IFGII receptors, the 
similar potencies of angiotensin I and angiotensin II in the human forearm, despite 
the fact that only about one-third of angiotensin I was converted to angiotensin II, 
and the comparable effects of prorenin plus angiotensinogen versus angiotensin II 
on myocyte proliferation, despite the 1 00-fold lower angiotensin II levels that were 
present in the medium during prorenin plus angiotensinogen incubation, show that 
local angiotensin II generation is of greater importance than angiotensin II delivery 
via the circulation. The lack of effect of mannose 6-phosphate during prorenin plus 
angiotensinogen incubations excludes a role of mannose 6-phoshate/IGFII receptors 
in the local angiotensin I generation on the cell surface. Since we were unable to 
demonstrate significant cellular uptake of angiotensinogen our data also argue 
against the possibility of intracellular angiotensin II generation. Possibly, therefore, 
(pro)renin binding to mannose 6-phoshate/IGFII receptors represents (pro)renin 
clearance, rather than the initial step leading to (intracellular) angiotensin II 
generation. 
Local transcription of renin and angiotensinogen: physiologically relevant? 
Regardless the conflicting data documenting the presence or absence of cardiac 
renin and/or angiotensinogen synthesis (i.e., transcription followed by translation), 
the majority of renin and angiotensinogen required for cardiac angiotensin I 
synthesis is derived from the circulation, both under normal and pathological 
conditions. 
In our experimental setup cardiac gene transcription of renin and angiotensinogen, if 
occurring, did not result in detectable levels of the mature proteins. The low renin 
transcription levels that have been detected in cardiac tissue could, however, 
represent a recently described renin splice variant (dubbed: renin-1A).33 This renin 
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splice-variant, originally discovered in adrenal tissue, lacks the secretion signal motif 
encoding sequence and one-third of the prosegment. Theoretically, therefore, it 
should give rise to a protein product that remains intracellularly and displays renin 
activity.33"34 Indeed, in vitro generated renin-1A protein products are translocated into 
adrenal mitochondria, when incubated with a cell-free mitochondria preparation, in 
accordance with previous described immunohistochemical evidence for its presence 
in adrenal mitochondria.34 Unfortunately, no attempts have been presented so far to 
unravel the capacity of renin-1 A to generate angiotensin I intracellularly (or to 
perform alternative functions). 
As far as angiotensinogen is concerned, there is currently no evidence for a naturally 
occurring angiotensinogen variant lacking the signal peptide that normally leads to 
secretion. 
Future study options: 
The results described in this thesis belong to the first characterizing the binding and 
activation of prorenin by extrarenal cells and investigating the involvement of the 
mannose 6-phosphate/IGFII receptor in this process. In addition, cardiac myocytes 
and fibroblasts were shown not to have (pro)renin- and angiotensinogen-generating 
capacity, thus emphasizing the importance of (pro)renin sequestration. Remarkably, 
however, (pro)renin binding to mannose 6-phosphate!IGFII receptors did not result in 
detectable angiotensin formation. The following future studies may help to clarify 
some of the remaining and newly raised questions. 
Is the mannose 6-phosphate!IGF/1 receptor the only (pro)renin-binding receptor on 
the cell surface? 
We have obtained compelling evidence that the mannose 6-phosphate/IGFII 
receptor is the only (pro)renin binding receptor on cardiomyocytes and -fibroblasts, 
isolated from neonatal rat hearts, and on endothelial cells, isolated from human 
umbilical cord veins. However, cardiac and endothelial cells isolated from adult 
tissue, as well as non-endothelial, non-cardiac cells, could express an additional 
(pro)renin binding site/receptor. Furthermore, pathological conditions might result in 
the expression of alternative (pro)renin binding sites. Therefore, it is worthwhile to 
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expand our binding studies with recombinant human prorenin to adult cardiac and 
endothelial cells and/or cells from other (pathological) tissues, in order to assess the 
presence or absence of binding sites for (pro)renin, other than mannose 6-
phosphate/IGFII receptors. 
One candidate is a recenUy cloned renin receptor, that is specifically expressed on 
the cell surface of vascular smooth muscle and mesangial cells.25 
Does local angiotensin II generation occur in close proximity of A T1 receptors? 
Studies on the molar ratio and the exact location of ACE and AT receptors on the 
cell surface of myocytes (in other words their vicinity) might explain the observed 
efficient AT, receptor activation (i.e., occurring at much lower extracellular 
angiotensin II levels) in cardiomyocytes and the forearm by locally generated 
angiotensin II in comparison to exogenous angiotensin II. Enhanced AT, receptor 
activation was not dependent on mannose 6-phosphate/IGFII receptor-binding of 
prorenin. However, binding of (pro)renin to the recently cloned renin receptors25 on 
vascular smooth muscle and glomerular mesangial cells might further enhance the 
efficiency of such a local angiotensin 11-generating system (Figure 2). 
Cardiac Myocytes 
.., 
,..~~ 
Cytosol 7 -•. 
(P)R : (Pro)Renin 
Aog : Angiotensinogen 
Ang I :Angiotensin I 
Ang II :Angiotensin II 
Vascular Smooth Muscle Cells 
ACE :Angiotensin !-converting Enzyme 
AT, :Angiotensin U, type 1 receptor 
(P)R-BP: (Pro)Renin Binding Protein 
Figure 2: Efficient A T1 receptor activation in the heart (left) following cell surface 
angiotensin II generation. (Pro)renin binding to (Pro)Renin Binding Proteins (i.e., the 
renin receptors that have been identified in vascular smooth muscle cells) might further 
enhance the efficiency (right). 
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is prorenin binding to mannose 6-phosphate/IGF/1 receptors of functional importance? 
Prorenin binding to mannose 6-phosphate/IGFII receptors did not result in 
angiotensin generation and is not required for angiotensin generation in the 
presence of angiotensinogen, suggesting that this receptor might be involved in local 
(pro)renin clearance, rather than local angiotensin generation. In this regard the role 
of soluble mannose 6-phosphate/IGFII receptors in the circulation is also of interest; 
such binding might play a role in (pro)renin transport. 
Uptake of native prorenin from human plasma is relatively low compared to the 
uptake of recombinant prorenin. Explanations for this phenomenon include the 
presence of soluble mannose 6-phosphate/IGFII receptors, the presence of growth 
factors affecting the number of cell surface-expressed mannose 6-phosphate/IGFII 
receptors, and the possibility that a lower proportion of circulating (pro)renin is 
man nose 6-phosphate-labeled. The latter might be due to the fact that in vivo most 
mannose 6-phosphate labeled (pro)renin has already been removed from blood 
plasma by binding to mannose 6-phosphate/IGFII receptors, e.g. on the vascular 
endothelium. Establishing the degree of man nose 6-phosphate labeling of 
endogenous (pro)renin is essential to extend our understanding of the importance of 
(pro)renin binding to mannose 6-phosphate/IGFII receptors in vivo. 
Furthermore, the possibility remains that a specific cellular effect induced directly 
upon prorenin binding to mannose 6-phosphate/IGFII receptors has been overlooked 
in the present experimental setup. Therefore, expanding the panel of cellular effects 
studied to discover mannose 6-phosphate-labeled (pro)renin-mediated mechanisms 
remains necessary. Proteomics and eDNA microarray might be of help with regard to 
this issue. 
Establishing the cardiac (pro)renin levels, as well as the cardiac morphology and/or 
physiology of mice devoid of mannose 6-phosphate/IGFII receptors in the heart (due 
to cardiac-specific deletion of the man nose 6-phosphate/IGFII receptors using the 
Cre-LoxP system) might also shed light on the functional consequences of man nose 
6-phosphate/IGFII receptor dependent (pro)renin binding in the heart. As (pro)renin 
measurements in cardiac tissue of mice are cumbersome, angiotensin levels could 
be determined instead in the hearts of such mice. Differences could be augmented 
by first generating double transgenics by back-crossing with mice overexpressing 
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either prorenin or renin.35 Glycosylation and phosphorylation profiles should, 
however, be monitored when (pro)renin originates from non-renal tissue and/or 
(pro)renin overexpressing kidneys. Additionally, to circumvent compensatory 
mechanisms during development, introduction of an inducible overexpression 
36 
system would be preferable. 
Do alternative renin and angiotensinogen gene-transcripts yield intracellular proteins? 
Studies are required addressing whether the cardiac expression of the recently 
discovered renin splice-variant (renin-1A) actually results in measurable renin levels 
and/or a renin-1A -specific intracellular function.33 A method would be to generate, 
via homologous recombination techniques, cell lines and/or mice expressing the 
renin-1A transcript with a small peptide tag (e.g. the triple HIS tag) and follow 
mitochondrial translocation and/or cellular uptake of renal (pro)renin by 
microscopical techniques. The peptide tag offers sensitive purification and/or 
imaging options. More importantly, tagging might facilitate discrimination between 
in vivo cardiac uptake of renal non-tagged (pro)renin and cardiac 
transcription/translation of the renin-1A mRNA protein product, and between 
endogenous production versus cellular uptake of serum components in the case of 
in vitro cell studies. Therefore, the tag should preferably be located 5-prime of the 
remaining prosegment, resulting in expression wherever the renin-1 A mRNA splice-
variant is generated or, when not feasible, reliable tissue-specific gene promoters 
should be introduced. 
The existence of alternative splicing of the renin gene, either ignored or overlooked 
previously, implies the same possibility for angiotensinogen. A systematical analysis 
of alternative transcription by primer walking and RT-PCR of the angiotensinogen 
gene is therefore required. 
'Transgenics to the rescue!?!" 
The question whether and to which degree the heart contributes to its own levels of 
(pro)renin and angiotensinogen is still being debated, despite hundreds of 
publications on this issue, and is of importance for, among others, the following 
reasons. First, cardiac expression of renin and local activation of circulating prorenin 
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might represent new targets for interference with the local generation of 
angiotensin II. Second. speculative but intriguing, the postulated mitochondrial 
presence of the renin-1A isoform in heart tissue might coincide with a recently 
h h "d d" d h" 37.38 ypot es1ze car 1ac al osterone synt es1s system. 
Problems regarding sensitivity and discussions regarding ex vivo experiments versus 
non-physiological conditions in vivo (e.g., bilateral nephrectomy) could perhaps be 
resolved by a set of experiments involving transgenic mice expressing a 3-prime 
tagged renin gene, generated by homologous recombination, followed by 
transplantation of the heart of such transgenic animals to wild type mice (Figure 3). 
\ 
/«~~ ~ 
Y I Transgenic Wild Type 
0: Normal Ill: 3'~Tagged 
Transplanted Heart « :Kidneys Q :Heart 
Figure 3: Use of transgenic mice and transplantation to differentiate the sources of 
cardiac renin (i.e., cardiac renin-1A synthesis versus uptake of circulating (pro)renin). 
The insertion of a small protein-tag located 3-prime of renin promises improved 
sensitivity over earlier performed experiments, without interference with renin's 
angiotensin !-generating activity, and will allow, after transplantation, determination 
of wild type and tagged renin. The use of transplantation is necessary to 
unambiguously discriminate between endogenous cardiac renin synthesis and/or 
(pro)renin uptake by the heart and, as transplantation from a parental strain donor to 
a transgenic acceptor does not require immunosuppression, should affect the normal 
physiology of the animal to a limited degree only. It also circumvents the problems 
arising from differences in glycosylation and/or phosphorylation when using infusions 
of recombinant (pro)renin or when using mice overexpressing (pro)renin. 
Transplantation of a normal heart to a transgenic animal will shed further light on the 
cardiac uptake of circulating (pro)renin and its translocation to specific cellular 
compartments (e.g., mitochondria) in the heart. Similar experiments could be 
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performed with mice transgenic for 3-prime tagged angiotensinogen or transgenic for 
both such renin and angiotensinogen genes. As this proposal is quite ambitious, due 
to the complex manipulations and the required expertise on the RAS system, the 
initiation of a concerted action between specialized groups in angiotensin II research 
is desirable. 
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tntroductie 
Het "renine-angiotensine II systeem" (RAS) in de bloedvaten is van oudsher 
voorgesteld als een op afstand werkend hormonaal systeem, dat de "normale" 
bloeddruk en de water- en zouthuishouding van het lichaam regelt. 
Het eindproduct van het RAS is het hormoon angiotensine II (zie figuur 1). Dit 
ontstaat in het bloed uit het eiwit angiotensinogeen (afkomstig uit de lever) door 
inwerking van de enzymen renine (afkomstig van de nieren) en ACE (het 
"angiotensine 1-converterend enzym", aanwezig op de endotheelcellaag). 
Door binding van angiotensine II moleculen aan speciale bindingsplaatsen (de AT-
receptoren) op het oppervlak van cellen worden deze AT-receptoren "geactiveerd". 
Dit houdt in dat de vorm van de receptoren verandert (zie figuur 2), waardoor in de 
eel een signaal wordt afgegeven met een bepaald gevolg, dat specifiek is voor het 
type eel. Voorbeelden hiervan zijn "vasoconstrictie" (d.w.z. bloedvatvernauwing door 
samenknijpen van de spiercellen in de bloedvatwand), het vasthouden van water en 
zout in de nieren en "hypertrofie" (d.w.z. de vergroting van individuele 
hartspiercellen). 
prorenine 
\ angiotensinogeen 
renine ........ I 4·--. t .. 
angiotensine I 
· .. 
alternatieve ?? 
enzymen 
angiotensine I ..... 
converting .._ ! ..._ . -·· 
•••• • Ill""'"" ........... 
enzyme 
angiotensine II 
~ 
angiotensine II receptoren 
Figuur 1: Vorming van angiotensine II en binding aan "angiotensine II receptoren". 
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Figuur 2: Binding van angiotensine II (Ang II) aan een AT-receptor in de celwand (links) 
veroorzaakt een vervorming van deze AT-receptor (midden), waardoor aan de binnenzijde 
van de eel de "staart" van deze receptor zjch openvouwt. Daardoor kunnen verschillende 
andere eiwitten in de eel zich binden aan de staart van de receptor (rechts) zodat een 
"effect", zoa/s samentrekking van een spiercel, kan optreden. 
Het RAS is betrokken bij het ontstaan van hartfalen (verlies van pompfunctie) en 
hypertensie (te hoge bloeddruk}. 
Overmatige belasting van het hart kan leiden tot verlies van voldoende capaciteit om 
het bloed door het lichaam te pompen. Dit hartfalen kent vele oorzaken, bijvoorbeeld 
een hartinfarct (d.w.z. een deel van de hartspier sterft door zuurstoftekort) en 
hypertensie (bijvoorbeeld als gevolg van een te hoge weerstand in de bloedvaten). 
Een overmatig belaste hartspier zal in eerste instantie diverse compenserende 
mechanismen activeren. Dit leidt tot "hypertrofie" van de individuele hartspiercellen 
en vergroting van de spiermassa. Dit remodelleringsproces gaat vaak gepaard met 
"fibrose" (d.w.z. verstijving van de spierbundels). Blijft de oorzaak van de 
overbelasting bestaan, bijvoorbeeld de genoemde te hoge bloeddruk, dan zal de 
remodellering doorgaan. Dit laatste kan uiteindelijk resulteren in een te sterke 
verstijving van het hart en/of uitval van hartspiercellen met als gevolg een sterk 
verminderde pompcapacititeit van de hartspier. 
Vaak is bij hartfalen ook het RAS geactiveerd en wordt extra angiotensine II 
gevormd. 
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Hoewel ingrijpen aan het begin van een cascade zeals het RAS (figuur 1 ), meestal 
de meest wenselijke stap is, worden remmers van renine (neg) niet gebruikt door 
patienten. Middelen die de vorming van angiotensine II door ACE remmen of de 
binding ervan aan de AT-receptoren blokkeren (z.g. receptor antagonisten) worden 
wei in de klinische praktijk toegepast. Met name de ACE-remmers zijn succesvol bij 
de behandeling van hartfalen en hypertensie. Opmerkelijk is dat daarbij meer Ievens 
zijn gered dan verwacht op basis van de bereikte bloeddrukverlaging. Men neemt 
daarom aan dat angiotensine II vorming ook plaatsvindt in het hartweefsel zelf, naast 
die in de bloedbaan. In dit concept past ook dat lokale vorming van angiotensine II 
kan leiden tot efficientere activatie van de AT-receptoren op het celoppervlak dan 
AT-receptor activatie door angiotensine II afkomstig uit de bloedbaan. 
Recent onderzoek in ens laboratorium heeft uitgewezen dat zelfs vrijwel al in het 
hart aanwezige angiotensine II daar gevormd is. Dit betekent echter niet dat aile 
eiwitten die nodig zijn veer cardiale angiotensine II vorming ook zelf daadwerkelijk in 
het hart gemaakt worden. En inderdaad, na verwijdering van de nieren zijn renine en 
angiotensine niet meer aantoonbaar in hartweefsel. Ook bleek het mRNA (de 
boodschappermoleculen, nodig voor de vorming van eiwitten) van de genen van 
renine en angiotensinogeen nauwelijks aantoonbaar. Het in het hart aanwezige 
renine wordt dus, waarschijnlijk, uit het bleed opgenomen en is zodoende afkomstig 
van de nieren. Renine komt in de bloedcirculatie ook voor in een inactieve pro-vorm, 
het z.g. prorenine. De prorenine concentraties zijn ongeveer 1 Ox hoger dan die van 
renine. Het is niet onwaarschijnlijk dat ook dit prorenine door het hart wordt 
opgenomen. Het meet in het hart, na opname, neg wei worden omgezet in renine 
Bloed-
circulatie 
(Pro)renine 
Hart 
~ .::;:·····················. 
~ P~renine ? ~ 
~ ....... ,.. Renine ~ 
···--···················· 
Figuur 3: (Pro )renine in het hart is afkomstig van de nieren en wordt getransporteerd via 
de bloedbaan. Na opname zou prorenin geactiveerd moeten worden om angiotensine te 
kunnen vormen. 
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("activatie") om angiotensine I te kunnen vormen. 
Remming van de (pro)renine-opname en/of de activatie van prorenine in het hart zou 
een aanvullende medicatie kunnen zijn op de bestaande, succesvolle toepassing 
van ACE-remmers en AT-receptor-blokkers, of een vervangende therapie voor die 
mensen die deze medicijnen slecht verdragen. 
Het doel van het onderzoek in dit proefschrift was het verkrijgen van een beter 
inzicht in de lokale vorming van angiotensine II en de rol van (pro)renine in dit 
proces. 
Resultaten van de studie: 
Voorbereidende experimenten in ons laboratorium lieten zien dat hartspiercellen van 
ratten in staat zijn om renine en prorenine op te nemen, waarbij bovendien prorenine 
na opname werd geactiveerd (zie figuur 3). 
In de huidige studie hebben we gebruik gemaakt van hartspiercellen van ratten en 
van endotheelcellen van mensen om de opname van (pro)renine beter uit te zoeken. 
Het belang van lokale angiotensine II vorming in vivo (d.w.z. in het echt) is 
onderzocht door de doorbloeding van de onderarm te bestuderen van gezonde 
vrijwilligers tijdens infusie van angiotensine I of II. 
De resultaten Iaten zien dat hartspiercellen en endotheelcellen geen renine, 
prorenine of angiotensinogeen maken; wei hebben deze cell en ACE en AT-
receptoren op het celoppervlak. Ze kunnen dus wei angiotensine I omzetten in 
angiotensine II. Dit angiotensine II zou vervolgens de AT-receptoren kunnen 
activeren. 
Daarnaast werd duidelijk dat hartspiercellen en endotheelcellen prorenine efficient 
kunnen opnemen met behulp van speciale bindingseiwitten, de z.g. mannose-6-
fosfaat.IIGFII receptoren, op het celoppervlak. Aileen prorenine waaraan in de nieren 
het z.g. mannose-6-fosfaat molecuul was gekoppeld werd door de cell en gebonden. 
Na binding ging prorenine de eel in, waar het werd omgezet in renine. Het zo 
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gevormde renine bleef in de cellen. De binding en/of internalisatie van (pro)renine 
leidde niet tot (intra-) cellulaire effecten, zeals angiotensine II vorming in de eel of 
hypertrofie van de hartspiercellen. Tot onze verbazing bleek ook dat voor de lokale 
angiotensine II vorming door hartspiercellen, in aanwezigheid van angiotensinogeen, 
prorenine binding aan mannose-6-fosfaat/IGFII receptoren niet noodzakelijk was (zie 
figuur 4). 
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Figuur 4: Mogelijke mechanismen voor door prorenine veroorzaakle effecten op 
hartspierce/len. 1) Binding aan de mannose-6-fosfaat/IGF/1 bindingsplaatsen geeft een 
specifiek effect in de eel (links). 2) Na binding en opname wordt prorenine omgezet in 
renine. Dit zou, via de vorming van angiotensine II in de eel kunnen leiden tot een effect 
(rechts). 3) Angiotensine II wordt buiten de eel gevormd, waama activatie van AT-
receptoren op het celoppervlak leidt tot een effect in de eel (onder). 
Tijdens de experimenten met hartspiercellen waarbij prorenine en angiotensinogeen 
aan de kweekvloeistof (d.w.z. de vloeistof boven de cellen) waren toegevoegd, werd 
maar weinig angiotensine II gevormd. Echter, het effect daarvan op de cell en was 
even sterk als dat van in veel hogere (±1 OOx) concentraties toegevoegd. Dit kan 
verklaard worden met het idee dat de vorming van angiotensine II op het 
celoppervlak plaatsvindt, zodat aileen daar de concentratie van angiotensine II hoger 
is en niet in de gehele kweekvloeistof. 
Bovenstaande effect, de plaatselijke vorming en efficiente activatie van de AT-
receptoren, kwam ook naar voren bij bestudering van de bloeddoorstroming van de 
onderarm bij vrijwilligers. Een infuus met angiotensine lleverde dezelfde mate van 
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vermindering van doorstroming als een infuus met dezelfde hoeveelheid 
angiotensine II, terwijl maar een klein deel van de aangeboden angiotensine I werd 
omgezet in angiotensine I. De voor de activatie van de AT-receptoren (en dus 
vernauwing van de bloedvatwand) van belang zijnde omzetting van angiotensine I 
naar angiotensine II verliep geheel via het ACE op de cellen van de vaatwand van 
het bloedvatbed van de onderarm. 
Samenvattend: 
1) Uit de experimenten betreffende de hartspiercellen van ratten en de 
bloeddoorstroming van de onderarm van vrijwilligers werd duidelijk dat lokale 
angiotensine II vorming efficientertot AT-receptor activatie leidt, dan van buitenaf 
aangeboden angiotensine II. 
2) Prorenine bindt aan mannose-6-fosfaat/IGFII receptoren op hartspiercellen, gaat 
vervolgens de eel in en wordt daar dan omgezet in renine. Dit laatste leidt niet tot 
intracellulaire angiotensine II vorming. Mogelijk is de opname en omzetting in 
renine enkel de eerste stap van een intracellulair opruimingsproces. Dit opname-
en afbraakproces zou dan een mechanisme kunnen zijn dat de concentratie van 
renine en prorenine buiten de eel reguleert. 
3) De ontwikkeling van remmers van (pro)renine binding door het hart en/of activatie 
van prorenine (buiten de cellen) blijft een mogelijkheid voor toekomstig alternatief 
ingrijpen op de lokale angiotensine II vorming in het hart. 
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Dankwoord 
Bij het be rei ken van de kade blijkt deze maar smal en ligt er nog veel meer water 
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zijn nu 4% jaar verder en er ligt inderdaad een boekje. Maarten, Pramod en Jan, ik 
wil jullie hierbij bedanken voor het gestelde vertrouwen en de hulp waarnodig. Jan, jij 
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en Farmacologie en heb ondersteuning van veel verschillende mensen ervaren. 
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ervan. Jaap, Frans B., Ton, Annemiek, Nicole, Bianca en Thomas, Marjolein, Usha, 
Angelique, Richard en Gooftzen, bedankt voor de hulp, het theoretisch kader en de 
gezellige (koffie-) momenten. Marinel, als laatste van het stel, dank je voor de 
relativering. Nog even en dan schrijf jij dit ook. 
Biochemie, lab-5, als de bron van de hartspiercellen en lab-6, voor de 
endotheelcellen. Prof. dr. Jos Lamers, jij en Wtm Sluiter, E!ly, Karel, Jet en Han, 
stonden ook altijd klaar met hulp, (ant)woorden of een praatje. Dick Dekkers, op de 
s• was en ben jij mijn grote hulp. 
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bottere perioden. Vooral mijn kamergenoten lnge, Antoinette, Rene, Remon en Beril 
hebben dit van nabij mogen meemaken. Wie ook niet onvermeld mogen blijven zijn 
Martin, Mark en Wendy van het angiotensine clubje. Daarnaast nog Ingrid, Roeland, 
Erik en Richard. 
Niet ieder van de vel en is genoemd, maar de waardering is er wei. 
Van ''vroeger'' in Lei den wil ik hier nog graag noemen: Hans Dauwerse en Dorien 
Peters, maar ook Lia, Jeroen en Barbera. AI ben ik door de goede tijden bij jullie en 
de spanning van de cystenieren-genen wei ietwat te lang in Leiden blijven hangen. 
Leo, Edwin, Fred, Hans, Jurgen, Eugene, Frank, Gerard, Abraham, JvdG en Marcel, 
bedankt voor de interesse en weerklank. En dames, jullie horen daar natuurlijk ook 
bij. 
Bastiaan en Jan-Pieter, ik dank jullie voor de vriendschap en de steun als 
paranimfen. Corinne en Edilh, bedankt voor 't even mogen lenen van de mankracht. 
Pa2 en Ma2, Hennie en John, Neeltje en May, zonder jullie was ik niet op dit punt 
gekomen. Hoewel het vaak nogal vaag was, is het boekje toch heel duidelijk. 
Tenslotte, bovenal, Jose! Meissie, zonder jou was dit niet mogelijk geweest. 
Dankzij jouw liefde en geduld ben ik verder gegaan en is dit nu voltooid. Samen met 
Rick, Jente en Ranee vormen wij een mooi stel. 
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